<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002465</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>65</s160></s100><s200><s210>1</s210><s211>711</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 1atggtcagcg ttccaacagc ctcaccctcg gcatccagca gctcctctca gtgccggtcc     60agcatgtgtc aatcacgcta cctcctcttt ttggccaccc ttgccctcct aaaccacctc    120agtttggcca gggtcattcc agtctctgga cctgccaggt gtcttagcca gtcccgaaac    180ctgctgaaga ccacagatga catggtgaag acggccagag aaaaactgaa acattattcc    240tgcactgctg aagacatcga tcatgaagac atcacacggg accaaaccag cacattgaag    300acctgtttac cactggaact acacaagaac gagagttgcc tggctactag agagacttct    360tccacaacaa gagggagctg cctgccccca cagaagacgt ctttgatgat gaccctgtgc    420cttggtagca tctatgagga cttgaagatg taccagacag agttccaggc catcaacgca    480gcacttcaga atcacaacca tcagcagatc attctagaca agggcatgct ggtggccatc    540gatgagctga tgcagtctct gaatcataat ggcgagactc tgcgccagaa acctcctgtg    600ggagaagcag acccttacag agtgaaaatg aagctctgca tcctgcttca cgccttcagc    660acccgcgtcg tgaccatcaa cagggtgatg ggctatctga gctccgcctg a             711</s400><s200><s210>2</s210><s211>236</s211><s212>PRT</s212><s213>Mus musculus</s213></s200><s400> 2Met Val Ser Val Pro Thr Ala Ser Pro Ser Ala Ser Ser Ser Ser Ser1               5                   10                  15Gln Cys Arg Ser Ser Met Cys Gln Ser Arg Tyr Leu Leu Phe Leu Ala            20                  25                  30Thr Leu Ala Leu Leu Asn His Leu Ser Leu Ala Arg Val Ile Pro Val        35                  40                  45Ser Gly Pro Ala Arg Cys Leu Ser Gln Ser Arg Asn Leu Leu Lys Thr    50                  55                  60Thr Asp Asp Met Val Lys Thr Ala Arg Glu Lys Leu Lys His Tyr Ser65                  70                  75                  80Cys Thr Ala Glu Asp Ile Asp His Glu Asp Ile Thr Arg Asp Gln Thr                85                  90                  95Ser Thr Leu Lys Thr Cys Leu Pro Leu Glu Leu His Lys Asn Glu Ser            100                 105                 110Cys Leu Ala Thr Arg Glu Thr Ser Ser Thr Thr Arg Gly Ser Cys Leu        115                 120                 125Pro Pro Gln Lys Thr Ser Leu Met Met Thr Leu Cys Leu Gly Ser Ile    130                 135                 140Tyr Glu Asp Leu Lys Met Tyr Gln Thr Glu Phe Gln Ala Ile Asn Ala145                 150                 155                 160Ala Leu Gln Asn His Asn His Gln Gln Ile Ile Leu Asp Lys Gly Met                165                 170                 175Leu Val Ala Ile Asp Glu Leu Met Gln Ser Leu Asn His Asn Gly Glu            180                 185                 190Thr Leu Arg Gln Lys Pro Pro Val Gly Glu Ala Asp Pro Tyr Arg Val        195                 200                 205Lys Met Lys Leu Cys Ile Leu Leu His Ala Phe Ser Thr Arg Val Val    210                 215                 220Thr Ile Asn Arg Val Met Gly Tyr Leu Ser Ser Ala225                 230                 235</s400><s200><s210>3</s210><s211>1008</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 3atgtgtcctc agaagctaac catctcctgg tttgccatcg ttttgctggt gtctccactc     60atggccatgt gggagctgga gaaagacgtt tatgttgtag aggtggactg gactcccgat    120gcccctggag aaacagtgaa cctcacctgt gacacgcctg aagaagatga catcacctgg    180acctcagacc agagacatgg agtcataggc tctggaaaga ccctgaccat cactgtcaaa    240gagtttctag atgctggcca gtacacctgc cacaaaggag gcgagactct gagccactca    300catctgctgc tccacaagaa ggaaaatgga atttggtcca ctgaaatttt aaaaaatttc    360aaaaacaaga ctttcctgaa gtgtgaagca ccaaattact ccggacggtt cacgtgctca    420tggctggtgc aaagaaacat ggacttgaag ttcaacatca agagcagtag cagttcccct    480gactctcggg cagtgacatg tggaatggcg tctctgtctg cagagaaggt cacactggac    540caaagggact atgagaagta ttcagtgtcc tgccaggagg atgtcacctg cccaactgcc    600gaggagaccc tgcccattga actggcgttg gaagcacggc agcagaataa atatgagaac    660tacagcacca gcttcttcat cagggacatc atcaaaccag acccgcccaa gaacttgcag    720atgaagcctt tgaagaactc acaggtggag gtcagctggg agtaccctga ctcctggagc    780actccccatt cctacttctc cctcaagttc tttgttcgaa tccagcgcaa gaaagaaaag    840atgaaggaga cagaggaggg gtgtaaccag aaaggtgcgt tcctcgtaga gaagacatct    900accgaagtcc aatgcaaagg cgggaatgtc tgcgtgcaag ctcaggatcg ctattacaat    960tcctcatgca gcaagtgggc atgtgttccc tgcagggtcc gatcctag                1008</s400><s200><s210>4</s210><s211>335</s211><s212>PRT</s212><s213>Mus musculus</s213></s200><s400> 4Met Cys Pro Gln Lys Leu Thr Ile Ser Trp Phe Ala Ile Val Leu Leu1               5                   10                  15Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val            20                  25                  30Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val Lys65                  70                  75                  80Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Thr                85                  90                  95Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile Trp            100                 105                 110Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys        115                 120                 125Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gln    130                 135                 140Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Ser Pro145                 150                 155                 160Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys                165                 170                 175Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gln            180                 185                 190Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu        195                 200                 205Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser    210                 215                 220Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln225                 230                 235                 240Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr Pro                245                 250                 255Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val            260                 265                 270Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys        275                 280                 285Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gln    290                 295                 300Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn305                 310                 315                 320Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser                325                 330                 335</s400><s200><s210>5</s210><s211>1444</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 5tttcattttg ggccgagctg gaggcggcgg ggccgtcccg gaacggctgc ggccgggcac     60cccgggagtt aatccgaaag cgccgcaagc cccgcgggcc ggccgcaccg cacgtgtcac    120cgagaagctg atgtagagag agacacagaa ggagacagaa agcaagagac cagagtcccg    180ggaaagtcct gccgcgcctc gggacaatta taaaaatgtg gccccctggg tcagcctccc    240agccaccgcc ctcacctgcc gcggccacag gtctgcatcc agcggctcgc cctgtgtccc    300tgcagtgccg gctcagcatg tgtccagcgc gcagcctcct ccttgtggct accctggtcc    360tcctggacca cctcagtttg gccagaaacc tccccgtggc cactccagac ccaggaatgt    420tcccatgcct tcaccactcc caaaacctgc tgagggccgt cagcaacatg ctccagaagg    480ccagacaaac tctagaattt tacccttgca cttctgaaga gattgatcat gaagatatca    540caaaagataa aaccagcaca gtggaggcct gtttaccatt ggaattaacc aagaatgaga    600gttgcctaaa ttccagagag acctctttca taactaatgg gagttgcctg gcctccagaa    660agacctcttt tatgatggcc ctgtgcctta gtagtattta tgaagacttg aagatgtacc    720aggtggagtt caagaccatg aatgcaaagc ttctgatgga tcctaagagg cagatctttc    780tagatcaaaa catgctggca gttattgatg agctgatgca ggccctgaat ttcaacagtg    840agactgtgcc acaaaaatcc tcccttgaag aaccggattt ttataaaact aaaatcaagc    900tctgcatact tcttcatgct ttcagaattc gggcagtgac tattgataga gtgatgagct    960atctgaatgc ttcctaaaaa gcgaggtccc tccaaaccgt tgtcattttt ataaaacttt   1020gaaatgagga aactttgata ggatgtggat taagaactag ggagggggaa agaaggatgg   1080gactattaca tccacatgat acctctgatc aagtattttt gacatttact gtggataaat   1140tgtttttaag ttttcatgaa tgaattgcta agaagggaaa atatccatcc tgaaggtgtt   1200tttcattcac tttaatagaa gggcaaatat ttataagcta tttctgtacc aaagtgtttg   1260tggaaacaaa catgtaagca taacttattt taaaatattt atttatataa cttggtaatc   1320atgaaagcat ctgagctaac ttatatttat ttatgttata tttattaaat tatttatcaa   1380gtgtatttga aaaatatttt taagtgttct aaaaataaaa gtattgaatt aaagtgaaaa   1440aaaa                                                                1444</s400><s200><s210>6</s210><s211>253</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 6Met Trp Pro Pro Gly Ser Ala Ser Gln Pro Pro Pro Ser Pro Ala Ala1               5                   10                  15Ala Thr Gly Leu His Pro Ala Ala Arg Pro Val Ser Leu Gln Cys Arg            20                  25                  30Leu Ser Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val        35                  40                  45Leu Leu Asp His Leu Ser Leu Ala Arg Asn Leu Pro Val Ala Thr Pro    50                  55                  60Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn Leu Leu Arg65                  70                  75                  80Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe Tyr                85                  90                  95Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys            100                 105                 110Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn Glu        115                 120                 125Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly Ser Cys    130                 135                 140Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Ser Ser145                 150                 155                 160Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr Met Asn                165                 170                 175Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn            180                 185                 190Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser        195                 200                 205Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys    210                 215                 220Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala225                 230                 235                 240Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser                245                 250</s400><s200><s210>7</s210><s211>2347</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 7ctgtttcagg gccattggac tctccgtcct gcccagagca agatgtgtca ccagcagttg     60gtcatctctt ggttttccct ggtttttctg gcatctcccc tcgtggccat atgggaactg    120aagaaagatg tttatgtcgt agaattggat tggtatccgg atgcccctgg agaaatggtg    180gtcctcacct gtgacacccc tgaagaagat ggtatcacct ggaccttgga ccagagcagt    240gaggtcttag gctctggcaa aaccctgacc atccaagtca aagagtttgg agatgctggc    300cagtacacct gtcacaaagg aggcgaggtt ctaagccatt cgctcctgct gcttcacaaa    360aaggaagatg gaatttggtc cactgatatt ttaaaggacc agaaagaacc caaaaataag    420acctttctaa gatgcgaggc caagaattat tctggacgtt tcacctgctg gtggctgacg    480acaatcagta ctgatttgac attcagtgtc aaaagcagca gaggctcttc tgacccccaa    540ggggtgacgt gcggagctgc tacactctct gcagagagag tcagagggga caacaaggag    600tatgagtact cagtggagtg ccaggaggac agtgcctgcc cagctgctga ggagagtctg    660cccattgagg tcatggtgga tgccgttcac aagctcaagt atgaaaacta caccagcagc    720ttcttcatca gggacatcat caaacctgac ccacccaaga acttgcagct gaagccatta    780aagaattctc ggcaggtgga ggtcagctgg gagtaccctg acacctggag tactccacat    840tcctacttct ccctgacatt ctgcgttcag gtccagggca agagcaagag agaaaagaaa    900gatagagtct tcacggacaa gacctcagcc acggtcatct gccgcaaaaa tgccagcatt    960agcgtgcggg cccaggaccg ctactatagc tcatcttgga gcgaatgggc atctgtgccc   1020tgcagttagg ttctgatcca ggatgaaaat ttggaggaaa agtggaagat attaagcaaa   1080atgtttaaag acacaacgga atagacccaa aaagataatt tctatctgat ttgctttaaa   1140acgttttttt aggatcacaa tgatatcttt gctgtatttg tatagttaga tgctaaatgc   1200tcattgaaac aatcagctaa tttatgtata gattttccag ctctcaagtt gccatgggcc   1260ttcatgctat ttaaatattt aagtaattta tgtatttatt agtatattac tgttatttaa   1320cgtttgtctg ccaggatgta tggaatgttt catactctta tgacctgatc catcaggatc   1380agtccctatt atgcaaaatg tgaatttaat tttatttgta ctgacaactt ttcaagcaag   1440gctgcaagta catcagtttt atgacaatca ggaagaatgc agtgttctga taccagtgcc   1500atcatacact tgtgatggat gggaacgcaa gagatactta catggaaacc tgacaatgca   1560aacctgttga gaagatccag gagaacaaga tgctagttcc catgtctgtg aagacttcct   1620ggagatggtg ttgataaagc aatttagggc cacttacact tctaagcaag tttaatcttt   1680ggatgcctga attttaaaag ggctagaaaa aaatgattga ccagcctggg aaacataaca   1740agaccccgtc tctacaaaaa aaatttaaaa ttagccaggc gtggtggctc atgcttgtgg   1800tcccagctgt tcaggaggat gaggcaggag gatctcttga gcccaggagg tcaaggctat   1860ggtgagccgt gattgtgcca ctgcatacca gcctaggtga cagaatgaga ccctgtctca   1920aaaaaaaaaa tgattgaaat taaaattcag ctttagcttc catggcagtc ctcaccccca   1980cctctctaaa agacacagga ggatgacaca gaaacaccgt aagtgtctgg aaggcaaaaa   2040gatcttaaga ttcaagagag aggacaagta gttatggcta aggacatgaa attgtcagaa   2100tggcaggtgg cttcttaaca gccctgtgag aagcagacag atgcaaagaa aatctggaat   2160ccctttctca ttagcatgaa tgaacctgat acacaattat gaccagaaaa tatggctcca   2220tgaaggtgct acttttaagt aatgtatgtg cgctctgtaa agtgattaca tttgtttcct   2280gtttgtttat ttatttattt atttttgcat tctgaggctg aactaataaa aactcttctt   2340tgtaatc                                                             2347</s400><s200><s210>8</s210><s211>328</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 8Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu1               5                   10                  15Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln    50                  55                  60Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys65                  70                  75                  80Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val                85                  90                  95Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe        115                 120                 125Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp    130                 135                 140Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser                165                 170                 175Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu            180                 185                 190Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile        195                 200                 205Glu Val Met Val Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr    210                 215                 220Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn225                 230                 235                 240Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp                245                 250                 255Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr            260                 265                 270Phe Cys Val Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg        275                 280                 285Val Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala    290                 295                 300Ser Ile Ser Val Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser305                 310                 315                 320Glu Trp Ala Ser Val Pro Cys Ser                325</s400><s200><s210>9</s210><s211>1176</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>nucleic acid sequence encoding an IL-12p40-FG      polypeptide</s223></s220></s200><s400> 9atgtgtcctc agaagctaac catctcctgg tttgccatcg ttttgctggt gtctccactc     60atggccatgt gggagctgga gaaagacgtt tatgttgtag aggtggactg gactcccgat    120gcccctggag aaacagtgaa cctcacctgt gacacgcctg aagaagatga catcacctgg    180acctcagacc agagacatgg agtcataggc tctggaaaga ccctgaccat cactgtcaaa    240gagtttctag atgctggcca gtacacctgc cacaaaggag gcgagactct gagccactca    300catctgctgc tccacaagaa ggaaaatgga atttggtcca ctgaaatttt aaaaaatttc    360aaaaacaaga ctttcctgaa gtgtgaagca ccaaattact ccggacggtt cacgtgctca    420tggctggtgc aaagaaacat ggacttgaag ttcaacatca agagcagtag cagttcccct    480gactctcggg cagtgacatg tggaatggcg tctctgtctg cagagaaggt cacactggac    540caaagggact atgagaagta ttcagtgtcc tgccaggagg atgtcacctg cccaactgcc    600gaggagaccc tgcccattga actggcgttg gaagcacggc agcagaataa atatgagaac    660tacagcacca gcttcttcat cagggacatc atcaaaccag acccgcccaa gaacttgcag    720atgaagcctt tgaagaactc acaggtggag gtcagctggg agtaccctga ctcctggagc    780actccccatt cctacttctc cctcaagttc tttgttcgaa tccagcgcaa gaaagaaaag    840atgaaggaga cagaggaggg gtgtaaccag aaaggtgcgt tcctcgtaga gaagacatct    900accgaagtcc aatgcaaagg cgggaatgtc tgcgtgcaag ctcaggatcg ctattacaat    960tcctcatgca gcaagtgggc atgtgttccc tgcagggtcc gatccgggcc ggccggtggc   1020ggtgggagcg gtggtggggg ttccggaggc ggagggtcgg tgtcaaccat ctcatcattc   1080tctccacctg ggtaccaagt ctctttctgc ttggtgatgg tactcctttt tgcagtggac   1140acaggactat atttctctgt gaagacaaac atttga                             1176</s400><s200><s210>10</s210><s211>391</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>IL-12p40-FG polypeptide</s223></s220></s200><s400> 10Met Cys Pro Gln Lys Leu Thr Ile Ser Trp Phe Ala Ile Val Leu Leu1               5                   10                  15Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val            20                  25                  30Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val Lys65                  70                  75                  80Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Thr                85                  90                  95Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile Trp            100                 105                 110Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys        115                 120                 125Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gln    130                 135                 140Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Ser Pro145                 150                 155                 160Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys                165                 170                 175Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gln            180                 185                 190Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu        195                 200                 205Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser    210                 215                 220Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln225                 230                 235                 240Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr Pro                245                 250                 255Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val            260                 265                 270Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys        275                 280                 285Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gln    290                 295                 300Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn305                 310                 315                 320Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser Gly                325                 330                 335Pro Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly            340                 345                 350Ser Val Ser Thr Ile Ser Ser Phe Ser Pro Pro Gly Tyr Gln Val Ser        355                 360                 365Phe Cys Leu Val Met Val Leu Leu Phe Ala Val Asp Thr Gly Leu Tyr    370                 375                 380Phe Ser Val Lys Thr Asn Ile385                 390</s400><s200><s210>11</s210><s211>1203</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>nucleic acid sequence encoding an IL-12p40-RG      polypeptide</s223></s220></s200><s400> 11atgtgtcctc agaagctaac catctcctgg tttgccatcg ttttgctggt gtctccactc     60atggccatgt gggagctgga gaaagacgtt tatgttgtag aggtggactg gactcccgat    120gcccctggag aaacagtgaa cctcacctgt gacacgcctg aagaagatga catcacctgg    180acctcagacc agagacatgg agtcataggc tctggaaaga ccctgaccat cactgtcaaa    240gagtttctag atgctggcca gtacacctgc cacaaaggag gcgagactct gagccactca    300catctgctgc tccacaagaa ggaaaatgga atttggtcca ctgaaatttt aaaaaatttc    360aaaaacaaga ctttcctgaa gtgtgaagca ccaaattact ccggacggtt cacgtgctca    420tggctggtgc aaagaaacat ggacttgaag ttcaacatca agagcagtag cagttcccct    480gactctcggg cagtgacatg tggaatggcg tctctgtctg cagagaaggt cacactggac    540caaagggact atgagaagta ttcagtgtcc tgccaggagg atgtcacctg cccaactgcc    600gaggagaccc tgcccattga actggcgttg gaagcacggc agcagaataa atatgagaac    660tacagcacca gcttcttcat cagggacatc atcaaaccag acccgcccaa gaacttgcag    720atgaagcctt tgaagaactc acaggtggag gtcagctggg agtaccctga ctcctggagc    780actccccatt cctacttctc cctcaagttc tttgttcgaa tccagcgcaa gaaagaaaag    840atgaaggaga cagaggaggg gtgtaaccag aaaggtgcgt tcctcgtaga gaagacatct    900accgaagtcc aatgcaaagg cgggaatgtc tgcgtgcaag ctcaggatcg ctattacaat    960tcctcatgca gcaagtgggc atgtgttccc tgcagggtcc gatccgggcc ggccgctgaa   1020gctgccgcaa aagaggccgc tgcgaaggag gccgcggcta aggaggcggc agctaaagct   1080gcagccgtgt caaccatctc atcattctct ccacctgggt accaagtctc tttctgcttg   1140gtgatggtac tcctttttgc agtggacaca ggactatatt tctctgtgaa gacaaacatt   1200tga                                                                 1203</s400><s200><s210>12</s210><s211>400</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>IL-12p40-RG polypeptide</s223></s220></s200><s400> 12Met Cys Pro Gln Lys Leu Thr Ile Ser Trp Phe Ala Ile Val Leu Leu1               5                   10                  15Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val            20                  25                  30Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val Lys65                  70                  75                  80Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Thr                85                  90                  95Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile Trp            100                 105                 110Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys        115                 120                 125Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gln    130                 135                 140Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Ser Pro145                 150                 155                 160Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys                165                 170                 175Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gln            180                 185                 190Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu        195                 200                 205Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser    210                 215                 220Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln225                 230                 235                 240Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr Pro                245                 250                 255Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val            260                 265                 270Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys        275                 280                 285Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gln    290                 295                 300Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn305                 310                 315                 320Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser Gly                325                 330                 335Pro Ala Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala            340                 345                 350Ala Lys Glu Ala Ala Ala Lys Ala Ala Ala Val Ser Thr Ile Ser Ser        355                 360                 365Phe Ser Pro Pro Gly Tyr Gln Val Ser Phe Cys Leu Val Met Val Leu    370                 375                 380Leu Phe Ala Val Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr Asn Ile385                 390                 395                 400</s400><s200><s210>13</s210><s211>15</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220></s200><s400> 13Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1               5                   10                  15</s400><s200><s210>14</s210><s211>24</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220></s200><s400> 14Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1               5                   10                  15Glu Ala Ala Ala Lys Ala Ala Ala            20</s400><s200><s210>15</s210><s211>6</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220></s200><s400> 15Gly Gly Gly Gly Gly Gly1               5</s400><s200><s210>16</s210><s211>8</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220></s200><s400> 16Gly Gly Gly Gly Gly Gly Gly Gly1               5</s400><s200><s210>17</s210><s211>5</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220><s220><s221>REPEAT</s221><s222>(1)..(5)</s222><s223>residues 1-5 can be repeated 1-3 times</s223></s220></s200><s400> 17Glu Ala Ala Ala Lys1               5</s400><s200><s210>18</s210><s211>46</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220></s200><s400> 18Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1               5                   10                  15Glu Ala Ala Ala Lys Ala Leu Glu Ala Glu Ala Ala Ala Lys Glu Ala            20                  25                  30Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala        35                  40                  45</s400><s200><s210>19</s210><s211>5</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220><s220><s221>REPEAT</s221><s222>(1)..(5)</s222><s223>residues 1-5 can be repeated 1, 2, or 4 times</s223></s220></s200><s400> 19Gly Gly Gly Gly Ser1               5</s400><s200><s210>20</s210><s211>12</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220></s200><s400> 20Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala1               5                   10</s400><s200><s210>21</s210><s211>5</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220></s200><s400> 21Pro Ala Pro Ala Pro1               5</s400><s200><s210>22</s210><s211>20</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>peptide linker</s223></s220></s200><s400> 22Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly            20</s400><s200><s210>23</s210><s211>40</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 23ggcggtcgac gagctcatgt gtcctcagaa gctaaccatc                           40</s400><s200><s210>24</s210><s211>36</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 24ccgcgttaac ctaggatcgg accctgcagg gaacac                               36</s400><s200><s210>25</s210><s211>33</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 25ggcggtcgac atggtcagcg ttccaacagc ctc                                  33</s400><s200><s210>26</s210><s211>34</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 26cgcgggcgcg cctcaggcgg agctcagata gccc                                 34</s400><s200><s210>27</s210><s211>40</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 27ggcggtcgac gagctcatgt gtcctcagaa gctaaccatc                           40</s400><s200><s210>28</s210><s211>36</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 28ccgcggccgg cccggatcgg accctgcagg gaacac                               36</s400><s200><s210>29</s210><s211>40</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 29ggcggtcgac gagctcatgt gtcctcagaa gctaaccatc                           40</s400><s200><s210>30</s210><s211>32</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 30gcgcgttaac tcaaatgttt gtcttcacag ag                                   32</s400><s200><s210>31</s210><s211>33</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 31ggcggtcgac atggtcagcg ttccaacagc ctc                                  33</s400><s200><s210>32</s210><s211>34</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 32cgcgggcgcg cctcaggcgg agctcagata gccc                                 34</s400><s200><s210>33</s210><s211>60</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 33ggccggccgg ccgctgaagc tgccgcaaaa gaggccgctg cgaaggaggc cgcggctaag     60</s400><s200><s210>34</s210><s211>32</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 34gcgcgttaac tcaaatgttt gtcttcacag ag                                   32</s400><s200><s210>35</s210><s211>40</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 35ggcggtcgac gagctcatgt gtcctcagaa gctaaccatc                           40</s400><s200><s210>36</s210><s211>32</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 36gcgcgttaac tcaaatgttt gtcttcacag ag                                   32</s400><s200><s210>37</s210><s211>33</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 37ggcggtcgac atggtcagcg ttccaacagc ctc                                  33</s400><s200><s210>38</s210><s211>34</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>oligonucleotide primer</s223></s220></s200><s400> 38cgcgggcgcg cctcaggcgg agctcagata gccc                                 34</s400><s200><s210>39</s210><s211>20</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>membrane anchoring polypeptide</s223></s220></s200><s400> 39Ser Phe Ser Pro Pro Gly Tyr Gln Val Ser Phe Cys Leu Val Met Val1               5                   10                  15Leu Leu Phe Ala            20</s400><s200><s210>40</s210><s211>34</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>membrane anchoring polypeptide</s223></s220></s200><s400> 40Ser Ser Phe Ser Pro Pro Gly Tyr Gln Val Ser Phe Cys Leu Val Met1               5                   10                  15Val Leu Leu Phe Ala Val Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr            20                  25                  30Asn Ile</s400><s200><s210>41</s210><s211>47</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>membrane anchoring polypeptide</s223></s220></s200><s400> 41Cys Leu Glu Pro Tyr Thr Ala Cys Asp Leu Ala Pro Arg Ala Gly Thr1               5                   10                  15Thr Asp Ala Ala His Pro Gly Pro Ser Val Val Pro Ala Leu Leu Pro            20                  25                  30Leu Leu Ala Gly Thr Leu Leu Leu Leu Gly Thr Ala Thr Ala Pro        35                  40                  45</s400><s200><s210>42</s210><s211>48</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>membrane anchoring polypeptide</s223></s220></s200><s400> 42Thr Thr Cys Ile Pro Ser Ser Gly His Ser Arg His Arg Tyr Ala Leu1               5                   10                  15Ile Pro Ile Pro Leu Ala Val Ile Thr Thr Cys Ile Val Leu Tyr Met            20                  25                  30Asn Gly Ile Leu Lys Cys Asp Arg Lys Pro Asp Arg Thr Asn Ser Asn        35                  40                  45</s400><s200><s210>43</s210><s211>37</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>membrane anchoring polypeptide</s223></s220></s200><s400> 43Pro Asn Lys Gly Ser Gly Thr Thr Ser Gly Thr Thr Arg Leu Leu Ser1               5                   10                  15Gly His Thr Cys Phe Thr Leu Thr Gly Leu Leu Gly Thr Leu Val Thr            20                  25                  30Met Gly Leu Leu Thr        35</s400><s200><s210>44</s210><s211>32</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>membrane anchoring polypeptide</s223></s220></s200><s400> 44Tyr Thr Val Ser Asn Met Ala Thr Ile Ala Val Val Val Asp Leu Gly1               5                   10                  15Ala Val Ala Ile Ile Gly Ala Val Val Ala Phe Val Met Asn Arg Arg            20                  25                  30</s400><s200><s210>45</s210><s211>77</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>membrane anchoring polypeptide</s223></s220></s200><s400> 45Leu Gln Cys Tyr Asn Cys Pro Asn Pro Thr Ala Asp Cys Lys Thr Ala1               5                   10                  15Val Asn Cys Ser Ser Asp Phe Asp Ala Cys Leu Ile Thr Lys Ala Gly            20                  25                  30Leu Gln Val Tyr Asn Lys Cys Trp Lys Phe Glu His Cys Asn Phe Asn        35                  40                  45Asp Val Thr Thr Arg Leu Arg Glu Asn Glu Leu Thr Tyr Tyr Cys Cys    50                  55                  60Lys Lys Asp Leu Cys Asn Phe Asn Glu Gln Leu Glu Asn65                  70                  75</s400><s200><s210>46</s210><s211>221</s211><s212>PRT</s212><s213>Bos taurus</s213></s200><s400> 46Met Cys Pro Leu Arg Ser Leu Leu Leu Ile Ser Thr Leu Val Leu Leu1               5                   10                  15His His Leu Pro His Leu Ser Leu Gly Arg Ser Leu Pro Thr Thr Thr            20                  25                  30Ala Ser Pro Gly Arg Ser Cys Leu Asp Tyr Ser Gln Asn Leu Leu Arg        35                  40                  45Ala Val Ser Asn Thr Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe Tyr    50                  55                  60Ser Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys65                  70                  75                  80Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Ala Thr Asn Glu                85                  90                  95Ser Cys Leu Ala Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly His Cys            100                 105                 110Leu Ala Ser Gly Lys Thr Ser Phe Met Thr Thr Leu Cys Leu Arg Ser        115                 120                 125Ile Tyr Glu Asp Leu Lys Met Tyr His Val Glu Phe Gln Ala Met Asn    130                 135                 140Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn145                 150                 155                 160Met Leu Ala Ala Ile Ala Glu Leu Met Gln Ala Leu Asn Phe Asp Ser                165                 170                 175Glu Thr Val Pro Gln Lys Pro Ser Leu Lys Glu Leu Asp Phe Tyr Lys            180                 185                 190Thr Lys Val Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala        195                 200                 205Val Thr Ile Asp Arg Met Met Ser Tyr Leu Ser Ser Ser    210                 215                 220</s400><s200><s210>47</s210><s211>221</s211><s212>PRT</s212><s213>Ovis aries</s213></s200><s400> 47Met Cys Pro Leu Arg Ser Leu Leu Leu Ile Ser Thr Leu Val Leu Leu1               5                   10                  15His His Leu Pro His Leu Ser Leu Gly Arg Ser Leu Pro Thr Thr Thr            20                  25                  30Ala Gly Pro Gly Thr Ser Cys Leu Asp Tyr Ser Gln Asn Leu Leu Arg        35                  40                  45Ala Val Ser Asn Thr Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe Tyr    50                  55                  60Ser Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys65                  70                  75                  80Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Ala Thr Asn Glu                85                  90                  95Ser Cys Leu Ala Ser Arg Glu Thr Ser Leu Ile Thr Asn Gly His Cys            100                 105                 110Leu Ser Ser Gly Lys Thr Ser Phe Met Thr Thr Leu Cys Leu Arg Ser        115                 120                 125Ile Tyr Lys Asp Leu Lys Met Tyr His Met Glu Phe Gln Ala Met Asn    130                 135                 140Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Val Phe Leu Asp Gln Asn145                 150                 155                 160Met Leu Ala Ala Ile Ala Glu Leu Met Gln Ala Leu Asn Phe Asp Ser                165                 170                 175Glu Thr Val Pro Gln Lys Pro Ser Leu Glu Glu Leu Asp Phe Tyr Lys            180                 185                 190Thr Lys Val Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala        195                 200                 205Val Thr Ile Asp Arg Met Met Ser Tyr Leu Ser Ser Ser    210                 215                 220</s400><s200><s210>48</s210><s211>256</s211><s212>PRT</s212><s213>Sus scrofa</s213></s200><s400> 48Met Cys Ser Pro Gly Phe Gly Leu Gln Thr Ser Asp Leu Thr Cys Asp1               5                   10                  15Val His Pro Ser Ala Ser Ser Arg Arg Leu Ala Val Thr Ala Ala Pro            20                  25                  30Leu Ser Met Cys Pro Leu Arg Asn Leu Leu Leu Val Ala Thr Leu Val        35                  40                  45Leu Leu Asn His Leu Asp His Leu Ser Leu Gly Arg Ser Leu Pro Ala    50                  55                  60Thr Thr Ala Gly Pro Gly Met Phe Lys Cys Leu Asn His Ser Gln Asn65                  70                  75                  80Leu Leu Lys Ala Val Ser Asn Thr Leu Gln Lys Ala Lys Gln Thr Leu                85                  90                  95Glu Phe Tyr Ser Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr            100                 105                 110Lys Asp Lys Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Ala        115                 120                 125Thr Asn Glu Ser Cys Leu Ala Ala Arg Glu Thr Ser Leu Ile Thr Asn    130                 135                 140Gly Asn Cys Leu Thr Ser Gly Lys Thr Ser Phe Met Thr Thr Leu Cys145                 150                 155                 160Leu Ser Ser Ile Tyr Glu Asp Leu Lys Met Tyr His Val Glu Phe Gln                165                 170                 175Ala Met Asn Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu            180                 185                 190Asp Gln Asn Met Leu Thr Ala Ile Thr Glu Leu Met Gln Ala Leu Asn        195                 200                 205Phe Asn Ser Glu Thr Val Pro Gln Lys Pro Ser Leu Glu Glu Leu Asp    210                 215                 220Phe Tyr Lys Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg225                 230                 235                 240Ile Arg Ala Val Thr Ile Asp Arg Met Met Ser Tyr Leu Asn Ser Ser                245                 250                 255</s400><s200><s210>49</s210><s211>222</s211><s212>PRT</s212><s213>Felis catus</s213></s200><s400> 49Met Cys Pro Pro Arg Gly Leu Leu Leu Val Thr Ile Leu Val Leu Leu1               5                   10                  15Asn His Leu Asp His Leu Ser Leu Ala Arg Asn Leu Pro Thr Pro Thr            20                  25                  30Pro Ser Pro Gly Met Phe Gln Cys Leu Asn His Ser Gln Thr Leu Leu        35                  40                  45Arg Ala Ile Ser Asn Thr Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe    50                  55                  60Tyr Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp65                  70                  75                  80Lys Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Met Asn                85                  90                  95Glu Ser Cys Leu Ala Ser Arg Glu Ile Ser Leu Ile Thr Asn Gly Ser            100                 105                 110Cys Leu Ala Ser Arg Lys Thr Ser Phe Met Thr Thr Leu Cys Leu Ser        115                 120                 125Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Ala Met    130                 135                 140Asn Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln145                 150                 155                 160Asn Met Leu Thr Ala Ile Asp Glu Leu Leu Gln Ala Leu Asn Val Asn                165                 170                 175Ser Val Thr Val Pro Gln Asn Ser Ser Leu Glu Glu Pro Asp Phe Tyr            180                 185                 190Lys Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg        195                 200                 205Ala Val Thr Ile Asn Arg Met Met Ser Tyr Leu Asn Ser Ser    210                 215                 220</s400><s200><s210>50</s210><s211>253</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 50Met Trp Pro Pro Gly Ser Ala Ser Gln Pro Pro Pro Ser Pro Ala Ala1               5                   10                  15Ala Thr Gly Leu His Pro Ala Ala Arg Pro Val Ser Leu Gln Cys Arg            20                  25                  30Leu Ser Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val        35                  40                  45Leu Leu Asp His Leu Ser Leu Ala Arg Asn Leu Pro Val Ala Thr Pro    50                  55                  60Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn Leu Leu Arg65                  70                  75                  80Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe Tyr                85                  90                  95Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys            100                 105                 110Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn Glu        115                 120                 125Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly Ser Cys    130                 135                 140Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Ser Ser145                 150                 155                 160Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr Met Asn                165                 170                 175Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn            180                 185                 190Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser        195                 200                 205Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys    210                 215                 220Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala225                 230                 235                 240Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser                245                 250</s400><s200><s210>51</s210><s211>253</s211><s212>PRT</s212><s213>Papio anubis</s213></s200><s400> 51Met Trp Pro Pro Gly Ser Ala Ser Gln Pro Pro Pro Ser Pro Ala Thr1               5                   10                  15Ala Thr Gly Leu His Pro Ala Ala Arg Pro Val Ser Leu Gln Cys Arg            20                  25                  30Leu Ser Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val        35                  40                  45Leu Leu Asp Tyr Leu Ser Leu Ala Arg Asn Leu Ser Val Ala Thr Pro    50                  55                  60Gly Pro Glu Met Phe Pro Cys Leu His His Ser Gln Asn Leu Leu Lys65                  70                  75                  80Ala Ala Ser Asn Thr Leu Gln Lys Ala Arg Gln Ile Leu Glu Phe Tyr                85                  90                  95Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys            100                 105                 110Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Ile Lys Asn Glu        115                 120                 125Ser Cys Leu Asn Ser Arg Glu Thr Ser Val Ile Thr Lys Gly Ser Cys    130                 135                 140Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Arg Ser145                 150                 155                 160Ile Tyr Glu Asp Leu Gln Ile Tyr Gln Val Glu Phe Lys Thr Met Asn                165                 170                 175Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn            180                 185                 190Ile Leu Gly Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser        195                 200                 205Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys    210                 215                 220Thr Lys Ile Arg Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala225                 230                 235                 240Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser                245                 250</s400><s200><s210>52</s210><s211>328</s211><s212>PRT</s212><s213>Macaca mulatta</s213></s200><s400> 52Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu1               5                   10                  15Ala Ser Pro Leu Met Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln    50                  55                  60Ser Gly Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys65                  70                  75                  80Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Ala                85                  90                  95Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Val Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe        115                 120                 125Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp    130                 135                 140Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Ser Asn Pro Gln Gly Val Thr Cys Gly Ala Val Thr Leu Ser                165                 170                 175Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu            180                 185                 190Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Arg Leu Pro Ile        195                 200                 205Glu Val Met Val Asp Ala Ile His Lys Leu Lys Tyr Glu Asn Tyr Thr    210                 215                 220Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn225                 230                 235                 240Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp                245                 250                 255Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr            260                 265                 270Phe Cys Ile Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg        275                 280                 285Ile Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala    290                 295                 300Ser Phe Ser Val Gln Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser305                 310                 315                 320Glu Trp Ala Ser Val Pro Cys Ser                325</s400><s200><s210>53</s210><s211>236</s211><s212>PRT</s212><s213>Mus musculus</s213></s200><s400> 53Met Val Ser Val Pro Thr Ala Ser Pro Ser Ala Ser Ser Ser Ser Ser1               5                   10                  15Gln Cys Arg Ser Ser Met Cys Gln Ser Arg Tyr Leu Leu Phe Leu Ala            20                  25                  30Thr Leu Ala Leu Leu Asn His Leu Ser Leu Ala Arg Val Ile Pro Val        35                  40                  45Ser Gly Pro Ala Arg Cys Leu Ser Gln Ser Arg Asn Leu Leu Lys Thr    50                  55                  60Thr Asp Asp Met Val Lys Thr Ala Arg Glu Lys Leu Lys His Tyr Ser65                  70                  75                  80Cys Thr Ala Glu Asp Ile Asp His Glu Asp Ile Thr Arg Asp Gln Thr                85                  90                  95Ser Thr Leu Lys Thr Cys Leu Pro Leu Glu Leu His Lys Asn Glu Ser            100                 105                 110Cys Leu Ala Thr Arg Glu Thr Ser Ser Thr Thr Arg Gly Ser Cys Leu        115                 120                 125Pro Pro Gln Lys Thr Ser Leu Met Met Thr Leu Cys Leu Gly Ser Ile    130                 135                 140Tyr Glu Asp Leu Lys Met Tyr Gln Thr Glu Phe Gln Ala Ile Asn Ala145                 150                 155                 160Ala Leu Gln Asn His Asn His Gln Gln Ile Ile Leu Asp Lys Gly Met                165                 170                 175Leu Val Ala Ile Asp Glu Leu Met Gln Ser Leu Asn His Asn Gly Glu            180                 185                 190Thr Leu Arg Gln Lys Pro Pro Val Gly Glu Ala Asp Pro Tyr Arg Val        195                 200                 205Lys Met Lys Leu Cys Ile Leu Leu His Ala Phe Ser Thr Arg Val Val    210                 215                 220Thr Ile Asn Arg Val Met Gly Tyr Leu Ser Ser Ala225                 230                 235</s400><s200><s210>54</s210><s211>215</s211><s212>PRT</s212><s213>Rattus norvegicus</s213></s200><s400> 54Met Cys Gln Ser Arg Tyr Leu Leu Phe Leu Ala Thr Leu Val Leu Leu1               5                   10                  15Asn His Leu Thr Ser Ala Arg Val Ile Pro Val Ser Gly Pro Ala Lys            20                  25                  30Cys Leu Asn Gln Ser Gln Asn Leu Leu Lys Thr Thr Asp Asp Met Val        35                  40                  45Arg Thr Ala Arg Glu Lys Leu Lys His Tyr Ser Cys Thr Ala Gly Asp    50                  55                  60Ile Asp His Glu Asp Ile Thr Arg Asp Lys Thr Ser Thr Leu Glu Ala65                  70                  75                  80Cys Leu Pro Leu Glu Leu His Lys Asn Glu Ser Cys Leu Ala Thr Lys                85                  90                  95Glu Thr Ser Ser Ile Ile Arg Gly Ser Cys Leu Pro Pro Gln Lys Thr            100                 105                 110Ser Leu Met Met Thr Leu Cys Leu Gly Ser Ile Tyr Glu Asp Leu Lys        115                 120                 125Met Tyr Gln Ser Glu Phe Gln Ala Ile Asn Ala Ala Leu Gln Ser His    130                 135                 140Asn His Gln Gln Ile Thr Leu Asp Arg Asn Met Leu Met Ala Ile Asp145                 150                 155                 160Glu Leu Met Arg Ser Leu Asn His Ser Gly Glu Thr Leu His Gln Lys                165                 170                 175Ala Pro Met Gly Glu Ala Asp Pro Tyr Arg Val Lys Met Lys Leu Cys            180                 185                 190Ile Leu Leu His Ala Phe Ser Thr Arg Val Met Thr Ile Asn Arg Val        195                 200                 205Met Asn Tyr Leu Ser Ser Ser    210                 215</s400><s200><s210>55</s210><s211>139</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>consensus IL-12p35 polypeptide sequence</s223></s220></s200><s400> 55Asp Ile Thr Lys Asp Lys Thr Ser Thr Val Glu Ala Cys Leu Pro Leu1               5                   10                  15Glu Leu Asn Glu Ser Cys Leu Ala Ser Arg Glu Thr Ser Ile Thr Asn            20                  25                  30Gly Ser Cys Leu Ala Ser Lys Thr Ser Phe Met Met Thr Leu Cys Leu        35                  40                  45Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Gln Ala Met    50                  55                  60Asn Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln65                  70                  75                  80Asn Met Leu Ala Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser                85                  90                  95Glu Thr Val Pro Gln Lys Ser Leu Glu Glu Asp Phe Tyr Lys Thr Lys            100                 105                 110Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala Val Thr        115                 120                 125Ile Asp Arg Met Met Ser Tyr Leu Ser Ser Ser    130                 135</s400><s200><s210>56</s210><s211>250</s211><s212>PRT</s212><s213>Bos taurus</s213></s200><s400> 56Met His Pro Gln Gln Leu Val Val Ser Trp Phe Ser Leu Val Leu Leu1               5                   10                  15Ala Ser Pro Ile Val Ala Met Trp Glu Leu Glu Lys Asn Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Thr Val Val Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys65                  70                  75                  80Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Ala                85                  90                  95Leu Ser Arg Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Ala Lys Ser Phe        115                 120                 125Leu Lys Cys Glu Ala Lys Asp Tyr Ser Gly His Phe Thr Cys Trp Trp    130                 135                 140Leu Thr Ala Ile Ser Thr Asp Leu Lys Phe Ser Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Ser Asp Pro Arg Gly Val Thr Cys Gly Ala Ala Leu Leu Ser                165                 170                 175Ala Glu Lys Val Ser Leu Glu His Arg Glu Tyr Asn Lys Tyr Thr Val            180                 185                 190Glu Cys Gln Glu Gly Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Leu        195                 200                 205Ile Glu Val Val Val Glu Ala Val His Lys Leu Lys Tyr Glu Asn Tyr    210                 215                 220Thr Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys225                 230                 235                 240Asn Leu Gln Leu Arg Pro Leu Lys Asn Ser                245                 250</s400><s200><s210>57</s210><s211>327</s211><s212>PRT</s212><s213>Ovis aries</s213></s200><s400> 57Met His Pro Gln Gln Leu Val Val Ser Trp Phe Ser Leu Val Leu Leu1               5                   10                  15Ala Ser Pro Ile Val Ala Ile Trp Glu Leu Glu Lys Asn Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp Tyr Pro Asn Ala Pro Gly Glu Thr Val Val Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys65                  70                  75                  80Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val                85                  90                  95Leu Ser Arg Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Ala Lys Ser Phe        115                 120                 125Leu Lys Cys Glu Ala Lys Asp Tyr Ser Gly His Phe Thr Cys Ser Trp    130                 135                 140Leu Thr Ala Ile Ser Thr Asn Leu Lys Phe Ser Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Ser Asp Pro Arg Gly Val Thr Cys Gly Ala Ala Ser Leu Ser                165                 170                 175Ala Glu Lys Val Ser Met Asp His Arg Glu Tyr Asn Lys Tyr Thr Val            180                 185                 190Glu Cys Gln Glu Gly Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro        195                 200                 205Ile Glu Val Val Met Glu Ala Val His Lys Leu Lys Tyr Glu Asn Tyr    210                 215                 220Thr Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys225                 230                 235                 240Asn Leu Gln Leu Arg Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser                245                 250                 255Trp Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu            260                 265                 270Thr Phe Cys Val Gln Val Gln Gly Lys Asn Lys Arg Glu Lys Lys Leu        275                 280                 285Phe Thr Asp Gln Thr Ser Ala Lys Val Thr Cys His Lys Asp Ala Asn    290                 295                 300Ile Arg Val Gln Ala Arg Asp Arg Tyr Tyr Ser Ser Phe Trp Ser Glu305                 310                 315                 320Trp Ala Ser Val Ser Cys Ser                325</s400><s200><s210>58</s210><s211>324</s211><s212>PRT</s212><s213>Sus scrofa</s213></s200><s400> 58Met His Leu Gln Gln Leu Val Val Ser Trp Phe Ser Leu Val Trp Leu1               5                   10                  15Ala Ser Pro Ile Val Ala Ile Trp Glu Leu Glu Lys Asn Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp Tyr Pro Asn Ala Pro Gly Glu Met Val Val Leu        35                  40                  45Thr Cys Asn Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Ser Ser Glu Val Leu Gly Thr Gly Lys Thr Leu Thr Ile His Val Lys65                  70                  75                  80Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys Arg Lys Gly Gly Ala Val                85                  90                  95Leu Ser Gln Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Ser Phe        115                 120                 125Leu Lys Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp    130                 135                 140Leu Thr Ala Ile Ser Thr Asp Leu Lys Phe Ser Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Thr Asp Pro Arg Gly Val Thr Cys Gly Thr Ala Thr Leu Ser                165                 170                 175Glu Asp Leu Gly Glu Tyr Lys Lys Tyr Arg Val Glu Cys Gln Glu Gly            180                 185                 190Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile Glu Val Val Leu        195                 200                 205Glu Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr Ser Ser Phe Phe    210                 215                 220Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln Leu Asn225                 230                 235                 240Pro Leu Lys Asn Ser Arg His Val Glu Ile Ser Trp Glu Tyr Pro Asp                245                 250                 255Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Met Phe Gly Val Gln            260                 265                 270Val Gln Gly Lys Asn Lys Arg Glu Lys Lys Asp Lys Leu Phe Thr Asp        275                 280                 285Gln Ile Ser Ala Lys Val Thr Cys His Lys Asp Ala Asn Ile Arg Val    290                 295                 300Gln Ala Arg Asp Arg Tyr Tyr Ser Ser Ser Trp Ser Glu Trp Ala Ser305                 310                 315                 320Val Ser Cys Asn</s400><s200><s210>59</s210><s211>329</s211><s212>PRT</s212><s213>Felis catus</s213></s200><s400> 59Met His Pro Gln Gln Leu Val Ile Ala Trp Leu Ser Leu Val Leu Leu1               5                   10                  15Ala Pro Pro Leu Met Ala Ile Trp Glu Leu Glu Lys Asn Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp His Pro Asp Ala Pro Gly Glu Met Val Val Leu        35                  40                  45Thr Cys Asn Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys65                  70                  75                  80Glu Phe Ala Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val                85                  90                  95Leu Ser His Ser Phe Leu Leu Ile His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Ile Leu Arg Glu Gln Lys Glu Ser Lys Asn Lys Ile Phe        115                 120                 125Leu Lys Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp    130                 135                 140Leu Thr Ala Ile Ser Thr Asp Leu Lys Phe Thr Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Ser Asp Pro Gln Glu Val Thr Cys Gly Ala Ala Thr Leu Ser                165                 170                 175Ala Glu Lys Val Arg Val Asp Asn Arg Asp Tyr Lys Lys Tyr Thr Val            180                 185                 190Glu Cys Gln Glu Gly Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro        195                 200                 205Ile Glu Val Val Val Asp Ala Ile His Lys Leu Lys Tyr Glu Asn Tyr    210                 215                 220Thr Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys225                 230                 235                 240Asn Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg His Val Glu Val Ser                245                 250                 255Trp Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu            260                 265                 270Thr Phe Gly Val Gln Val Gln Gly Lys Asn Asn Arg Glu Lys Lys Asp        275                 280                 285Arg Leu Ser Val Asp Lys Thr Ser Ala Lys Val Val Cys His Lys Asp    290                 295                 300Ala Lys Ile Arg Val Gln Ala Arg Asp Arg Tyr Tyr Ser Ser Ser Trp305                 310                 315                 320Ser Asn Trp Ala Ser Val Ser Cys Ser                325</s400><s200><s210>60</s210><s211>328</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 60Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu1               5                   10                  15Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln    50                  55                  60Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys65                  70                  75                  80Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val                85                  90                  95Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe        115                 120                 125Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp    130                 135                 140Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser                165                 170                 175Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu            180                 185                 190Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile        195                 200                 205Glu Val Met Val Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr    210                 215                 220Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn225                 230                 235                 240Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp                245                 250                 255Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr            260                 265                 270Phe Cys Val Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg        275                 280                 285Val Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala    290                 295                 300Ser Ile Ser Val Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser305                 310                 315                 320Glu Trp Ala Ser Val Pro Cys Ser                325</s400><s200><s210>61</s210><s211>328</s211><s212>PRT</s212><s213>Macaca mulatta</s213></s200><s400> 61Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu1               5                   10                  15Ala Ser Pro Leu Met Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln    50                  55                  60Ser Gly Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys65                  70                  75                  80Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Ala                85                  90                  95Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Val Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe        115                 120                 125Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp    130                 135                 140Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Ser Asn Pro Gln Gly Val Thr Cys Gly Ala Val Thr Leu Ser                165                 170                 175Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu            180                 185                 190Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Arg Leu Pro Ile        195                 200                 205Glu Val Met Val Asp Ala Ile His Lys Leu Lys Tyr Glu Asn Tyr Thr    210                 215                 220Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn225                 230                 235                 240Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp                245                 250                 255Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr            260                 265                 270Phe Cys Ile Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg        275                 280                 285Ile Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala    290                 295                 300Ser Phe Ser Val Gln Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser305                 310                 315                 320Glu Trp Ala Ser Val Pro Cys Ser                325</s400><s200><s210>62</s210><s211>328</s211><s212>PRT</s212><s213>Papio anubis</s213></s200><s400> 62Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu1               5                   10                  15Ala Ser Pro Leu Met Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val            20                  25                  30Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln    50                  55                  60Ser Gly Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys65                  70                  75                  80Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Ala                85                  90                  95Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp            100                 105                 110Ser Thr Asp Val Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe        115                 120                 125Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp    130                 135                 140Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg145                 150                 155                 160Gly Ser Ser Asn Pro Gln Gly Val Thr Cys Gly Ala Val Thr Leu Ser                165                 170                 175Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu            180                 185                 190Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Arg Leu Pro Ile        195                 200                 205Glu Val Met Val Asp Ala Ile His Lys Leu Lys Tyr Glu Asn Tyr Thr    210                 215                 220Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn225                 230                 235                 240Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Ala Glu Val Ser Trp                245                 250                 255Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr            260                 265                 270Phe Cys Ile Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg        275                 280                 285Ile Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala    290                 295                 300Ser Phe Ser Val Gln Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser305                 310                 315                 320Glu Trp Ala Ser Val Pro Cys Ser                325</s400><s200><s210>63</s210><s211>335</s211><s212>PRT</s212><s213>Mus musculus</s213></s200><s400> 63Met Cys Pro Gln Lys Leu Thr Ile Ser Trp Phe Ala Ile Val Leu Leu1               5                   10                  15Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val            20                  25                  30Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu        35                  40                  45Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val Lys65                  70                  75                  80Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Thr                85                  90                  95Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile Trp            100                 105                 110Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys        115                 120                 125Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gln    130                 135                 140Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Ser Pro145                 150                 155                 160Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys                165                 170                 175Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gln            180                 185                 190Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu        195                 200                 205Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser    210                 215                 220Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln225                 230                 235                 240Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr Pro                245                 250                 255Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val            260                 265                 270Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys        275                 280                 285Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gln    290                 295                 300Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn305                 310                 315                 320Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser                325                 330                 335</s400><s200><s210>64</s210><s211>335</s211><s212>PRT</s212><s213>Rattus norvegicus</s213></s200><s400> 64Met Cys His Gln Lys Leu Thr Phe Ser Trp Phe Ala Met Val Leu Leu1               5                   10                  15Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val            20                  25                  30Val Glu Val Asp Trp Arg Pro Asp Ala Pro Gly Glu Thr Val Thr Leu        35                  40                  45Thr Cys Asp Ser Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln    50                  55                  60Arg Arg Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val Arg65                  70                  75                  80Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Arg Gly Gly Glu Thr                85                  90                  95Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile Trp            100                 105                 110Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys        115                 120                 125Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val His    130                 135                 140Arg Asn Thr Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Ser Pro145                 150                 155                 160Glu Ser Arg Ala Val Thr Cys Gly Arg Ala Ser Leu Ser Ala Glu Lys                165                 170                 175Val Thr Leu Asn Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ala Cys Gln            180                 185                 190Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu        195                 200                 205Val Val Glu Ala Gln Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser    210                 215                 220Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln225                 230                 235                 240Val Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr Pro                245                 250                 255Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val            260                 265                 270Arg Ile Gln Arg Lys Lys Glu Lys Thr Lys Glu Thr Glu Glu Glu Cys        275                 280                 285Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Ala Glu Val Gln    290                 295                 300Cys Lys Gly Ala Asn Ile Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn305                 310                 315                 320Ser Ser Cys Ser Lys Trp Thr Cys Val Pro Cys Arg Gly Arg Ser                325                 330                 335</s400><s200><s210>65</s210><s211>319</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>consensus IL-12p40 polypeptide sequence</s223></s220></s200><s400> 65Met Cys Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Leu Leu Ala1               5                   10                  15Ser Pro Leu Met Ala Ile Trp Glu Leu Glu Lys Asp Val Tyr Val Val            20                  25                  30Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu Thr        35                  40                  45Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Ser Asp Gln Ser    50                  55                  60Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys Glu65                  70                  75                  80Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Leu Ser                85                  90                  95His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp Ser Thr            100                 105                 110Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe Leu Lys        115                 120                 125Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp Leu Thr    130                 135                 140Ile Ser Thr Asp Leu Lys Phe Ser Val Lys Ser Ser Arg Gly Ser Ser145                 150                 155                 160Asp Pro Arg Gly Val Thr Cys Gly Ala Ala Thr Leu Ser Ala Glu Lys                165                 170                 175Val Leu Asp Asn Arg Asp Tyr Lys Tyr Ser Val Glu Cys Gln Glu Asp            180                 185                 190Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile Glu Val Val Val        195                 200                 205Glu Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr Ser Ser Phe Phe    210                 215                 220Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln Leu Lys225                 230                 235                 240Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp Glu Tyr Pro Asp                245                 250                 255Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr Phe Cys Val Gln            260                 265                 270Val Gln Gly Lys Lys Arg Glu Lys Lys Asp Arg Leu Phe Thr Asp Lys        275                 280                 285Thr Ser Ala Val Cys Arg Lys Ala Asn Ile Val Gln Ala Gln Asp Arg    290                 295                 300Tyr Tyr Ser Ser Ser Trp Ser Glu Trp Ala Ser Val Pro Cys Ser305                 310                 315</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002466A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002466</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17634688</doc-number><date>20200813</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>55</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>715</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>55</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>7155</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>55</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>622</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>31</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">ENGINEERED INTERLEUKIN-2 RECEPTOR BETA AGONISTS</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>62886148</doc-number><date>20190813</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Elpis Biopharmaceuticals</orgname><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>CHEN</last-name><first-name>Yan</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>ZHAO</last-name><first-name>Kehao</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>SWANSON</last-name><first-name>Christina</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>NGUYEN</last-name><first-name>Jenna</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>KALLEN</last-name><first-name>Nathan</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>HASSAN</last-name><first-name>Samuel Clement</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>JIANG</last-name><first-name>Ning</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/046244</doc-number><date>20200813</date></document-id><us-371c12-date><date>20220211</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Provided herein are engineered IL2 polypeptides and fusion proteins thereof. Also provided are methods of modulating an immune response by administering an engineered IL2 polypeptide or a fusion protein thereof. The engineered IL2 polypeptides and fusion proteins thereof demonstrate increased binding to IL2R&#x3b2;, decreased binding to IL2R&#x3b1;, or both.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="16.43mm" wi="158.75mm" file="US20230002466A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="232.58mm" wi="152.99mm" orientation="landscape" file="US20230002466A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="219.29mm" wi="127.59mm" orientation="landscape" file="US20230002466A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="166.54mm" wi="111.17mm" orientation="landscape" file="US20230002466A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="145.03mm" wi="123.36mm" orientation="landscape" file="US20230002466A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="145.71mm" wi="164.42mm" orientation="landscape" file="US20230002466A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="221.57mm" wi="71.63mm" orientation="landscape" file="US20230002466A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="225.98mm" wi="113.88mm" orientation="landscape" file="US20230002466A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="194.39mm" wi="161.37mm" orientation="landscape" file="US20230002466A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="160.61mm" wi="164.00mm" orientation="landscape" file="US20230002466A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="128.27mm" wi="110.49mm" orientation="landscape" file="US20230002466A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="235.80mm" wi="103.55mm" orientation="landscape" file="US20230002466A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="239.95mm" wi="94.91mm" orientation="landscape" file="US20230002466A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="248.33mm" wi="94.49mm" orientation="landscape" file="US20230002466A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="207.43mm" wi="152.15mm" orientation="landscape" file="US20230002466A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="201.59mm" wi="155.11mm" orientation="landscape" file="US20230002466A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="172.80mm" wi="149.52mm" orientation="landscape" file="US20230002466A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="195.24mm" wi="149.69mm" orientation="landscape" file="US20230002466A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="196.93mm" wi="153.08mm" orientation="landscape" file="US20230002466A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="228.35mm" wi="151.47mm" orientation="landscape" file="US20230002466A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="222.00mm" wi="157.90mm" orientation="landscape" file="US20230002466A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="220.22mm" wi="155.87mm" orientation="landscape" file="US20230002466A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="247.65mm" wi="114.05mm" orientation="landscape" file="US20230002466A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="245.03mm" wi="159.17mm" orientation="landscape" file="US20230002466A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="247.99mm" wi="162.56mm" orientation="landscape" file="US20230002466A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="226.82mm" wi="83.31mm" orientation="landscape" file="US20230002466A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="255.95mm" wi="162.22mm" orientation="landscape" file="US20230002466A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="211.07mm" wi="144.36mm" orientation="landscape" file="US20230002466A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="228.52mm" wi="145.88mm" orientation="landscape" file="US20230002466A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00029" num="00029"><img id="EMI-D00029" he="227.75mm" wi="139.45mm" orientation="landscape" file="US20230002466A1-20230105-D00029.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00030" num="00030"><img id="EMI-D00030" he="192.53mm" wi="144.70mm" orientation="landscape" file="US20230002466A1-20230105-D00030.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00031" num="00031"><img id="EMI-D00031" he="229.95mm" wi="166.45mm" orientation="landscape" file="US20230002466A1-20230105-D00031.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00032" num="00032"><img id="EMI-D00032" he="229.70mm" wi="164.42mm" orientation="landscape" file="US20230002466A1-20230105-D00032.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00033" num="00033"><img id="EMI-D00033" he="185.76mm" wi="144.61mm" orientation="landscape" file="US20230002466A1-20230105-D00033.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00034" num="00034"><img id="EMI-D00034" he="233.85mm" wi="162.14mm" orientation="landscape" file="US20230002466A1-20230105-D00034.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00035" num="00035"><img id="EMI-D00035" he="240.96mm" wi="160.61mm" orientation="landscape" file="US20230002466A1-20230105-D00035.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00036" num="00036"><img id="EMI-D00036" he="204.98mm" wi="109.22mm" orientation="landscape" file="US20230002466A1-20230105-D00036.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00037" num="00037"><img id="EMI-D00037" he="206.59mm" wi="109.98mm" orientation="landscape" file="US20230002466A1-20230105-D00037.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00038" num="00038"><img id="EMI-D00038" he="203.54mm" wi="149.10mm" orientation="landscape" file="US20230002466A1-20230105-D00038.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00039" num="00039"><img id="EMI-D00039" he="230.97mm" wi="155.62mm" orientation="landscape" file="US20230002466A1-20230105-D00039.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00040" num="00040"><img id="EMI-D00040" he="218.78mm" wi="154.60mm" orientation="landscape" file="US20230002466A1-20230105-D00040.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00041" num="00041"><img id="EMI-D00041" he="195.33mm" wi="150.71mm" orientation="landscape" file="US20230002466A1-20230105-D00041.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00042" num="00042"><img id="EMI-D00042" he="203.71mm" wi="153.59mm" orientation="landscape" file="US20230002466A1-20230105-D00042.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00043" num="00043"><img id="EMI-D00043" he="208.45mm" wi="158.83mm" orientation="landscape" file="US20230002466A1-20230105-D00043.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00044" num="00044"><img id="EMI-D00044" he="216.83mm" wi="158.33mm" orientation="landscape" file="US20230002466A1-20230105-D00044.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00045" num="00045"><img id="EMI-D00045" he="221.91mm" wi="161.37mm" orientation="landscape" file="US20230002466A1-20230105-D00045.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00046" num="00046"><img id="EMI-D00046" he="229.19mm" wi="163.49mm" orientation="landscape" file="US20230002466A1-20230105-D00046.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00047" num="00047"><img id="EMI-D00047" he="231.14mm" wi="163.41mm" orientation="landscape" file="US20230002466A1-20230105-D00047.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00048" num="00048"><img id="EMI-D00048" he="228.68mm" wi="159.26mm" orientation="landscape" file="US20230002466A1-20230105-D00048.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00049" num="00049"><img id="EMI-D00049" he="236.30mm" wi="122.17mm" orientation="landscape" file="US20230002466A1-20230105-D00049.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00050" num="00050"><img id="EMI-D00050" he="221.32mm" wi="109.47mm" orientation="landscape" file="US20230002466A1-20230105-D00050.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00051" num="00051"><img id="EMI-D00051" he="212.60mm" wi="92.03mm" orientation="landscape" file="US20230002466A1-20230105-D00051.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00052" num="00052"><img id="EMI-D00052" he="227.33mm" wi="145.88mm" orientation="landscape" file="US20230002466A1-20230105-D00052.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00053" num="00053"><img id="EMI-D00053" he="233.93mm" wi="158.41mm" orientation="landscape" file="US20230002466A1-20230105-D00053.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00054" num="00054"><img id="EMI-D00054" he="237.07mm" wi="139.19mm" orientation="landscape" file="US20230002466A1-20230105-D00054.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00055" num="00055"><img id="EMI-D00055" he="235.29mm" wi="159.68mm" orientation="landscape" file="US20230002466A1-20230105-D00055.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00056" num="00056"><img id="EMI-D00056" he="188.04mm" wi="102.62mm" orientation="landscape" file="US20230002466A1-20230105-D00056.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00057" num="00057"><img id="EMI-D00057" he="185.93mm" wi="103.38mm" orientation="landscape" file="US20230002466A1-20230105-D00057.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00058" num="00058"><img id="EMI-D00058" he="233.17mm" wi="124.29mm" orientation="landscape" file="US20230002466A1-20230105-D00058.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00059" num="00059"><img id="EMI-D00059" he="210.65mm" wi="102.19mm" orientation="landscape" file="US20230002466A1-20230105-D00059.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00060" num="00060"><img id="EMI-D00060" he="211.92mm" wi="102.02mm" orientation="landscape" file="US20230002466A1-20230105-D00060.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00061" num="00061"><img id="EMI-D00061" he="229.79mm" wi="107.44mm" orientation="landscape" file="US20230002466A1-20230105-D00061.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00062" num="00062"><img id="EMI-D00062" he="229.79mm" wi="83.65mm" orientation="landscape" file="US20230002466A1-20230105-D00062.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00063" num="00063"><img id="EMI-D00063" he="213.28mm" wi="109.90mm" orientation="landscape" file="US20230002466A1-20230105-D00063.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00064" num="00064"><img id="EMI-D00064" he="210.82mm" wi="112.44mm" orientation="landscape" file="US20230002466A1-20230105-D00064.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00065" num="00065"><img id="EMI-D00065" he="173.57mm" wi="107.44mm" orientation="landscape" file="US20230002466A1-20230105-D00065.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00066" num="00066"><img id="EMI-D00066" he="226.48mm" wi="128.61mm" orientation="landscape" file="US20230002466A1-20230105-D00066.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00067" num="00067"><img id="EMI-D00067" he="143.76mm" wi="157.65mm" orientation="landscape" file="US20230002466A1-20230105-D00067.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS-REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application claims the benefit of priority to U.S. Provisional Application No. 62/886,148, filed Aug. 13, 2019, which is hereby incorporated by reference in its entirety.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">STATEMENT REGARDING SEQUENCE LISTING</heading><p id="p-0003" num="0002">The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 300096_401WO_SEQUENCE_LISTING.txt. The text file is 230 KB, was created on Aug. 13, 2020, and is being submitted electronically via EFS-Web.</p><heading id="h-0003" level="1">BACKGROUND</heading><p id="p-0004" num="0003">Interleukin-2 (IL2) is a cytokine that modulates lymphocyte proliferation and activation. It has a length of 133 amino acids and the structure includes four antiparallel, amphipathic C-helices. IL2 mediates its action by binding to IL2 receptors (IL2R), which includes up to three individual subunits. Association of all three subunits, the interleukin-2 receptor alpha chain (IL2R&#x3b1;, or CD25), interleukin-2 receptor beta chain (IL2R&#x3b2;, or CD122), and interleukin-2 receptor gamma chain (IL2R&#x3b3;, or CD132), results in a trimeric IL2R&#x3b1;&#x3b2;&#x3b3;, which is a high-affinity receptor for IL2. Association of the IL2R&#x3b2; and IL2R&#x3b3; subunits results in the dimeric receptor IL2R&#x3b2;&#x3b3;, and is termed an intermediate affinity IL2R. The IL2R&#x3b1; subunit forms a monomeric low affinity IL2 receptor. Expression of IL2R&#x3b1; is involved in the expansion of immunosuppressive regulatory T cells (Tregs); whereas dimeric IL2R&#x3b2;&#x3b3; can result in cytolytic CD8<sup>+</sup> T cell and NK cell proliferation and killing in the absence of IL2R&#x3b1;.</p><heading id="h-0004" level="1">BRIEF SUMMARY</heading><p id="p-0005" num="0004">The present disclosure provides engineered IL2 polypeptides having improved binding to IL2R&#x3b2; as compared to wild-type IL2 and/or reduced binding to IL2R&#x3b1; as compared to wild-type IL2.</p><p id="p-0006" num="0005">In one aspect, the present disclosure provides an engineered interleukin-2 (IL2) polypeptide comprising an engineered IL2 receptor &#x3b2; (IL2R&#x3b2;) binding region 2 comprising: X<sub>1</sub>-X<sub>2</sub>- X<sub>3</sub>-D-X<sub>4</sub>-X-<sub>5</sub>-X<sub>6</sub>-N-X<sub>7</sub>-X<sub>8</sub>-X<sub>9</sub>-X<sub>10</sub>-X<sub>11</sub>-X<sub>12</sub>-X<sub>13 </sub>(SEQ ID NO: 1),</p><p id="p-0007" num="0006">wherein X<sub>1</sub>, X<sub>3</sub>, X<sub>6</sub>, X<sub>8</sub>, X<sub>12</sub>, and X<sub>13 </sub>each comprise any residue,</p><p id="p-0008" num="0007">wherein X<sub>2</sub>, X<sub>4</sub>, and X<sub>10 </sub>are uncharged residues,</p><p id="p-0009" num="0008">wherein X<sub>5</sub>, X<sub>7</sub>, X<sub>9</sub>, and X<sub>11 </sub>each comprise uncharged, nonpolar residues, and</p><p id="p-0010" num="0009">wherein the engineered IL2 polypeptide binds to IL2R&#x3b2; at a K<sub>D </sub>at least 10-fold greater than a wild-type IL2.</p><p id="p-0011" num="0010">In certain aspects, X<sub>1 </sub>is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue; X<sub>1 </sub>is selected from C, T, G, W, I, S, E, and K; or X<sub>1 </sub>is selected from G, K, E, C, and T. In certain aspects, X<sub>2 </sub>is an uncharged polar residue or an uncharged nonpolar residue; X<sub>2 </sub>is selected from Y, P, V, W, L, A, and G; or X<sub>2 </sub>is selected from V, P, W, and A. In certain aspects, X<sub>3 </sub>is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue; X<sub>3 </sub>is selected from S, T, Q, G, M, E, R, and K; or X<sub>3 </sub>is selected from T, G, S, R, and E. In certain aspects, X<sub>4 </sub>is not L; X<sub>4 </sub>is an uncharged nonpolar residue or an uncharged polar residue; or X<sub>4 </sub>is selected from A, V, S, and T. In certain aspects, X<sub>5 </sub>is selected from I, L, T, and V; or X<sub>5 </sub>is selected from I and V. In certain aspects, X<sub>6 </sub>is an uncharged polar residue, a basic residue, or an acidic residue; X<sub>6 </sub>is selected from S, T, E, D, and R; or X<sub>6 </sub>is selected from S, D, E, and T. In certain aspects, X<sub>7 </sub>is selected from I, A, M, and V; or X<sub>7 </sub>is selected from I, A, and M. In certain aspects, X<sub>8 </sub>is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue; X<sub>8 </sub>is selected from S, T, N, Q, I, G, E, K, and R; or X<sub>8 </sub>is selected from I, R, N, and T. In certain aspects, X<sub>9 </sub>is selected from V, L, and I; or X<sub>9 </sub>is V. In certain aspects, X<sub>10 </sub>is an uncharged polar residue or an uncharged nonpolar residue; X<sub>10 </sub>is selected from N, T, I, and L; or X<sub>10 </sub>is selected from I and L. In certain aspects, X<sub>11 </sub>is a uncharged nonpolar residue; or X<sub>11 </sub>is selected from V, A, and I. In certain embodiments, X<sub>12 </sub>is an uncharged polar residue, an uncharged nonpolar residue, or an acidic residue; X<sub>12 </sub>is selected from Q, L, G, K, and R; or X<sub>12 </sub>is selected from R, G, Q, and K. In certain aspects, X<sub>13 </sub>is an uncharged nonpolar residue or a basic residue; X<sub>13 </sub>is selected from A, D, and E; or X<sub>13 </sub>is selected from E and A.</p><p id="p-0012" num="0011">In some aspects, the present disclosure provides an engineered IL2 polypeptide comprising a substitution to at least one residue selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94. In certain aspects, the R81 substitution is selected from R81G, R81K, R81E, R81C, and R81T; the R83 substitution is selected from R83T, R83G, R83S, and R83E; the L85 substitution is selected from L85S, L85A, L85V, and L85T; the I92 substitution is I92L; and the L94 substitution is selected from L94R, L94G, L94Q, and L94K. In certain aspects, the engineered IL2 polypeptide comprises substitutions to R81 and L83. In certain aspects, the engineered IL2 polypeptide comprises substitutions to R81, L83, S87, N90, and N94; substitutions to R81, L83, S87, N90, and V93; substitutions to R81, L83, P82, and V93; or substitutions to R81, L83, and N90.</p><p id="p-0013" num="0012">In one aspect, the present disclosure provides an engineered interleukin-2 (IL2) polypeptide comprising an engineered IL2 receptor &#x3b1; (IL2R&#x3b1;) binding region 1 motif. comprising a substitution selected from: a substitution at position K35, a substitution at R38, a substitution at F42, a substitution at Y45, or combinations thereof, wherein the engineered IL2 polypeptide binds to IL2R&#x3b1; with at least 2-fold reduced binding kinetics as compared to wild-type IL2.</p><p id="p-0014" num="0013">In some aspects, the present disclosure provides an engineered IL2 polypeptide including an engineered IL2 receptor &#x3b2; (IL2R&#x3b2;) binding region 2 as previously described and an engineered IL2 receptor a (IL2R&#x3b1;) binding region 1 as previously described.</p><p id="p-0015" num="0014">In some aspects, the present disclosure provides an engineered IL2 polypeptide as provided herein, fused to a half-life extending molecule.</p><p id="p-0016" num="0015">In some aspects, the present disclosure provides a fusion polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises an engineered IL2 polypeptide as provided herein.</p><p id="p-0017" num="0016">In some aspects, the present disclosure provides an isolated polynucleotide encoding an engineered IL2 polypeptide or a fusion polypeptide thereof, an expression vector comprising the isolated polynucleotide, or a modified cell comprising the isolated polynucleotide or expression vector.</p><p id="p-0018" num="0017">In some aspects, the present disclosure provides a pharmaceutical composition comprising the engineered IL2 polypeptide or fusion polypeptide thereof, and a pharmaceutically acceptable carrier.</p><p id="p-0019" num="0018">In some aspects, the present disclosure provides a method of modulating an immune response in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide or fusion polypeptide thereof, or a pharmaceutical composition thereof. In certain aspects, modulating the immune response comprises at least one of: enhancing effector T cell activity, enhancing NK cell activity, and suppressing regulatory T cell activity.</p><p id="p-0020" num="0019">In some aspects, the present disclosure provides a method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide or fusion polypeptide thereof, or a pharmaceutical composition thereof. In certain aspects, the disease is cancer. In certain aspects, the method further comprises administering an additional therapeutic agent, such as an antigen binding moiety, an immune cell expressing a chimeric antigen receptor, an immune cells expressing an engineered T cell receptor, a tumor infiltrating lymphocyte, an immune checkpoint inhibitor, an oncolytic virus, a tumor microenvironment (TME) inhibitor, or a cancer vaccine. In certain aspects, the methods comprise administering to the subject an immune cell comprising a polynucleotide encoding the engineered IL2 polypeptide or fusion polypeptide thereof.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0005" level="1">BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS</heading><p id="p-0021" num="0020"><figref idref="DRAWINGS">FIG. <b>1</b>A</figref> shows the regions of IL2 responsible for binding IL2R&#x3b1; (solid open boxes), IL2R&#x3b2; (dashed boxes), and IL2R&#x3b3; (gray boxes), <figref idref="DRAWINGS">FIG. <b>1</b>B</figref> shows a graphic depiction of IL2R&#x3b1;, IL2R&#x3b2;, and IL2R&#x3b3; bound to IL2, and <figref idref="DRAWINGS">FIG. <b>1</b>C</figref> shows the IL2R&#x3b1; binding site of IL2 highlighting four residues (K35, R38, F42 and Y45) of IL2 critical for IL2R&#x3b1; interaction.</p><p id="p-0022" num="0021"><figref idref="DRAWINGS">FIGS. <b>2</b>A-<b>2</b>B</figref> show the identification of IL2R&#x3b1; reduced binding mutations by ELISA.</p><p id="p-0023" num="0022"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows characterization of IL2R&#x3b1;-reduced binding mutations by surface plasmon resonance sequence alignments of IL2R&#x3b1; reduced binding mutations.</p><p id="p-0024" num="0023"><figref idref="DRAWINGS">FIG. <b>4</b></figref> shows characterization of IL2R&#x3b1;-reduced binding mutations by surface plasmon resonance.</p><p id="p-0025" num="0024"><figref idref="DRAWINGS">FIG. <b>5</b></figref> shows the IL2R&#x3b2; agonist mutagenic libraries <figref idref="DRAWINGS">FIG. <b>6</b></figref> shows IL2R&#x3b2; agonist expression in <i>E. coli </i>and binding to IL2R&#x3b2;.</p><p id="p-0026" num="0025"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows a multiple sequence alignment of the IL2R&#x3b2; binding region 2 for IL2R&#x3b2; agonists identified through mRNA display.</p><p id="p-0027" num="0026"><figref idref="DRAWINGS">FIG. <b>8</b></figref> shows SDS analysis of IL2R&#x3b2; agonist clones produced in <i>E. coli. </i></p><p id="p-0028" num="0027"><figref idref="DRAWINGS">FIGS. <b>9</b>A-<b>9</b>B</figref> show sensorgrams and binding kinetics of wild-type IL2 to IL2R&#x3b1; (<figref idref="DRAWINGS">FIG. <b>9</b>A</figref>) and IL2R&#x3b2; (<figref idref="DRAWINGS">FIG. <b>9</b>B</figref>) in SPR.</p><p id="p-0029" num="0028"><figref idref="DRAWINGS">FIGS. <b>10</b>A-<b>10</b>H</figref> show sensorgrams of <i>E. coli </i>produced wild-type IL2 and engineered IL2R&#x3b2; agonists to IL2R&#x3b1; in SPR. <figref idref="DRAWINGS">FIG. <b>10</b>A</figref> shows a sensorgram of wild-type</p><p id="p-0030" num="0029">IL2; <figref idref="DRAWINGS">FIG. <b>10</b>B</figref> shows a sensorgram of EP001; <figref idref="DRAWINGS">FIG. <b>10</b>C</figref> shows a sensorgram of EP004; <figref idref="DRAWINGS">FIG. <b>10</b>D</figref> shows a sensorgram of EP005; <figref idref="DRAWINGS">FIG. <b>10</b>E</figref> shows a sensorgram of EP002; <figref idref="DRAWINGS">FIG. <b>10</b>F</figref> shows a sensorgram of EP03; <figref idref="DRAWINGS">FIG. <b>10</b>G</figref> shows a sensorgram of EPIM-06; and <figref idref="DRAWINGS">FIG. <b>10</b>H</figref> shows a sensorgram of EP007.</p><p id="p-0031" num="0030"><figref idref="DRAWINGS">FIGS. <b>11</b>A-<b>11</b>H</figref> show sensorgrams of <i>E. coli </i>produced wild-type IL2 and engineered IL2R&#x3b2; agonists to IL2R&#x3b2; in SPR. <figref idref="DRAWINGS">FIG. <b>11</b>A</figref> shows a sensorgram of EP003; <figref idref="DRAWINGS">FIG. <b>11</b>B</figref> shows a sensorgram of EP005; <figref idref="DRAWINGS">FIG. <b>11</b>C</figref> shows a sensorgram of E002; <figref idref="DRAWINGS">FIG. <b>11</b>D</figref> shows a sensorgram of EP001; <figref idref="DRAWINGS">FIG. <b>11</b>E</figref> shows a sensorgram of EP007; <figref idref="DRAWINGS">FIG. <b>11</b>F</figref> shows a sensorgram of EP006; <figref idref="DRAWINGS">FIG. <b>11</b>G</figref> shows a sensorgram of EP004; and <figref idref="DRAWINGS">FIG. <b>11</b>H</figref> shows a sensorgram of wild-type IL2.</p><p id="p-0032" num="0031"><figref idref="DRAWINGS">FIGS. <b>12</b>A-<b>12</b>D</figref> show sensorgrams of IL2R&#x3b2; binding to mammalian produced wild-type IL2 (<figref idref="DRAWINGS">FIG. <b>12</b>A</figref>) and engineered IL2R&#x3b2; agonists EP0001 (<figref idref="DRAWINGS">FIG. <b>12</b>B</figref>), EP0003 (<figref idref="DRAWINGS">FIG. <b>12</b>C</figref>), and EP004 (<figref idref="DRAWINGS">FIG. <b>12</b>D</figref>) in SPR.</p><p id="p-0033" num="0032"><figref idref="DRAWINGS">FIGS. <b>13</b>A-<b>13</b>D</figref> show sensorgrams of IL2R&#x3b1; binding to mammalian produced wild-type IL2 (<figref idref="DRAWINGS">FIG. <b>13</b>A</figref>) and engineered IL2R&#x3b2; agonists EP001 (<figref idref="DRAWINGS">FIG. <b>13</b>B</figref>), EP003 (<figref idref="DRAWINGS">FIG. <b>13</b>C</figref>), and EP004 (<figref idref="DRAWINGS">FIG. <b>13</b>D</figref>) in SPR.</p><p id="p-0034" num="0033"><figref idref="DRAWINGS">FIGS. <b>14</b>A-<b>14</b>I</figref> show pSTAT5 expression as measured from blood donors 1-3, following stimulation of human PBMCs with wild-type IL2 and engineered IL2R&#x3b2; agonists, as measured for CD8+ T cells (<figref idref="DRAWINGS">FIG. <b>14</b>A</figref> for blood donor 1, <figref idref="DRAWINGS">FIG. <b>14</b>D</figref> for blood donor 2, and <figref idref="DRAWINGS">FIG. <b>14</b>G</figref> for blood donor 3), NK cells (<figref idref="DRAWINGS">FIG. <b>14</b>B</figref> for blood donor 1, <figref idref="DRAWINGS">FIG. <b>14</b>E</figref> for blood donor 2, and <figref idref="DRAWINGS">FIG. <b>14</b>H</figref> for blood donor 3), and T regs (<figref idref="DRAWINGS">FIG. <b>14</b>C</figref> for blood donor 1, <figref idref="DRAWINGS">FIG. <b>14</b>F</figref> for blood donor 2, and <figref idref="DRAWINGS">FIG. <b>14</b>I</figref> for blood donor 3).</p><p id="p-0035" num="0034"><figref idref="DRAWINGS">FIGS. <b>15</b>A-<b>15</b>B</figref> show characterization by ELISA of IL2R&#x3b2; agonist EP001 back-mutation clones for binding to IL2R&#x3b1; (<figref idref="DRAWINGS">FIG. <b>15</b>A</figref>) and IL2R&#x3b2; (<figref idref="DRAWINGS">FIG. <b>15</b>B</figref>) by ELISA.</p><p id="p-0036" num="0035"><figref idref="DRAWINGS">FIGS. <b>16</b>A-<b>16</b>H</figref> show IL2R&#x3b2; binding sensorgrams of IL2R&#x3b2; agonist EP001 back-mutation clones by SPR.</p><p id="p-0037" num="0036"><figref idref="DRAWINGS">FIG. <b>17</b></figref> shows examples of SDS-PAGE results for purified clones of IL2R&#x3b1;/IL2R&#x3b2; clones.</p><p id="p-0038" num="0037"><figref idref="DRAWINGS">FIGS. <b>18</b>A-<b>18</b>H</figref> show binding sensorgrams of engineered IL2R&#x3b1;/IL2R&#x3b2; clones to human IL2a by SPR.</p><p id="p-0039" num="0038"><figref idref="DRAWINGS">FIGS. <b>19</b>A-<b>19</b>H</figref> show binding sensorgrams of engineered IL2R&#x3b1;/IL2R&#x3b2; clones to human IL2&#x3b2; by SPR.</p><p id="p-0040" num="0039"><figref idref="DRAWINGS">FIGS. <b>20</b>A-<b>20</b>G</figref> show single concentration binding sensorgrams of engineered IL2R&#x3b1;/IL2R&#x3b2; clones to human IL2R&#x3b1; by SPR.</p><p id="p-0041" num="0040"><figref idref="DRAWINGS">FIGS. <b>21</b>A-<b>21</b>G</figref> show single concentration binding of engineered IL2R&#x3b1;/IL2R&#x3b2; clones to human IL2R&#x3b2; by SPR.</p><p id="p-0042" num="0041"><figref idref="DRAWINGS">FIGS. <b>22</b>A-<b>22</b>B</figref> show multi-concentration binding of engineered IL2R&#x3b1;/IL2R&#x3b2; clones to human IL2R&#x3b1; (<figref idref="DRAWINGS">FIG. <b>22</b>A</figref>) and IL2R&#x3b2; (<figref idref="DRAWINGS">FIG. <b>22</b>B</figref>) by SPR.</p><p id="p-0043" num="0042"><figref idref="DRAWINGS">FIGS. <b>23</b>A-<b>23</b>E</figref> show ELISA binding to human IL2R&#x3b1;. <figref idref="DRAWINGS">FIG. <b>23</b>A</figref> shows the ELISA binding of EP252 and its IL2R&#x3b1; binding reduced mutations to human IL2R&#x3b1;. <figref idref="DRAWINGS">FIG. <b>23</b>B</figref> shows the ELISA binding of EP253 and its IL2R&#x3b1; binding reduced mutations to human IL2R&#x3b1;. <figref idref="DRAWINGS">FIG. <b>23</b>C</figref> shows the ELISA binding of EP258 and its IL2R&#x3b1; binding reduced mutations to human IL2R&#x3b1;. <figref idref="DRAWINGS">FIG. <b>23</b>D</figref> shows the ELISA binding of EP260 and its IL2R&#x3b1; binding reduced mutations to human IL2R&#x3b1;. <figref idref="DRAWINGS">FIG. <b>23</b>E</figref> shows dose dependent binding for selected engineered IL2R&#x3b2;/IL2R&#x3b1; clones.</p><p id="p-0044" num="0043"><figref idref="DRAWINGS">FIGS. <b>24</b>A-<b>24</b>D</figref> show ELISA binding to human IL2R&#x3b2;. <figref idref="DRAWINGS">FIG. <b>24</b>A</figref> shows the ELISA binding of EP252 and its IL2R&#x3b1; binding reduced mutations to human IL2R&#x3b2;. <figref idref="DRAWINGS">FIG. <b>24</b>B</figref> shows the ELISA binding of EP253 and its IL2R&#x3b1; binding reduced mutations to human IL2R&#x3b2;. <figref idref="DRAWINGS">FIG. <b>24</b>C</figref> shows the ELISA binding of EP258 and its IL2R&#x3b1; binding reduced mutations to human IL2R&#x3b2;. <figref idref="DRAWINGS">FIG. <b>24</b>D</figref> shows the ELISA binding of EP260 and its IL2R&#x3b1; binding reduced mutations to human IL2R&#x3b2;.</p><p id="p-0045" num="0044"><figref idref="DRAWINGS">FIGS. <b>25</b>A-<b>25</b>D</figref> show p-STAT5 activation of human CD8+ T cells from donor 656, by engineered IL2R&#x3b1;/IL2R&#x3b2; clones. <figref idref="DRAWINGS">FIG. <b>25</b>A</figref> shows p-STAT5 activation of human CD8+ T cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>25</b>B</figref> shows p-STAT5 activation of human CD8+ T cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>25</b>C</figref> shows p-STAT5 activation of human CD8+ T cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>25</b>D</figref> shows p-STAT5 activation of human CD8+ T cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0046" num="0045"><figref idref="DRAWINGS">FIGS. <b>26</b>A-<b>26</b>D</figref> show p-STAT5 activation of human CD8+ T cells from donor 648, by engineered IL2R&#x3b1;/IL2R&#x3b2; clones. <figref idref="DRAWINGS">FIG. <b>26</b>A</figref> shows p-STAT5 activation of human CD8+ T cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>26</b>B</figref> shows p-STAT5 activation of human CD8+ T cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>26</b>C</figref> shows p-STAT5 activation of human CD8+ T cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>26</b>D</figref> shows p-STAT5 activation of human CD8+ T cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0047" num="0046"><figref idref="DRAWINGS">FIGS. <b>27</b>A-<b>27</b>D</figref> show p-STAT5 activation of human NK cells from donor 656, by engineered IL2R&#x3b1;/IL2R&#x3b2; clones. <figref idref="DRAWINGS">FIG. <b>27</b>A</figref> shows p-STAT5 activation of human NK cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>25</b>B</figref> shows p-STAT5 activation of human NK cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>27</b>C</figref> shows p-STAT5 activation of human NK cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>27</b>D</figref> shows p-STAT5 activation of human NK cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0048" num="0047"><figref idref="DRAWINGS">FIGS. <b>28</b>A-<b>28</b>D</figref> show p-STAT5 activation of human NK cells from donor 648, by engineered IL2R&#x3b1;/IL2R&#x3b2; clones. <figref idref="DRAWINGS">FIG. <b>28</b>A</figref> shows p-STAT5 activation of human NK cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>28</b>B</figref> shows p-STAT5 activation of human NK cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>28</b>C</figref> shows p-STAT5 activation of human NK cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>28</b>D</figref> shows p-STAT5 activation of human NK cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0049" num="0048"><figref idref="DRAWINGS">FIGS. <b>29</b>A-<b>29</b>D</figref> show p-STAT5 activation of human T reg cells from donor 656, by engineered IL2R&#x3b1;/IL2R&#x3b2; clones. <figref idref="DRAWINGS">FIG. <b>29</b>A</figref> shows p-STAT5 activation of human T reg cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>29</b>B</figref> shows p-STAT5 activation of human T reg cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>29</b>C</figref> shows p-STAT5 activation of human T reg cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>29</b>D</figref> shows p-STAT5 activation of human T reg cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0050" num="0049"><figref idref="DRAWINGS">FIGS. <b>30</b>A-<b>30</b>D</figref> show p-STAT5 activation of human T reg cells from donor 648, by engineered IL2R&#x3b1;/IL2R&#x3b2; clones. <figref idref="DRAWINGS">FIG. <b>30</b>A</figref> shows p-STAT5 activation of human T reg cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>30</b>B</figref> shows p-STAT5 activation of human T reg cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>30</b>C</figref> shows p-STAT5 activation of human T reg cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>30</b>D</figref> shows p-STAT5 activation of human T reg cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0051" num="0050"><figref idref="DRAWINGS">FIGS. <b>31</b>A-<b>31</b>D</figref> show p-STAT5 activation of murine CD8+ T cells. <figref idref="DRAWINGS">FIG. <b>31</b>A</figref> shows p-STAT5 activation of murine CD8+ T cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>31</b>B</figref> shows p-STAT5 activation of murine CD8+ T cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>31</b>C</figref> shows p-STAT5 activation of murine CD8+ T cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>31</b>D</figref> shows p-STAT5 activation of murine CD8+ T cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0052" num="0051"><figref idref="DRAWINGS">FIGS. <b>32</b>A-<b>32</b>D</figref> show p-STAT5 activation of murine NK cells. <figref idref="DRAWINGS">FIG. <b>32</b>A</figref> shows p-STAT5 activation of murine NK cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>32</b>B</figref> shows p-STAT5 activation of murine NK cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>32</b>C</figref> shows p-STAT5 activation of murine NK cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>32</b>D</figref> shows p-STAT5 activation of murine NK cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0053" num="0052"><figref idref="DRAWINGS">FIGS. <b>33</b>A-<b>33</b>D</figref> show p-STAT5 activation of murine T regulatory cells. <figref idref="DRAWINGS">FIG. <b>33</b>A</figref> shows p-STAT5 activation of murine T regulatory cells for EP252 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>33</b>B</figref> shows p-STAT5 activation of murine T regulatory cells for EP253 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>33</b>C</figref> shows p-STAT5 activation of murine T regulatory cells for EP258 and its IL2R&#x3b1; binding reduced mutations. <figref idref="DRAWINGS">FIG. <b>33</b>D</figref> shows p-STAT5 activation of murine T regulatory cells for EP260 and its IL2R&#x3b1; binding reduced mutations.</p><p id="p-0054" num="0053"><figref idref="DRAWINGS">FIG. <b>34</b></figref> shows a summary of p-STAT5 activation of murine CD8+ T cells, NK cells, and Tregs.</p><p id="p-0055" num="0054"><figref idref="DRAWINGS">FIGS. <b>35</b>A-<b>35</b>C</figref> show structure diagrams of monovalent and bivalent IL2R&#x3b2; agonist Fc fusion proteins.</p><p id="p-0056" num="0055"><figref idref="DRAWINGS">FIGS. <b>36</b>A-<b>36</b>B</figref> show SDS-PAGE analysis of the purified IL2R&#x3b2; agonist Fc fusion proteins.</p><p id="p-0057" num="0056"><figref idref="DRAWINGS">FIGS. <b>37</b>A-<b>37</b>G</figref> show receptor binding analysis by ELISA of bivalent IL2R&#x3b2; agonist Fc fusion proteins.</p><p id="p-0058" num="0057"><figref idref="DRAWINGS">FIGS. <b>38</b>A-<b>38</b>B</figref> show receptor binding analysis by ELISA of monovalent IL2R&#x3b2; agonist Fc fusion proteins.</p><p id="p-0059" num="0058"><figref idref="DRAWINGS">FIGS. <b>39</b>A-<b>39</b>D</figref> show receptor binding analysis of monovalent IL2R&#x3b2; Fc fusion proteins by SPR.</p><p id="p-0060" num="0059"><figref idref="DRAWINGS">FIGS. <b>40</b>A-<b>40</b>C</figref> show p-STAT5 activation of human PBMCs by bivalent IL2R&#x3b2; agonist Fc-fusion proteins.</p><p id="p-0061" num="0060"><figref idref="DRAWINGS">FIGS. <b>41</b>A-<b>41</b>C</figref> show p-STAT5 activation of human PBMCs by monovalent IL2R&#x3b2; agonist Fc-fusion proteins.</p><p id="p-0062" num="0061"><figref idref="DRAWINGS">FIGS. <b>42</b>A-<b>42</b>B</figref> show pharmacokinetics with murine i.v. (<figref idref="DRAWINGS">FIG. <b>42</b>A</figref>) and i.p. (<figref idref="DRAWINGS">FIG. <b>42</b>B</figref>) administration of IL2R&#x3b2; agonist.</p><p id="p-0063" num="0062"><figref idref="DRAWINGS">FIGS. <b>43</b>A-<b>43</b>D</figref> show normalized counts of tumor infiltrating immune cells following administration of IL2R&#x3b2; agonist.</p><p id="p-0064" num="0063"><figref idref="DRAWINGS">FIGS. <b>44</b>A-<b>44</b>B</figref> show ratios of effector cells to T regulatory cell in tumors.</p><p id="p-0065" num="0064"><figref idref="DRAWINGS">FIGS. <b>45</b>A-<b>45</b>C</figref> show percentages of effector and memory T cells.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0006" level="1">DETAILED DESCRIPTION</heading><p id="p-0066" num="0065">IL2 has been a promising new immunotherapy, but therapies based on wild-type human IL2 may activate T regulatory cells in addition to activating effector T cells and NK cells. Activation of T regulatory cells by IL2 may hamper the anti-cancer response that may otherwise be elicited by IL2. Thus, IL2-based therapies with reduced activation of T regulatory cells and/or preferential activation of T effector cells, NK cells, or a combination thereof are needed.</p><p id="p-0067" num="0066">Presented herein are rationally designed IL2R&#x3b2; agonists, which are engineered IL2 polypeptides having amino acid substitutions in IL2R&#x3b2; binding region 2 that enhance binding to IL2R&#x3b2;. The engineered IL2R&#x3b2; agonists provide the advantage of increasing stimulation of NK cells and T effector cells compared to wild-type IL2, but not T regulatory cells. Thus, the engineered IL2R&#x3b2; agonists are useful for modulating or activating an immune response, for example, for treatment of cancer.</p><p id="p-0068" num="0067">The term &#x201c;interleukin-2 or &#x201c;IL2&#x201d; as used herein, refers to an IL2 from any vertebrate source, including mammals such humans or mice, unless otherwise indicated. The term encompasses precursor or unprocessed IL2, as well as any form of IL2 that results from cellular processing. The term also encompasses naturally occurring variants of IL2, such as splice variants or allelic variants. The amino acid sequence of an example mature human IL2 is shown in SEQ ID NO: 65. Precursor or unprocessed human IL2 is shown in SEQ ID NO: 66, and includes a 20-residue signal peptide, which is absent in the mature IL2 polypeptide. &#x201c;Wild-type&#x201d; or &#x201c;native&#x201d; when used in reference to IL2 is intended to mean the mature IL2 molecule (e.g., SEQ ID NO: 65). The term &#x201c;engineered IL2&#x201d; or &#x201c;engineered IL2 polypeptide&#x201d; as used herein encompasses an IL2 having at least one residue that differs from a native or wild-type IL2, and includes full-length IL2, truncated forms of IL2, and forms where IL2 is linked or fused with another molecule, such as another polypeptide. The various forms of engineered IL2 are characterized in having at least one amino acid substitution affecting the interaction of IL2 with IL2R&#x3b2; and/or IL2R&#x3b1;. Identification of various engineered forms of IL2 as described herein are made with respect to the sequence shown in, e.g., SEQ ID NO: 22. Various identifiers may be used herein to indicate the same residue substitution. For example, a substitution from arginine at position 81 to threonine can be indicated as R81T or 81T.</p><p id="p-0069" num="0068">IL2R&#x3b2; binding region 1 and IL2R&#x3b2; binding region 2 are responsible for IL2 binding to IL2R&#x3b2;. &#x201c;IL2R&#x3b2; binding region 1&#x201d; as used herein refers to residues 11-23 of wild-type or native human IL2. The amino acid sequence of IL2R&#x3b2; binding region 1 is provided in SEQ ID NO: 67. &#x201c;IL2R&#x3b2; binding region 2&#x201d; as used herein refers to residues 81-95 of wild-type or native human IL2. The amino acid sequence of IL2R&#x3b2; binding region 2 is provided in SEQ ID NO: 68.</p><p id="p-0070" num="0069">IL2R&#x3b1; binding region 1 and IL2R&#x3b1; binding region 2 are responsible for IL2 binding to IL2R&#x3b1;. &#x201c;IL2R&#x3b1; binding region 1&#x201d; as used herein refers to residues 34-45 of wild-type or native human IL2. The amino acid sequence of IL2R&#x3b1; binding region 1 is provided in SEQ ID NO: 223.</p><p id="p-0071" num="0070">The term &#x201c;substitution&#x201d; or &#x201c;residue substitution&#x201d; as used herein refers to replacement of a native or wild-type residue with a different residue.</p><p id="p-0072" num="0071">&#x201c;Any residue&#x201d; as used herein refers to an amino acid residue having one of the twenty canonical amino acid side chains: alanine (Ala, A); arginine (Arg, R); asparagine (Asn, N); aspartic acid (Asp, D); cysteine (Cys, C); glutamine (Gln, Q); glutamic acid (Glu, E); glycine (Gly, G); histidine (His, H); isoleucine (Ile, I); leucine (Leu, L); lysine (Lys, K); methionine (Met, M); phenylalanine (Phe, F); proline (Pro, P); serine (Ser, S); threonine (Thr, T); tryptophan (Trp, W); tyrosine (Tyr, Y); and valine (Val, V).</p><p id="p-0073" num="0072">&#x201c;Uncharged residue&#x201d; as used herein refers to an amino acid residue with a side chain that does not hold a charge at physiologic pH (pH=7). The uncharged residues are: alanine (Ala, A); asparagine (Asn, N); cysteine (Cys, C); glutamine (Gln, Q); glycine (Gly, G); histidine (His, H); isoleucine (Ile, I); leucine (Leu, L); methionine (Met, M); phenylalanine (Phe, F); proline (Pro, P); serine (Ser, S); threonine (Thr, T); tryptophan (Trp, W); tyrosine (Tyr, Y); and valine (Val, V).</p><p id="p-0074" num="0073">&#x201c;Uncharged polar residue&#x201d; as used herein refers to an amino acid residue with a side chain that does not hold a charge at physiologic pH (pH=7) and is hydrophilic. The uncharged polar residues are: asparagine (Asn, N); cysteine (Cys, C); glutamine (Gln, Q); serine (Ser, S); threonine (Thr, T); and tyrosine (Tyr, Y).</p><p id="p-0075" num="0074">&#x201c;Uncharged nonpolar residue&#x201d; as used herein refers an amino acid residue with a side chain that does not hold a charge at physiologic pH (pH=7) and is hydrophobic. The uncharged nonpolar residues are: alanine (Ala, A); glycine (Gly, G); histidine (His, H); isoleucine (Ile, I); leucine (Leu, L); methionine (Met, M); phenylalanine (Phe, F); proline (Pro, P); tryptophan (Trp, W); and valine (Val, V).</p><p id="p-0076" num="0075">&#x201c;Basic residue&#x201d; as used herein refers to an amino acid residue with a side chain that holds a positive charge at physiologic pH (pH=7). The basic residues are lysine (Lys, K); and arginine (Arg, R).</p><p id="p-0077" num="0076">&#x201c;Acidic residue&#x201d; as used herein refers to an amino acid residue with a side chain that holds a negative charge at physiologic pH (pH=7). The acidic residues are aspartic acid (Asp, D); and glutamic acid (Glu, E).</p><p id="p-0078" num="0077">&#x201c;Fusion polypeptide&#x201d; or &#x201c;fusion protein&#x201d; refers to a polypeptide that is encoded by at least two different DNA sequences corresponding to genes or fragments thereof, which are not naturally expressed from the same gene. An example of a fusion polypeptide is an engineered IL2-Fc fusion polypeptide, which includes an amino acid sequence of an engineered IL2 polypeptide and an amino acid sequence of an Fc domain.</p><p id="p-0079" num="0078">&#x201c;Affinity&#x201d; refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). Unless indicated otherwise, as used herein, &#x201c;binding affinity&#x201d; refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., receptor and a ligand). The affinity of a molecule-X for its partner Y can generally be represented by the dissociation constant (K<sub>D</sub>), which is the ratio of dissociation and association rate constants (k<sub>off </sub>and k<sub>on</sub>, respectively). Thus, equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by methods known by persons of skill in the art, including those described herein.</p><p id="p-0080" num="0079">&#x201c;Half-life extending molecule&#x201d; as used herein refers to a molecule that when attached (e.g., covalently) to a second molecule, extends the half-life of the second molecule. Examples of half-life extending molecules include an Fc domain, human serum albumin (HSA), an HSA binding molecule, polyethylene glycol (PEG), and polypropylene glycol (PPG).</p><p id="p-0081" num="0080">&#x201c;Fc domain&#x201d; or &#x201c;Fc region&#x201d; as used herein refers to a polypeptide derived from a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes polypeptides having a native sequence Fc region, or variants thereof. Although the boundaries of the Fc region of an IgG heavy chain might vary slightly, the human IgG heavy chain Fc region is usually defined to extend from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Examples of Fc regions are disclosed in U.S. Pat. Nos. 7,317,091; 8,735,545; 7,371,826; 7,670,600; and 9,803,023; all of which are incorporated by reference in their entirety.</p><p id="p-0082" num="0081">&#x201c;Human serum albumin&#x201d; or &#x201c;HSA&#x201d; refers to the serum albumin found in human blood. The commonly used form of HSA has a molecular mass of 66.5 kDa and a half-life of approximately 20 days. Examples of HSA molecules are disclosed in U.S. Pat. Nos. 8,143,026 and 7,189,690, which are incorporated by reference in their entirety.</p><p id="p-0083" num="0082">&#x201c;HSA binding molecule&#x201d; refers to a molecule that specifically binds to human serum albumin (HSA), such as an antigen binding moiety having an HSA binding domain.</p><p id="p-0084" num="0083">&#x201c;Polyethylene glycol&#x201d; or &#x201c;PEG,&#x201d; also referred to as polyethylene oxide or polyoxyethylene is a polyether polymer that may be used to extend half-life.</p><p id="p-0085" num="0084">&#x201c;Polypropylene glycol&#x201d; or &#x201c;PPG,&#x201d; also referred to as polypropylene oxide, is a polymer of propylene glycol that may be used to extend half-life.</p><p id="p-0086" num="0085">&#x201c;Antigen binding moiety&#x201d; refers to the site (i.e., amino acid residues) of an antigen binding molecule (e.g., antibody) that provides interaction with the antigen epitope. An antigen binding moiety may include one or more antibody variable domains (also called antibody variable regions). Preferably, an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). Examples of antigen binding moieties include immunoglobulins, Fab molecules, scFv, bispecific antibodies, diabodies, bi-specific T-cell engagers, and nanobodies. Specific examples of antigen binding moieties include nivolumab, pembrolizumab, pidilizumab, atezolizumab, ipilimumab, tremelimumab, rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, ublituximab, and bevacizumab.</p><p id="p-0087" num="0086">&#x201c;Immunoglobulin&#x201d; refers to a protein having the structure of a naturally occurring antibody. As an example, immunoglobulins of the IgG class are heterotetrameric glycoproteins with two light chains and two heavy chains that are disulfide-bonded. From N- to C-terminus, the heavy chains each have a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from N- to C-terminus, light chain each have a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain, also called a light chain constant region. The heavy chain of an immunoglobulin may be assigned to one of five classes, called &#x3b1; (IgA), &#x3b4; (IgD), &#x3b5; (IgE), &#x3b3; (IgG), or &#x3bc; (IgM), some of which may be further divided into subclasses, e.g., &#x3b3;1 (IgG1), &#x3b3;2 (IgG2), &#x3b3;3 (IgG3), &#x3b3;4 (IgG4), &#x3b1;1 (IgA1) and &#x3b1;2 (IgA2). The light chain of an immunoglobulin may be assigned to one of two types, called kappa (&#x3ba;) and lambda (&#x3bb;), based on the sequence of its constant domain. An immunoglobulin includes two Fab molecules and an Fc domain, linked via the immunoglobulin hinge region.</p><p id="p-0088" num="0087">&#x201c;Fab molecule&#x201d; or &#x201c;antigen binding fragment&#x201d; is an antigen binding fragment of an antibody that includes the variable domain and constant domain of a light chain, and a variable domain and a CH1 domain of a heavy chain.</p><p id="p-0089" num="0088">&#x201c;Single chain variable domain&#x201d; or &#x201c;scFv&#x201d; refers to an antigen binding moiety that includes variable regions of a heavy chain and light chain, which are linked by a linker peptide.</p><p id="p-0090" num="0089">&#x201c;Bispecific antibody,&#x201d; refers to an artificial antibody with two different antigen binding sites. Bispecific antibody can refer to a full immunoglobulin protein with two different antigen binding sites, or can refer to other molecules having two antigen binding moieties, such as a fusion protein including two Fabs or two scFvs.</p><p id="p-0091" num="0090">&#x201c;Diabody&#x201d; refers to a class of antigen binding molecules that are bivalent and bispecific. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) on the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.</p><p id="p-0092" num="0091">&#x201c;Bi-specific T-cell engager&#x201d; refers to a class of bispecific antibodies having a first antigen binding moiety that binds to a T cell (e.g., by binding CD3), and a second antigen binding moiety that binds a different antigen (e.g., a tumor antigen).</p><p id="p-0093" num="0092">&#x201c;Nanobody&#x201d; or &#x201c;single domain antibody&#x201d; refers to an antigen binding moiety that consists of a single monomeric variable antibody domain.</p><p id="p-0094" num="0093">&#x201c;Transferrin&#x201d; is an iron transporter protein that may be used in a fusion protein to extend half-life. Human transferrin has a half-life of 12 days in serum.</p><p id="p-0095" num="0094">&#x201c;Cytokine&#x201d; as used herein refers to a class of small (&#x3c;25 kDa) proteins that are involved in cell signaling and immunomodulation. Cytokines include, for example, IL2, interleukin-10 (IL-10), interleukin-1 (IL-1), interleukin-17 (IL-17), interleukin-18 (IL-18), interferon &#x3b1;, interferon &#x3b2;, interferon &#x3b3;, TGF-&#x3b2;1, TGF-&#x3b2;2, and TGF-&#x3b2;3, chemokine (C-C motif) ligand 2 (CCL2), and chemokine (C-C motif) ligand 19 (CCL19).</p><p id="p-0096" num="0095">A &#x201c;subject&#x201d; according to any of the above embodiments is a mammal. Mammals include but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., human and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). Preferably the subject is a human.</p><p id="p-0097" num="0096">&#x201c;Modulating an immune response&#x201d; may include one or more of a general increase, an increase in T effector cell response (e.g., cytotoxicity against tumor cells and virus infected cells), an increase in B cell activation, restoration of lymphocyte activation and proliferation, an increase in the expression of IL2 receptors, an increase in T cell responsiveness, an increase in natural killer cell activity or lymphokine-activated killer (LAK) cell activity, a decrease in regulatory T cells response to other T cells, and the like.</p><p id="p-0098" num="0097">&#x201c;Regulatory T cell&#x201d; or &#x201c;Treg cell&#x201d; refers to a specialized type of CD4+ T cell that can function to suppress the responses of other T cells. Treg cells express the &#x3b1;-subunit of the IL2 receptor (CD25) and the transcription factor forkhead box P3 (FOXP3) (Sakaguchi, <i>Annu Rev Immunol </i>22, 531-62 (2004)), and are involved in the induction and maintenance of peripheral self-tolerance to antigens, including those expressed by tumors. Treg cells require IL2 for their function and development and induction of their suppressive characteristics.</p><p id="p-0099" num="0098">&#x201c;T effector cells&#x201d; refers to a population of T cells that respond to stimulus, such as IL2. T effector cells include CD8+ cytotoxic T cells and CD4+ helper T cells. As used herein, T effector cell does not include a T regulatory cell.</p><p id="p-0100" num="0099">&#x201c;Natural Killer cells&#x201d; or &#x201c;NK cells&#x201d; are a component of the innate immune system and are cytotoxic lymphocytes that play a major role in rejection of tumors and virus infected cells.</p><p id="p-0101" num="0100">&#x201c;Treatment,&#x201d; &#x201c;treating&#x201d; or &#x201c;ameliorating&#x201d; refers to medical management of a condition, disease, or disorder of a subject (e.g., patient), which may be therapeutic, prophylactic/preventative, or a combination treatment thereof.</p><p id="p-0102" num="0101">An &#x201c;effective amount&#x201d; or a &#x201c;therapeutically effective amount&#x201d; may refer to an amount of therapeutic agent (e.g., an engineered IL2 polypeptide or engineered IL2 fusion polypeptide described herein) that provides a desired physiological change, such as an anti-cancer effect. The desired physiological change may, for example, be a decrease in symptoms of a disease, or a decrease in severity of a disease, or may be a reduction in the progression of a disease. With respect to cancer, the desired physiological changes may include, for example, tumor regression, a decreased rate of tumor progression, a reduced level of a cancer biomarker, reduced symptoms associated with cancer, a prevention or delay in metastasis, or clinical remission.</p><p id="p-0103" num="0102">&#x201c;Checkpoint inhibitor&#x201d; refers to an agent that reduces the activity of an immune checkpoint protein. A checkpoint inhibitor can be an antigen binding moiety that binds to and reduces activity of an immune checkpoint protein. Immune checkpoint proteins include, for example, programmed cell death protein 1 (PD-1 or CD279), programmed death-ligand 1 (PD-L1 or CD274), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4 or CD152), T-cell immunoglobulin mucin-3 (TIM3), Lymphocyte Activating 3 (LAG3 or CD223), B7-H2 (ICOSL or CD275), and B7-H3 (CD276). Examples of checkpoint inhibitors includes ipilimumab (an anti-CTLA-4 antibody), nivolumab (an anti-PD-1 antibody), and pembrolizumab (an anti-PD-1 antibody).</p><p id="p-0104" num="0103">&#x201c;Cancer antigen&#x201d; refers to a molecule that is preferentially expressed by cancer cells. Examples of cancer antigens include CD19, CD20, ROR1, fibroblast activation protein-&#x3b1;, and carcinoembryonic antigen (CEA).</p><p id="p-0105" num="0104">&#x201c;Oncolytic virus&#x201d; refers to a virus that preferentially infects and kills cancer cells. For example oncolytic herpes viruses have been engineered to delete ICP34.5, resulting in a virus that only replicates in cancer (not healthy cells). An example of an oncolytic virus is Talimogene laherparepvec, which is used to treat melanoma.</p><p id="p-0106" num="0105">&#x201c;Cancer vaccine&#x201d; refers to a vaccine that presents a cancer epitope to the immune system to elicit an anti-cancer response from the immune system. For example, sipuleucel-T is a vaccine for metastatic prostate cancer, which targets the immune response to the prostate cancer antigen prostatic acid phosphatase (PAP).</p><p id="p-0107" num="0106">&#x201c;Chimeric antigen receptors&#x201d; or &#x201c;CARs&#x201d; are engineered antigen binding receptors that, when expressed in certain types of immune cells, activate the immune cell upon antigen binding. CARs typically include an extracellular domain comprising an antigen binding moiety (e.g., an scFv), a transmembrane domain, and an intracellular immune signaling domain (e.g., including signaling domains from CD3, 4-1BB, and/or CD28). CARs may be expressed, for example, by T cells or NK cells, and may include an antigen binding moiety that targets a cancer antigen, such as CD19 or ROR1.</p><p id="p-0108" num="0107">&#x201c;Tumor infiltrating lymphocyte&#x201d; or &#x201c;TIL&#x201d; refers to a lymphocyte that is isolated from tumor tissue, manipulated in vitro (e.g., stimulated using a cytokine such as interleukin-2), and then infused back into a patient so that the activating TIL returns to the tumor site and induces tumor regression.</p><p id="p-0109" num="0108">&#x201c;Tumor microenvironment inhibitor&#x201d; refers to an agent that inhibits one or more conditions or cell types that promote tumor growth and are present in the local environment surrounding a tumor. For example, bevacizumab can inhibit the tumor microenvironment by reducing angiogenesis in a tumor microenvironment.</p><p id="p-0110" num="0109">In the present description, the term &#x201c;about&#x201d; means&#xb1;20% of the indicated range, value, or structure, unless otherwise indicated. The term &#x201c;consisting essentially of&#x201d; limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. It should be understood that the terms &#x201c;a&#x201d; and &#x201c;an&#x201d; as used herein refer to &#x201c;one or more&#x201d; of the enumerated components. The use of the alternative (e.g., &#x201c;or&#x201d;) should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the terms &#x201c;include&#x201d; and &#x201c;have&#x201d; are used synonymously, which terms and variants thereof are intended to be construed as non-limiting. The term &#x201c;comprise&#x201d; means the presence of the stated features, integers, steps, or components as referred to in the claims, but that it does not preclude the presence or addition of one or more other features, integers, steps, components, or groups thereof.</p><p id="p-0111" num="0110">Recombinant DNA, molecular cloning, and gene expression techniques used in the present disclosure are known in the art and described in references, such as Sambrook et al., Molecular Cloning: A Laboratory Manual, 3<sup>rd </sup>Ed., Cold Spring Harbor Laboratory, New York, 2001, and Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md., 1999.</p><heading id="h-0007" level="2">Engineered Interleukin-2 Polypeptide</heading><p id="p-0112" num="0111">As noted above, IL2 polypeptides of the present disclosure include IL2R&#x3b2; agonists having an engineered IL2 receptor &#x3b2; (IL2R&#x3b2;) binding region 2. In some embodiments, the binding region 2 comprises:</p><p id="p-0113" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="196pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry></row><row><entry/><entry>X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>-D-X<sub>4</sub>-X<sub>5</sub>-X<sub>6</sub>-N-X<sub>7</sub>-X<sub>8</sub>-X<sub>9</sub>-X<sub>10</sub>-X<sub>11</sub>-X<sub>12</sub>-X<sub>13</sub>,</entry></row></tbody></tgroup></table></tables></p><p id="p-0114" num="0112">wherein X<sub>1</sub>, X<sub>3</sub>, X<sub>6</sub>, X<sub>8</sub>, X<sub>12</sub>, and X<sub>13 </sub>each comprise any residue,</p><p id="p-0115" num="0113">wherein X<sub>2</sub>, X<sub>4</sub>, and X<sub>10 </sub>are uncharged residues, and</p><p id="p-0116" num="0114">wherein X<sub>5</sub>, X<sub>7</sub>, X<sub>9</sub>, and X<sub>11 </sub>each comprise uncharged, nonpolar residues.</p><p id="p-0117" num="0000">For example, in some embodiments the engineered IL2 polypeptide has the amino acid sequence:</p><p id="p-0118" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;22)</entry></row><row><entry>APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA</entry></row><row><entry> </entry></row><row><entry>TELKHLQCLEEELKPLEEVLNLAQSKNFHLX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>DX<sub>4</sub>X<sub>5</sub>X<sub>6</sub>NX<sub>7</sub>X<sub>8</sub>X<sub>9</sub></entry></row><row><entry> </entry></row><row><entry>X<sub>10</sub>X<sub>11</sub>X<sub>12</sub>X<sub>13</sub>LKGSETTFMCEYADETATIVEFLNRWITFCQSIISTL</entry></row><row><entry> </entry></row><row><entry>T,</entry></row></tbody></tgroup></table></tables></p><p id="p-0119" num="0115">wherein X<sub>1</sub>, X<sub>3</sub>, X<sub>6</sub>, X<sub>8</sub>, X<sub>12</sub>, and X<sub>13 </sub>each comprise any residue,</p><p id="p-0120" num="0116">wherein X<sub>2</sub>, X<sub>4</sub>, and X<sub>10 </sub>are uncharged residues, and</p><p id="p-0121" num="0117">wherein X<sub>5</sub>, X<sub>7</sub>, X<sub>9</sub>, and X<sub>11 </sub>each comprise uncharged, nonpolar residues.</p><p id="p-0122" num="0000">In certain embodiments, X<sub>1 </sub>is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue. In some embodiments, X<sub>1 </sub>is selected from C, T, G, W, I, S, E, and K. In some embodiments, X<sub>1 </sub>is selected from G, K, E, C, and T. In certain embodiments, X<sub>2 </sub>is an uncharged polar residue or an uncharged nonpolar residue. In some embodiments, X<sub>2 </sub>is selected from Y, P, V, W, L, A, and G. In some embodiments, X<sub>2 </sub>is selected from V, P, W, and A. In certain embodiments, X<sub>3 </sub>is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue. In some embodiments, X<sub>3 </sub>is selected from S, T, Q, G, M, E, R, and K. In some embodiments, X<sub>3 </sub>is selected from T, G, S, R, and E. In certain embodiments, X<sub>4 </sub>is not L. In some embodiments, X<sub>4 </sub>is an uncharged nonpolar residue or an uncharged polar residue. In some embodiments, X<sub>4 </sub>is selected from A, V, S, and T. In certain embodiments, X<sub>5 </sub>is selected from I, L, T, and V. In some embodiments, X<sub>5 </sub>is selected from I and V. In certain embodiments, X<sub>6 </sub>is an uncharged polar residue, a basic residue, or an acidic residue. In some embodiments, X<sub>6 </sub>is selected from S, T, E, D, and R. In some embodiments, X<sub>6 </sub>is selected from S, D, E, and T. In certain embodiments, X<sub>7 </sub>is selected from I, A, M, and V. In some embodiments, X<sub>7 </sub>is selected from I, A, and M. In certain embodiments, X<sub>8 </sub>is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue. In some embodiments, X<sub>8 </sub>is selected from S, T, N, Q, I, G, E, K, and R. In some embodiments, X<sub>8 </sub>is selected from I, R, N, and T. In certain embodiments, X<sub>9 </sub>is selected from V, L, and I. In some embodiments, X<sub>9 </sub>is V. In certain embodiments, X<sub>10 </sub>is an uncharged polar residue or an uncharged nonpolar residue. In some embodiments, X<sub>10 </sub>is selected from N, T, I, and L. In some embodiments, X<sub>10 </sub>is selected from I and L. In certain embodiments, X<sub>11 </sub>is selected from V, A, and I. In certain embodiments, X<sub>12 </sub>is an uncharged polar residue, an uncharged nonpolar residue, or an acidic residue. In some embodiments, X<sub>12 </sub>is selected from Q, L, G, K, and R. In some embodiments, X<sub>12 </sub>is selected from R, G, Q, and K. In certain embodiments, X<sub>13 </sub>is an uncharged nonpolar residue or a basic residue. In some embodiments, X<sub>13 </sub>is selected from A, D, and E. In some embodiments, X<sub>13 </sub>is selected from E and A.</p><p id="p-0123" num="0118">In some embodiments, the IL2R&#x3b2; binding region 2 is selected from:</p><p id="p-0124" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="70pt" align="left"/><colspec colname="1" colwidth="147pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry></row><row><entry/><entry>GVTDSISNAIVLARE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;3)</entry></row><row><entry/><entry>KWGDAVSNARVLAGE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;4)</entry></row><row><entry/><entry>KWGDAVSNARVLAGA;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;5)</entry></row><row><entry/><entry>TLMDTTDNIGVLVRE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry></row><row><entry/><entry>EPSDVISNINVLVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry></row><row><entry/><entry>SPQDSIENISVLVRE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;8)</entry></row><row><entry/><entry>WASDSIENITLLIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;9)</entry></row><row><entry/><entry>CPTDTIENITVLIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;10)</entry></row><row><entry/><entry>RYKDSLENMQIIIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;11)</entry></row><row><entry/><entry>TARDAVDNMRVIIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;12)</entry></row><row><entry/><entry>TPRDVVENMNVLVLE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;13)</entry></row><row><entry/><entry>TPSDVIENMEVLILD;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;14)</entry></row><row><entry/><entry>TPSDAIENINVLIRE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;15)</entry></row><row><entry/><entry>TPSDVIENITVLVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;16)</entry></row><row><entry/><entry>GVGDTIDNINVLVKE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;17)</entry></row><row><entry/><entry>IGRDSIDNIKVIVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;18)</entry></row><row><entry/><entry>WATDTIRNVEVLVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;19)</entry></row><row><entry/><entry>TAEDVVTNITVLVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;20)</entry></row><row><entry/><entry>TAEDVISNIRVNVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;21)</entry></row><row><entry/><entry>TPSDVIDNVSITVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;210)</entry></row><row><entry/><entry>TARDAISNIRVIVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;211)</entry></row><row><entry/><entry>RARDAIDNIRVIVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;212)</entry></row><row><entry/><entry>TPRDAIDNINVIIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;213)</entry></row><row><entry/><entry>TPRDAIDNIRVIVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;214)</entry></row><row><entry/><entry>TPRDAIDNIRVIILE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;215)</entry></row><row><entry/><entry>TARDAISNINVIIQE;</entry></row><row><entry/><entry>and</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;216)</entry></row><row><entry/><entry>TARDAIDNINVIVQE;</entry></row><row><entry/><entry>and</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;217)</entry></row><row><entry/><entry>TARDAIDNIRVIVLE.</entry></row></tbody></tgroup></table></tables></p><p id="p-0125" num="0119">In some embodiments, the engineered IL2R&#x3b2; binding region 2 is selected from: TPRDAIDNIRVIVQE (SEQ ID NO: 213); TPRDAIDNIRVIILE (SEQ ID NO:214); TARDAISNINVIIQE (SEQ ID NO: 215); and TARDAIDNINVIVQE (SEQ ID NO: 216).</p><p id="p-0126" num="0120">In some embodiments, the engineered IL2R&#x3b2; binding region 2 is selected from: GVTDSISNAIVLARE (SEQ ID NO:2); KWGDAVSNARVLAGA (SEQ ID NO:4); EPSDVISNINVLVQE (SEQ ID NO:6); CPTDTIENITVLIQE (SEQ ID NO: 9); TARDAVDNMRVIIQE (SEQ ID NO:11); GVGDTIDNINVLVKE (SEQ ID NO: 16); TAEDVVTNITVLVQE (SEQ ID NO:19).</p><p id="p-0127" num="0121">In some embodiments, the engineered IL2R&#x3b2; binding region 2 is selected from: GVTDSISNAIVLARE (SEQ ID NO:2); CPTDTIENITVLIQE (SEQ ID NO: 9); and TARDAVDNMRVIIQE (SEQ ID NO:11).</p><p id="p-0128" num="0122">In some embodiments, the engineered IL2 polypeptide has an amino acid sequence of SEQ ID NO: 22. In some embodiments, the engineered IL2 polypeptide has an amino acid sequence of any one of SEQ ID NOs: 23-42.</p><p id="p-0129" num="0123">In some embodiments, the IL2R&#x3b2; agonists of the present disclosure include engineered IL2 polypeptides comprising a substitution to at least one residue selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94, relative to SEQ ID NO: 65. In certain embodiments, the at least one substitution is a substitution to residue L85. In certain embodiments, the IL2 polypeptide includes substitutions to at least two residues selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94. In some embodiments, the at least two residues are selected from R81, R83, L85, I92, and L94. In some embodiments, the IL2 polypeptide includes substitutions to at least three residues selected from R81, R83, L85, I92, and L94. In some embodiments, the engineered IL2 polypeptide includes substitutions to R81, R83, L85, I92, and L94. In some embodiments, the R81 substitution is selected from R81G, R81K, R81E, R81C, and R81T. In some embodiments, the R83 substitution is selected from R83T, R83G, R83S, and R83E. In some embodiments, the L85 substitution is selected from L85S, L85A, L85V, and L85T. In some embodiments, the I92 substitution is I92L. In some embodiments, the L94 substitution is selected from L94R, L94G, L94Q, and L94K. In some embodiments, the engineered IL2 polypeptide comprising a substitution to at least one residue selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94 has an IL2R&#x3b2; binding region 2 of any of SEQ ID NOs: 2-24.</p><p id="p-0130" num="0124">In some embodiments, the engineered IL2 polypeptide has increased affinity for IL2R&#x3b2; as compared to the wild-type IL2. In certain embodiments, the binding of the engineered IL2 polypeptide to IL2R&#x3b2; has a K<sub>D </sub>at least 10-fold greater, at least 15-fold greater, at least 20-fold greater, at least 25-fold greater, or at least 30-fold greater than binding of a wild-type IL2 to IL2R&#x3b2;. In some embodiments, the engineered IL2 polypeptide binds to IL2R&#x3b2; with a K<sub>D </sub>at least 30-fold greater than a wild-type IL2. In some embodiments, the engineered IL2 polypeptide has at least a 10-fold increase, at least a 15-fold increase, at least a 20-fold increase, at least a 25-fold increase, or at least a 30-fold increase in affinity for IL2R&#x3b2; as compared to wild-type IL2.</p><p id="p-0131" num="0125">In some embodiments, the engineered IL2 polypeptide has a decrease in affinity for IL2R&#x3b1; as compared to wild-type IL2. In certain embodiments, the engineered IL2 polypeptide has at least a 5% decrease, at least a 10% decrease, at least a 15% decrease, or at least a 20% decrease in affinity for IL2R&#x3b1; as compared to wild-type IL2.</p><p id="p-0132" num="0126">In some embodiments, the engineered IL2 polypeptide has a similar affinity for IL2R&#x3b1; as compared to wild-type IL2. In certain embodiments, the engineered IL2 polypeptide has an affinity for IL2R&#x3b1; that varies from the affinity of wild-type IL2 for IL2R&#x3b1; by no more than &#xb1;20%, no more than &#xb1;15%, no more than &#xb1;10% or no more than &#xb1;5%.</p><p id="p-0133" num="0127">Some embodiments of the present disclosure provide an engineered IL2 polypeptide comprising an engineered IL2 receptor &#x3b1; (IL2R&#x3b1;) binding region 1. The engineered IL2R&#x3b1; binding region 1 can comprise a substitution selected from: a substitution at position K35, a substitution at R38, a substitution at F42, a substitution at Y45, or combinations thereof. In some embodiments, the engineered IL2 polypeptide binds to IL2R&#x3b1; with at least 2-fold reduced binding kinetics as compared to wild-type IL2.</p><p id="p-0134" num="0128">In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position K35. In some embodiments, the substitution at position K35 comprises a non-basic residue. In some embodiments, the substitution at position K35 comprises an uncharged residue or an acidic residue. In some embodiments, the substitution at position K35 is selected from: K35G, K35L, K35S, K35V, K35D, K35E, and K35C.</p><p id="p-0135" num="0129">In some embodiments, the engineered IL2 polypeptide comprises a substitution at position R38. In some embodiments, the substitution at position R38 comprises a non-basic residue. In some embodiments, the substitution at position R38 comprises an uncharged residue or an acidic residue. In some embodiments, the substitution at position R38 is selected from: R38V, R38D, R38E, R38S, R38I, R38A, R38Y, R38G, R38C, and R38N.</p><p id="p-0136" num="0130">In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position F42. In some embodiments, the substitution at position F42 comprises an uncharged residue. In some embodiments, the substitution at position F42 comprises a basic residue. In some embodiments, the substitution at position F42 is selected from: F42A, F42R, F42G, F42I, F42L, F42P and F42H.</p><p id="p-0137" num="0131">In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position Y45. In some embodiments, the substitution at position Y45 comprises an uncharged residue. In some embodiments, the substitution at position Y45 comprises an uncharged polar residue or an uncharged non-polar residue. In some embodiments, the Y45 substitution is Y45S, Y45P, Y45A, Y45V, Y45C, Y45T, and Y45F.</p><p id="p-0138" num="0132">In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position K35 and a substitution at position R38. In some embodiments, the engineered IL2 polypeptide comprises a K35G substitution and R38E substitution.</p><p id="p-0139" num="0133">In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position K35 and a substitution at position F42. In some embodiments, the engineered IL2 polypeptide comprises a K35S substitution and an F42G substitution.</p><p id="p-0140" num="0134">In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position K35, a substitution at position R38, and a substitution at position F42. In some embodiments, the engineered IL2 polypeptide comprises a K35L substitution, an R38D substitution, and an F42R substitution.</p><p id="p-0141" num="0135">In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position R38 and a substitution at position Y45S. In some embodiments, the engineered IL2 polypeptide comprises an R38D substitution and an Y45S substitution. In some embodiments, the engineered IL2 polypeptide comprises an R38V substitution and an Y45S substitution.</p><p id="p-0142" num="0136">In some embodiments, the engineered IL2 polypeptide binds to IL2R&#x3b1; with at least 10-fold reduced binding kinetics as compared to wild-type IL2.</p><p id="p-0143" num="0137">In some embodiments, the IL2R&#x3b1; binding region 1 is selected from:</p><p id="p-0144" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="70pt" align="left"/><colspec colname="1" colwidth="147pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;183)</entry></row><row><entry/><entry>PVLTRMLTIKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;184)</entry></row><row><entry/><entry>PKLTRMLTLKFP;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;185)</entry></row><row><entry/><entry>PDLTSMLAFKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;186)</entry></row><row><entry/><entry>PGLTEMLTFKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;187)</entry></row><row><entry/><entry>PSLTRMLTGKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;188)</entry></row><row><entry/><entry>PELTIMLTPKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;189)</entry></row><row><entry/><entry>PCLTAMLTLKFA;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;190)</entry></row><row><entry/><entry>PCLTAMLTLKFA;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;191)</entry></row><row><entry/><entry>PKLTRMLTHKFV;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;192)</entry></row><row><entry/><entry>PCLTDMLTFKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;193)</entry></row><row><entry/><entry>PLLTDMLTRKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;194)</entry></row><row><entry/><entry>PLLTDMLTFKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;195)</entry></row><row><entry/><entry>PKLTDMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;196)</entry></row><row><entry/><entry>PKLTYMLTRKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;197)</entry></row><row><entry/><entry>PKLTRMLTFKFC;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;198)</entry></row><row><entry/><entry>PKLTSMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;199)</entry></row><row><entry/><entry>PKLTSMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;200)</entry></row><row><entry/><entry>PKLTYMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;201)</entry></row><row><entry/><entry>PKLTYMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;202)</entry></row><row><entry/><entry>PKLTGMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;203)</entry></row><row><entry/><entry>PKLTVMLTFKFT;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;204)</entry></row><row><entry/><entry>PKLTYMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;205)</entry></row><row><entry/><entry>PKLTVMLTFKFP;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;206)</entry></row><row><entry/><entry>PKLTVMLTFKFF;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;207)</entry></row><row><entry/><entry>PKLTCMLTFKFA;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;208)</entry></row><row><entry/><entry>PKLTNMLTFKFA;</entry></row><row><entry/><entry>and</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;209)</entry></row><row><entry/><entry>PKLTNMLTFKFS.</entry></row></tbody></tgroup></table></tables></p><p id="p-0145" num="0138">In some embodiments, the engineered IL2 polypeptide shares at least 80%, for example, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity with the residues outside of the IL2R&#x3b2; binding region 2 (i.e., residues 1-80 and 96-133) of SEQ ID NO: 22 and binds to IL2R&#x3b2;. In some embodiments, the engineered IL2 polypeptide shares at least 80%, for example, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity with the residues outside of the IL2R&#x3b1; binding region 1 (i.e., residues 1-33 and 46-133) of SEQ ID NO: 223 and has reduced binding to IL2R&#x3b1; and binds to IL2R&#x3b2;. In some embodiments, the engineered IL2 polypeptide shares at least 80%, for example, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity with the residues outside of the IL2R&#x3b1; binding region 1 and IL2R&#x3b2; binding region 2 (i.e., residues 1-33, 46-80, 96-133) of SEQ ID NO: 22 or SEQ ID NO: 223 and has reduced binding to IL2R&#x3b1; and binds to IL2R&#x3b2;. In some embodiments, the present disclosure provides an engineered IL2 polypeptide including an engineered IL2R&#x3b2; binding region 2 as previously described and an engineered IL2R&#x3b1; binding region 1 as previously described. In certain embodiments, the engineered IL2 polypeptide comprises an engineered IL2R&#x3b1; binding region 1 selected from PVLTRMLTIKFY (SEQ ID NO: 183); PKLTRMLTLKFP (SEQ ID NO:184); PDLTSMLAFKFY (SEQ ID NO:185); PGLTEMLTFKFY (SEQ ID NO:186); PSLTRMLTGKFY (SEQ ID NO:187); PELTIMLTPKFY (SEQ ID NO:188); PCLTAMLTLKFA (SEQ ID NO:189); PCLTAMLTLKFA (SEQ ID NO:190); PKLTRMLTHKFV (SEQ ID NO:191); PCLTDMLTFKFY (SEQ ID NO:192); PLLTDMLTRKFY (SEQ ID NO:193); PLLTDMLTFKFY (SEQ ID NO:194); PKLTDMLTFKFS (SEQ ID NO:195); PKLTYMLTRKFY (SEQ ID NO:196); PKLTRMLTFKFC (SEQ ID NO:197); PKLTSMLTFKFS (SEQ ID NO:198); PKLTSMLTFKFS (SEQ ID NO:199); PKLTYMLTFKFS (SEQ ID NO:200); PKLTYMLTFKFS (SEQ ID NO:201); PKLTGMLTFKFS (SEQ ID NO:202); PKLTVMLTFKFT (SEQ ID NO:203); PKLTVMLTFKFS (SEQ ID NO:204); PKLTVMLTFKFP (SEQ ID NO:205); PKLTVMLTFKFF (SEQ ID NO:206); PKLTCMLTFKFA (SEQ ID NO:207); PKLTNMLTFKFA (SEQ ID NO:208); and PKLTNMLTFKFS (SEQ ID NO:209); and comprises an engineered IL2R&#x3b2; binding region 2 is selected from:</p><p id="p-0146" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="70pt" align="left"/><colspec colname="1" colwidth="147pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry></row><row><entry/><entry>GVTDSISNAIVLARE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;3)</entry></row><row><entry/><entry>KWGDAVSNARVLAGE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;4)</entry></row><row><entry/><entry>KWGDAVSNARVLAGA;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;5)</entry></row><row><entry/><entry>TLMDTTDNIGVLVRE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry></row><row><entry/><entry>EPSDVISNINVLVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry></row><row><entry/><entry>SPQDSIENISVLVRE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;8)</entry></row><row><entry/><entry>WASDSIENITLLIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;9)</entry></row><row><entry/><entry>CPTDTIENITVLIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;10)</entry></row><row><entry/><entry>RYKDSLENMQIIIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;11)</entry></row><row><entry/><entry>TARDAVDNMRVIIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;12)</entry></row><row><entry/><entry>TPRDVVENMNVLVLE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;13)</entry></row><row><entry/><entry>TPSDVIENMEVLILD;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;14)</entry></row><row><entry/><entry>TPSDAIENINVLIRE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;15)</entry></row><row><entry/><entry>TPSDVIENITVLVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;16)</entry></row><row><entry/><entry>GVGDTIDNINVLVKE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;17)</entry></row><row><entry/><entry>IGRDSIDNIKVIVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;18)</entry></row><row><entry/><entry>WATDTIRNVEVLVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;19)</entry></row><row><entry/><entry>TAEDVVTNITVLVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;20)</entry></row><row><entry/><entry>TAEDVISNIRVNVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;21)</entry></row><row><entry/><entry>TPSDVIDNVSITVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;210)</entry></row><row><entry/><entry>TARDAISNIRVIVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;211)</entry></row><row><entry/><entry>RARDAIDNIRVIVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;212)</entry></row><row><entry/><entry>TPRDAIDNINVIIQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;213)</entry></row><row><entry/><entry>TPRDAIDNIRVIVQE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;214)</entry></row><row><entry/><entry>TPRDAIDNIRVIILE;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;215)</entry></row><row><entry/><entry>TARDAISNINVIIQE;</entry></row><row><entry/><entry>and</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;216)</entry></row><row><entry/><entry>TARDAIDNINVIVQE;</entry></row><row><entry/><entry>and</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;217)</entry></row><row><entry/><entry>TARDAIDNIRVIVLE.</entry></row></tbody></tgroup></table></tables></p><p id="p-0147" num="0139">In particular embodiments, the engineered IL2 polypeptide includes an engineered IL2R&#x3b2; binding region 2 selected from GVTDSISNAIVLARE (SEQ ID NO: 2); TARDAVDNMRVIIQE (SEQ ID NO: 11); TPRDAIDNIRVIVQE (SEQ ID NO: 213); TPRDAIDNIRVIILE (SEQ ID NO:214); TARDAISNINVIIQE (SEQ ID NO: 215); and TARDAIDNINVIVQE (SEQ ID NO: 216); and an engineered IL2R&#x3b1; binding region 1 as previously described.</p><p id="p-0148" num="0140">In some embodiments, the engineered IL2 polypeptide is selected from any one of SEQ ID NOs: 147-170, with the C-terminal histidine tag optionally included (or excluded). In some embodiments, the C-terminal histidine tag is replaced another linker, such as a gly-ser linker.</p><heading id="h-0008" level="2">Engineered IL2 Fusion Polypeptides</heading><p id="p-0149" num="0141">Some embodiments of the present disclosure provide engineered IL2 fusion polypeptides. The engineered IL2 fusion polypeptide may include an engineered IL2 polypeptide as previously described herein, and at least one additional molecule covalently attached to the engineered IL2 polypeptide via a peptide bond or other chemical linkage. In some embodiments, the at least one additional molecule of the fusion polypeptide is a half-life extending molecule. In some embodiments, the half-life extending molecule comprises a half-life extending polypeptide. In some embodiments, the half-life extending polypeptide comprises an Fc domain, human serum albumin (HSA), an HSA binding molecule, or transferrin.</p><p id="p-0150" num="0142">In certain embodiments, the IL2 fusion polypeptide comprises an Fc domain. In some embodiments, the Fc domain is derived from an IgG antibody. Human IgG antibodies have several subclasses, including, but not limited to IgG1, IgG2, IgG3, and IgG4. In particular embodiments, the Fc domain is derived from an IgG1 antibody or an IgG4 antibody. In some embodiments, the Fc domain has one or more substitutions that reduce effector function of the Fc domain. Examples of substitutions that reduce Fc effector function include L34A, L235A, and P329G. &#x201c;LALAPG&#x201d; may refer to a modified Fc domain including each of L34A, L235A, and P329G. In some embodiments, the Fc domain comprises at least one amino acid residue modification to increase serum half-life. Representative modifications to the Fc domain are described in U.S. Pat. Nos. 7,317,091; 8,735,545; 7,371,826; 7,670,600; and 9,803,023. In some embodiments, the Fc domain is SEQ ID NO: 64. In some embodiments, the engineered IL2-Fc fusion polypeptide comprises a sequence selected from SEQ ID NOs: 39-49.</p><p id="p-0151" num="0143">In some embodiments, the at least one additional molecule of the fusion polypeptide is an antigen binding moiety. In some embodiments, the antigen binding moiety comprises an immunoglobulin, a Fab molecule, an scFv, a bi-specific T-cell engager, a diabody, a single domain antibody, or a nanobody. An antigen binding moiety may bind, for example, carcinoembryonic antigen (CEA), GD2, or CD20. An example of a CEA antigen moiety is CH1A1A-2F. An example of a GD-2 antigen binding moiety is dinutuximab, and an example of a CD20 antigen binding moiety is rituximab.</p><p id="p-0152" num="0144">In some embodiments, the at least one additional molecule of the fusion polypeptide is a cytokine. In some embodiments, the cytokine is selected from interleukin-2, interleukin-15, interleukin-7, interleukin-10, and C-C motif chemokine ligand 19 (CCL19). In some embodiments, the additional molecule of the fusion polypeptide is a second engineered IL2 polypeptide as described herein.</p><p id="p-0153" num="0145">In some embodiments, the half-life extending molecule comprises poly-ethylene glycol (PEG) or polypropylene glycol (PPG).</p><p id="p-0154" num="0146">In some embodiments, the fusion polypeptide is a monovalent fusion polypeptide. A monovalent fusion polypeptide refers to a fusion polypeptide that has one copy of an engineered IL2 polypeptide.</p><p id="p-0155" num="0147">In certain embodiments, the monovalent fusion polypeptide includes an engineered IL2 polypeptide linked to a fusion partner, such as an Fc region. A variety of linkers are known in the art and may be used to covalently link an engineered IL2 described herein to a fusion partner, such as an Fc region. By &#x201c;linker&#x201d;, &#x201c;linker sequence&#x201d;, herein is meant a molecule or group of molecules (such as a monomer or polymer) that connects two molecules and often serves to place the two molecules in a preferred configuration. The linker may contain amino acid residues that provide flexibility. Thus, the linker peptide may predominantly include the following amino acid residues: Gly, Ser, Ala, or Thr. The linker peptide should have a length that is adequate to link two molecules in such a way that they assume the correct conformation relative to one another so that they retain the desired activity. Suitable lengths for this purpose include at least one and not more than 30 amino acid residues. Preferably, the linker is from about 1 to 30 amino acids in length, with linkers of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 19 and 20 amino acids in length being preferred. Useful linkers include glycine-serine polymers (including, for example, (GS)n, (GSGGS)n (SEQ ID NO:218), (GGGGS)n (SEQ ID NO:219) and (GGGS)n (SEQ ID NO:220), where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers. In some embodiments, the fusion polypeptide is a bivalent fusion polypeptide. A bivalent fusion protein may refer to a molecular complex that includes two copies of engineered IL2 polypeptides, which may be of the same sequence or different sequences. The molecular complex may be bound non-covalently. For example, a bivalent fusion protein may include two Fc regions bound together non-covalently such as by one or more disulfide bridges, or by knobs-into-holes chemistry.</p><heading id="h-0009" level="2">Methods of Making Engineered IL2 Polypeptides</heading><p id="p-0156" num="0148">Engineered IL2 polypeptides or engineered IL2 fusion polypeptides can be prepared by genetic or chemical methods well known in the art and by the methods disclosed in the Examples below. Genetic methods may include, for example, site-specific mutagenesis of the DNA sequence encoding the polypeptide, PCR, and gene synthesis. The intended nucleotide changes can be verified by sequencing. The nucleotide sequence of native IL2 has been described by Taniguchi et al. (Nature 302, 305-10 (1983)) and a nucleic acid encoding native human IL2 is available from, for example, American Type Culture Collection (Rockville Md.).</p><p id="p-0157" num="0149">Engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be obtained, for example, by recombinant production or solid-state peptide synthesis. For recombinant production, a polynucleotide encoding an engineered IL2 polypeptide or engineered IL2 fusion polypeptide can be isolated and inserted into one or more vectors for cloning and/or expression in a host cell. Such polynucleotides may be readily isolated and sequenced by conventional procedures. In certain embodiments, a vector, such as an expression vector, comprising one or more of the polynucleotides of the instant disclosure is provided. Methods which are well known to those skilled in the art can be used to construct expression vectors containing the coding sequence engineered IL2 polypeptide or engineered IL2 fusion polypeptide along with appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL (FOURTH EDITION), Cold Spring Harbor Laboratory, N.Y. (2012); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, N.Y (1993). The expression vector can be part of a plasmid, virus, or may be a nucleic acid fragment. The expression vector includes an expression cassette into which the polynucleotide encoding engineered IL2 polypeptide or engineered IL2 fusion polypeptide (i.e. the coding region) is cloned in operable association with a promoter and/or other transcription or translation control elements. As used herein, a &#x201c;coding region&#x201d; is a portion of nucleic acid which consists of codons translated into amino acids. Although a &#x201c;stop codon&#x201d; (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, if present, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, 5&#x2032; and 3&#x2032; untranslated regions, and the like, are not part of a coding region. Two or more coding regions can be present in a single polynucleotide construct, e.g., on a single vector, or in separate polynucleotide constructs, e.g., on separate (different) vectors. Furthermore, any vector may contain a single coding region, or may comprise two or more coding regions, e.g., a vector of the disclosed herein may encode one or more polyproteins, which are post- or co-translationally separated into the final proteins via proteolytic cleavage. In addition, a vector, polynucleotide, or nucleic acid of the instant disclosure may encode heterologous coding regions, either fused of unfused to a first or second polynucleotide encoding the polypeptides disclosed herein, or variant or derivative thereof. Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain. An operable association is when a coding region for a gene product, e.g., a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s). Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are &#x201c;operably associated&#x201d; if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed. Thus, a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid. The promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. Other transcription control elements, besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription. Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. These include, without limitation, transcription control regions, which function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (e.g., the immediate early promoter, in conjunction with intron-A), simian virus 40 (e.g., the early promoter), and retroviruses (e.g., Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit &#x3b2;-globin, as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers as well as inducible promoters (e.g., promoters inducible tetracyclins). Similarly, a variety of translation control elements are known to those of ordinary skill in the art. These include, but are not limited to ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence). The expression cassette may also include other features such as an origin of replication, and/or chromosome integration elements such as retroviral long terminal repeats (LTRs), or adeno-associated viral (AAV) inverted terminal repeats (ITRs).</p><p id="p-0158" num="0150">Polynucleotide and nucleic acid coding regions of the present disclosure may be associated with additional coding regions that encode secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the present disclosure. For example, if secretion of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide is desired, DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding the mature amino acids of the an engineered IL2 polypeptide or engineered IL2 fusion polypeptide. Those of ordinary skill in the art are aware that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to produce a secreted or &#x201c;mature&#x201d; form of the polypeptide. For example, native human IL2 is translated with a 20 amino acid signal sequence at the N-terminus of the polypeptide, which is subsequently cleaved off to produce mature, 133 amino acid human IL2. In some embodiments, the native signal peptide, e.g. the IL2 signal peptide or an immunoglobulin heavy chain or light chain signal peptide is used, or a functional derivative of that sequence that retains the ability to direct the secretion of the polypeptide that is operably associated with it.</p><p id="p-0159" num="0151">In some embodiments, a polynucleotide encoding the engineered IL2 polypeptide or engineered IL2 fusion polypeptide further includes a DNA sequence encoding a sequence to facilitate purification (e.g., a histidine tag) or for labeling the engineered IL2 polypeptide or engineered IL2 fusion polypeptide within or at the ends of the polynucleotide encoding the engineered IL2 polypeptide or engineered IL2 fusion polypeptide.</p><p id="p-0160" num="0152">In certain embodiments, a host cell comprising one or more polynucleotides encoding an engineered IL2 polypeptide or engineered IL2 fusion polypeptide is provided. In certain embodiments, the host cell comprises one or more vectors encoding the engineered IL2 polypeptide or engineered IL2 fusion. The host cell can be any kind of cellular system that can be used to generate the engineered IL2 polypeptide or engineered IL2 fusion polypeptide. Such cells may be transfected or transduced as appropriate with the particular expression vector encoding the engineered IL2 polypeptide or engineered IL2 fusion, and large quantities of vector containing cells can be grown for seeding large scale fermenters to obtain sufficient quantities of encoding the engineered IL2 polypeptide or engineered IL2 fusion for clinical applications. Suitable host cells include prokaryotic microorganisms, such as <i>E. coli</i>, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, or the like. For example, polypeptides may be produced in bacteria in particular when glycosylation is not needed. After expression, the polypeptide may be isolated from the bacterial cell in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been &#x201c;humanized,&#x201d; resulting in the production of a polypeptide with a partially or fully human glycosylation pattern. Suitable host cells for the expression of (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of <i>Spodoptera frugiperda </i>cells. Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES&#x2122; technology for producing antibodies in transgenic plants). Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells as described, e.g., in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, e.g., in Mather et al., Annals N.Y. Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr<sup>&#x2212;</sup> CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and Sp2/0. For a review of certain mammalian host cell lines suitable for protein production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003). Host cells include cultured cells, e.g., mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell, a human embryonic kidney (HEK) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell).</p><p id="p-0161" num="0153">Standard technologies are known in the art to express foreign genes in these systems. Cells expressing an engineered IL2 polypeptide fused to either the heavy or the light chain of an antigen binding moiety, such as an antibody, may be engineered so as to also express the other of the antibody chains such that the expressed engineered IL2 fusion polypeptide comprises an antibody that has both a heavy and a light chain.</p><p id="p-0162" num="0154">In some embodiments, a method of producing an engineered IL2 polypeptide or engineered IL2 fusion polypeptide is provided. In some embodiments, the method comprises culturing a host cell comprising a polynucleotide encoding the an engineered IL2 polypeptide or engineered IL2 fusion polypeptide, as provided herein, under conditions suitable for expression of the an engineered IL2 polypeptide or engineered IL2 fusion polypeptide, and optionally recovering and/or purifying the an engineered IL2 polypeptide or engineered IL2 fusion polypeptide from the host cell (or host cell culture medium, for example, if the host cell secretes the polypeptide).</p><heading id="h-0010" level="2">Pharmaceutical Compositions</heading><p id="p-0163" num="0155">Provided herein are pharmaceutical compositions comprising an engineered IL2 polypeptide or engineered IL2 fusion polypeptide as described herein and a pharmaceutically acceptable diluent(s), excipient(s), or carrier(s). In some embodiments, the pharmaceutical compositions comprise an engineered IL2 polypeptide or an engineered IL2 fusion polypeptide as disclosed herein and an additional therapeutic agent (e.g., combination therapy). Non-limiting examples of such therapeutic agents are described herein below. The pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the engineered IL2 or IL2 fusion polypeptide into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any pharmaceutically acceptable techniques, carriers, and excipients are used as suitable to formulate the pharmaceutical compositions described herein: Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams &#x26; Wilkins 1999). Examples of IL-2 compositions are described in U.S. Pat. Nos. 4,604,377 and 4,766,106, which are incorporated by reference herein.</p><p id="p-0164" num="0156">As used herein, &#x201c;pharmaceutically acceptable carrier&#x201d; and &#x201c;physiologically acceptable carriers&#x201d; are used interchangeably and include any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g. antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, antioxidants, proteins, drugs, drug stabilizers, polymers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art and are molecular entities and compositions that are generally non-toxic to recipients at the dosages and concentrations employed, i.e., do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.</p><p id="p-0165" num="0157">The pharmaceutical composition may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection. Engineered IL2 polypeptides or engineered IL2 fusion polypeptides as describe herein (and any additional therapeutic agent) can be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrasplenically, intrarenally, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularally, orally, topically, locally, by inhalation (e.g. aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g. liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference). Parenteral administration, in particular intravenous injection, is most commonly used for administering polypeptide molecules such as the engineered IL2 polypeptides or engineered IL2 fusion polypeptides describe herein.</p><p id="p-0166" num="0158">Parenteral compositions include those designed for administration by injection, e.g. subcutaneous, intradermal, intralesional, intravenous, intraarterial intramuscular, intrathecal or intraperitoneal injection. For injection, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. Sterile injectable solutions are prepared by incorporating the engineered IL2 polypeptides or engineered IL2 fusion polypeptides in the required amount in the appropriate solvent with various of the other ingredients enumerated below, as required. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsion, methods of preparation include vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium thereof. The liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose. The pharmaceutical composition is preferably stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less that 0.5 ng/mg protein. Suitable pharmaceutically acceptable carriers include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, or the like. In some embodiments, the suspension may also contain suitable stabilizers or agents, which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl cleats or triglycerides, or liposomes.</p><p id="p-0167" num="0159">In some embodiments, aqueous suspensions contain one or more polymers as suspending agents. Example polymers include water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose, and water-insoluble polymers such as cross-linked carboxyl-containing polymers. Certain pharmaceutical compositions described herein comprise a mucoadhesive polymer, selected for example from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.</p><p id="p-0168" num="0160">In some embodiments, the pharmaceutical compositions include solubilizing agents to aid in the solubility of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide. The term &#x201c;solubilizing agent&#x201d; generally includes agents that result in formation of a micellar solution or a true solution of the agent. Certain acceptable nonionic surfactants, for example polysorbate 80, are useful as solubilizing agents. Examples include glycols, polyglycols, e.g., polyethylene glycol 400, and glycol ethers.</p><p id="p-0169" num="0161">In some embodiments, the pharmaceutical compositions include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.</p><p id="p-0170" num="0162">In some embodiments, the pharmaceutical compositions include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.</p><p id="p-0171" num="0163">In some embodiments, the pharmaceutical compositions include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.</p><p id="p-0172" num="0164">In some embodiments, the pharmaceutical compositions include one or more surfactants to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.</p><p id="p-0173" num="0165">In some embodiments, the pharmaceutical compositions include one or more antioxidants to enhance chemical stability where required. Suitable antioxidants include, by way of example only, ascorbic acid and sodium metabisulfite.</p><p id="p-0174" num="0166">In certain embodiments, aqueous suspension compositions are packaged in single-dose non-reclosable containers. Alternatively, multiple-dose reclosable containers are used, in which case it is typical to include a preservative in the composition.</p><p id="p-0175" num="0167">In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein are delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials are useful herein. In some embodiments, sustained-release capsules release the engineered IL2 polypeptide or engineered IL2 fusion polypeptides for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization are employed. Examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g. films, or microcapsules. In some embodiments, prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.</p><p id="p-0176" num="0168">In some embodiments, engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990).</p><p id="p-0177" num="0169">In some embodiments, engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.</p><p id="p-0178" num="0170">Pharmaceutical compositions comprising the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein may be manufactured by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.</p><p id="p-0179" num="0171">In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be formulated into a composition in a free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base. These include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.</p><p id="p-0180" num="0172">In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein are formulated for oral administration. In various embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein are formulated in oral dosage forms that include, by way of example only, tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like.</p><p id="p-0181" num="0173">In certain embodiments, pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. In specific embodiments, disintegrating agents are optionally added. Disintegrating agents include, by way of example only, cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.</p><p id="p-0182" num="0174">In some embodiments, dosage forms, such as dragee cores and tablets, are provided with one or more suitable coating. In specific embodiments, concentrated sugar solutions are used for coating the dosage form. The sugar solution, optionally contain additional components, such as by way of example only, gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs and/or pigments are also optionally added to the coatings for identification purposes. Additionally, the dyestuffs and/or pigments are optionally utilized to characterize different combinations of active agent doses.</p><p id="p-0183" num="0175">In certain embodiments, therapeutically effective amounts of at least one of the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein are formulated into other oral dosage forms. Oral dosage forms include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In specific embodiments, push-fit capsules contain the active ingredients in admixture with one or more filler. Fillers include lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In some embodiments, soft capsules contain one or more active agent that is dissolved or suspended in a suitable liquid. Suitable liquids may include one or more fatty oil, liquid paraffin, or liquid polyethylene glycol. In addition, stabilizers are optionally added.</p><p id="p-0184" num="0176">In some embodiments, therapeutically effective amounts of at least one of the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein are formulated for buccal or sublingual administration. Formulations suitable for buccal or sublingual administration include, by way of example only, tablets, lozenges, or gels.</p><p id="p-0185" num="0177">In some embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptide is administered topically. The engineered IL2 polypeptide or engineered IL2 fusion polypeptide described herein are formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compositions optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.</p><p id="p-0186" num="0178">In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides are formulated for transdermal administration. In specific embodiments, transdermal formulations employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. In various embodiments, such patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. In additional embodiments, the transdermal delivery of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide is accomplished by means of iontophoretic patches and the like. In certain embodiments, transdermal patches provide controlled delivery of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide. In specific embodiments, the rate of absorption is slowed by using rate-controlling membranes or by trapping the engineered IL2 polypeptide or engineered IL2 fusion polypeptide within a polymer matrix or gel. In alternative embodiments, absorption enhancers are used to increase absorption. Absorption enhancers or carriers include absorbable pharmaceutically acceptable solvents that assist passage through the skin. For example, in one embodiment, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the engineered IL2 polypeptide or engineered IL2 fusion polypeptide optionally with carriers, optionally a rate controlling barrier to deliver the engineered IL2 polypeptide or engineered IL2 fusion polypeptide to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.</p><p id="p-0187" num="0179">In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides are formulated for administration by inhalation. Various forms suitable for administration by inhalation include, but are not limited to, aerosols, mists or powders. Pharmaceutical compositions of the engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In specific embodiments, the dosage unit of a pressurized aerosol is determined by providing a valve to deliver a metered amount. In certain embodiments, capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator is formulated containing a powder mix of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide and a suitable powder base such as lactose or starch.</p><p id="p-0188" num="0180">In some embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptides are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.</p><p id="p-0189" num="0181">In certain embodiments, the formulations described herein comprise one or more antioxidants, metal chelating agents, thiol containing compounds and/or other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.</p><p id="p-0190" num="0182">In some embodiments, the concentration of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w/w, w/v or v/v.</p><p id="p-0191" num="0183">In some embodiments, the concentration of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25% 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w/w, w/v, or v/v.</p><p id="p-0192" num="0184">In some embodiments, the concentration of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v.</p><p id="p-0193" num="0185">In some embodiments, the concentration of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.</p><p id="p-0194" num="0186">In some embodiments, the amount the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g.</p><p id="p-0195" num="0187">In some embodiments, the amount of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g.</p><p id="p-0196" num="0188">In some embodiments, the amount of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.</p><heading id="h-0011" level="2">Methods of Treatment and Use</heading><p id="p-0197" num="0189">In some embodiments of the present disclosure provided herein are methods of modulating an immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide, an engineered IL2 fusion polypeptide, or a pharmaceutical composition thereof as previously described herein. In certain embodiments, modulating the immune response includes at least one of: enhancing effector T cell activity, enhancing NK cell activity, and suppressing regulatory T cell activity. In some embodiments of the present disclosure provided herein engineered IL2 polypeptides as previously described, fusion polypeptides as previously described, and/or pharmaceutical compositions as previously described, for use in a method of modulating an immune response in a subject in need thereof. In some embodiments, modulating the immune response comprising increasing STAT5 phosphorylation compared to WT IL2.</p><p id="p-0198" num="0190">In some embodiments of the present disclosure is a method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide, an engineered IL2 fusion polypeptide, or a pharmaceutical composition thereof as previously described herein. In some embodiments of the present disclosure provided herein engineered IL2 polypeptides as previously described, fusion polypeptides as previously described, and/or pharmaceutical compositions as previously described, for use in a method of treating a subject for a disease. Non-limiting examples of diseases or condition contemplated in the method include proliferative disorders, such as cancer, and immunosuppression.</p><p id="p-0199" num="0191">In some embodiments, is a method of treating a proliferative disorder comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide, an engineered IL2 fusion polypeptide, or a pharmaceutical composition thereof as previously described herein. In some embodiments, the proliferative disorder is cancer. Non-limiting examples of cancers include bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, glioblastoma, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, skin cancer, melanoma, bone cancer, renal cell carcinoma, and kidney cancer. Also included are pre-cancerous conditions or lesions and cancer metastases. Other cell proliferation disorders include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic region, and urogenital system. Similarly, other cell proliferation disorders can also be treated, such as hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other cell proliferation disease, besides neoplasia, located in an organ system listed above.</p><p id="p-0200" num="0192">In some embodiments, the method of treatment or modulating the immune response further comprises administering to the subject a therapeutically effective amount of at least one additional therapeutic agent (e.g., a combination therapy). In certain embodiments, the additional therapeutic agent is an anti-cancer agent. Examples of anti-cancer agents include checkpoint inhibitors (e.g., anti-PD1 antibodies), chemotherapeutic agents, agents that inhibit a tumor microenvironment, cancer vaccines (e.g., Sipuleucel-T), oncolytic viruses (e.g., talimogene laherparepvec), immune cells expressing a chimeric antigen receptor, and tumor infiltrating lymphocytes. In certain embodiments, the additional therapeutic agent is a molecule including an antigen binding moiety. In certain specific embodiments, the antigen binding moiety is selected from a single domain antibody, a Fab molecule, an scFv, a diabody, a nanobody, a bi-specific T cell engager, or an immunoglobulin. In certain embodiments, the antigen binding moiety is specific to a tumor antigen (e.g., carcinoembryonic antigen, fibroblast activation protein-&#x3b1;, CD20) or a check point protein (e.g., CTLA-4, PD-1 or PD-L1). In some embodiments, the additional therapeutic agent comprises an immune cell expressing a chimeric antigen receptor, an immune cell expressing an engineered T cell receptor, or a tumor infiltrating lymphocyte. In certain embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptide may be encoded by a polynucleotide transfected, transvected, or otherwise introduced into the immune cell that expresses the chimeric antigen receptor, the immune cell expressing an engineered T cell receptor, or the tumor infiltrating lymphocyte. In such embodiments, the immune cell may be an armored chimeric antigen receptor-expressing cell. The polynucleotide may additionally encode a secretion signal (e.g., the native IL2 signal sequence or a signal sequence derived from another protein) directly upstream of the engineered IL2 polypeptide coding sequence, to allow the cell to secrete the engineered IL2 polypeptide or engineered IL2 fusion polypeptide.</p><p id="p-0201" num="0193">In some embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 polypeptide having an IL2R&#x3b2; binding region two of SEQ ID NO: 1. In certain embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 polypeptide having an IL2R&#x3b2; binding region two of any one of SEQ ID NOs: 2-21. In certain embodiments, the method includes administering to the subject an engineered IL2 polypeptide of any of SEQ ID NOs: 23-42, any one of SEQ ID NOs: 44-63, any one of SEQ ID NOs: 147-170 (with the C-terminal histidine tag optionally included), or an Fc fusion polypeptide of SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 144 or SEQ ID NO: 145. In certain embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 polypeptide of SEQ ID NO: 22, or of any one of SEQ ID NOs: 23-42. In certain embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 fusion polypeptide of SEQ ID NO: 51. In certain embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 fusion polypeptide of SEQ ID NO: 43, or of any one of SEQ ID NOs: 44-63.</p><p id="p-0202" num="0194">Suitable routes of administration include, but are not limited to, intravenous, parenteral, transdermal, oral, rectal, aerosol, ophthalmic, pulmonary, transmucosal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.</p><p id="p-0203" num="0195">In certain embodiments, an engineered IL2 polypeptide or IL2 fusion polypeptide is administered systemically. In certain embodiments, an engineered IL2 polypeptide or engineered IL2 fusion polypeptide as described herein is administered in a local rather than systemic manner, for example, via injection of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide directly into an organ, tissue, or tumor. In some embodiments, long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in some embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific or cell-specific antibody. In such embodiments, the liposomes are targeted to and taken up selectively by the organ. In some embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptide as described herein is provided in the form of a rapid release formulation, in the form of an extended or sustained release formulation, in the form of an intermediate release formulation, or in the form of a depot preparation. In some embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptide described herein is administered topically.</p><p id="p-0204" num="0196">The appropriate dosage of an engineered IL2 polypeptide or engineered IL2 fusion polypeptide (used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease or condition, the route of administration, body weight of the subject, severity and progression of the disease, whether the polypeptide is administered for preventive or therapeutic purposes, previous or concurrent therapeutic interventions, the subject's clinical history and response to the engineered IL2 polypeptide or engineered IL2 fusion polypeptide, and the discretion of the attending physician. The practitioner responsible for administration will be able to determine the concentration of active ingredient(s) in a composition and appropriate dosing for the subject to be treated. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.</p><p id="p-0205" num="0197">A single administration of an engineered IL2 polypeptide may range from about 50,000 IU/kg to about 1,000,000 IU/kg or more of the engineered IL2 polypeptide. This may be repeated several times a day (e.g., 2-4 times per day), for several days (e.g., 3-5 consecutive days) and then may be repeated one or more times following a period of rest (e.g., 7-14 days). Thus, a therapeutically effective amount may comprise only a single administration or many administrations over a period of time (e.g. about 10-30 individual administrations of about 600,000 IU/kg of IL2 each given over about a 5-20 day period). When administered in the form of a fusion polypeptide, a therapeutically effective of the engineered IL2 fusion polypeptide may be lower than a non-fusion engineered IL2 polypeptide (e.g., 10,000 IU/kg to about 600,000 IU/kg). Similarly, the engineered IL2 fusion polypeptide may be administered to the patient at one time or over a series of treatments as described above.</p><p id="p-0206" num="0198">In certain embodiments, the daily dosage of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide ranges from about 1 &#x3bc;g/kg to about 100 mg/kg or more. For repeated administrations over several days or longer, depending on the condition, the treatment may be sustained until a desired suppression of disease symptoms occurs (e.g., tumor shrinkage). In some embodiments, a single dose of an engineered IL2 polypeptide or engineered IL2 fusion polypeptide is in the range from about 0.005 mg/kg to about 10 mg/kg. In some embodiments, a dose may be about 1 &#x3bc;g/kg/body weight, about 5 &#x3bc;g/kg/body weight, about 10 &#x3bc;g/kg/body weight, about 50 &#x3bc;g/kg/body weight, about 100 &#x3bc;g/kg/body weight, about 200 &#x3bc;g/kg/body weight, about 350 &#x3bc;g/kg/body weight, about 500 &#x3bc;g/kg/body weight, about 1 mg/kg/body weight, about 5 mg/kg/body weight, about 10 mg/kg/body weight, about 50 mg/kg/body weight, about 100 mg/kg/body weight, about 200 mg/kg/body weight, about 350 mg/kg/body weight, about 500 mg/kg/body weight, to about 1000 mg/kg/body weight per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above. Such doses may be administered intermittently, e.g., 2-3 times per day, every week, or every three weeks. An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful.</p><p id="p-0207" num="0199">The engineered IL2 polypeptides and engineered IL2 fusion polypeptides described herein may be used in an amount effective to achieve the intended purpose. For use to treat or prevent a disease condition, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides, or pharmaceutical compositions thereof, are administered in a therapeutically effective amount. Determination of a therapeutically effective amount is within the capabilities of those of skill in the art, especially in light of the details provided herein.</p><p id="p-0208" num="0200">For systemic administration, a therapeutically effective amount can be estimated initially from in vitro assays, such as cell culture assays. A dose can then be formulated in animal models to achieve a circulating concentration range that includes the IC<sub>50 </sub>as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Initial dosages can also be estimated from in vivo data, e.g., animal models, using techniques that are well known in the art. Administration to humans could readily be optimized by a person of ordinary skill in the art based on animal data. Dosage amount and interval may each be adjusted to provide plasma levels of engineered IL2 polypeptides and engineered IL2 fusion polypeptides which are sufficient to maintain therapeutic effect. Levels in plasma may be measured, for example, by HPLC.</p><heading id="h-0012" level="1">EXAMPLES</heading><heading id="h-0013" level="1">Example 1</heading><heading id="h-0014" level="1">Library Strategy to Identify IL2R&#x3b1;-Reduced Binding Mutations</heading><p id="p-0209" num="0201">The libraries of IL2 mutations to identify IL2R&#x3b1;-reduced binders were rationally designed based on the structural modeling of IL2 interactions with IL2R&#x3b1; (<figref idref="DRAWINGS">FIGS. <b>1</b>A &#x26; <b>1</b>B</figref>). Briefly, K35, R38, F42 and Y45 residues of IL2 were identified as the important residues interacting with IL2R&#x3b1; (<figref idref="DRAWINGS">FIG. <b>1</b>C</figref>). Mutagenic oligos carrying two, three and four randomized mutations at these residues were used for library construction (Table 1).</p><p id="p-0210" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="273pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Rationally designed IL2R&#x3b1;-reduced mutagenic libraries</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>K35</entry><entry>R38</entry><entry>F42</entry><entry>Y45</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>Library 1</entry><entry>2 amino acid</entry><entry>NNS</entry><entry>NNS</entry><entry>F</entry><entry>Y</entry></row><row><entry/><entry>mutagenesis</entry><entry>NNS</entry><entry>R</entry><entry>NNS</entry><entry>Y</entry></row><row><entry/><entry/><entry>NNS</entry><entry>R</entry><entry>F</entry><entry>NNS</entry></row><row><entry/><entry/><entry>K</entry><entry>NNS</entry><entry>NNS</entry><entry>Y</entry></row><row><entry/><entry/><entry>K</entry><entry>NNS</entry><entry>F</entry><entry>NNS</entry></row><row><entry/><entry/><entry>K</entry><entry>R</entry><entry>NNS</entry><entry>NNS</entry></row><row><entry>Library 2</entry><entry>3 amino acid</entry><entry>NNS</entry><entry>NNS</entry><entry>NNS</entry><entry>Y</entry></row><row><entry/><entry>mutagenesis</entry><entry>NNS</entry><entry>R</entry><entry>NNS</entry><entry>NNS</entry></row><row><entry/><entry/><entry>K</entry><entry>NNS</entry><entry>NNS</entry><entry>NNS</entry></row><row><entry>Library 3</entry><entry>4 amino acid</entry><entry>K50%/</entry><entry>R50%/</entry><entry>A50%/</entry><entry>Y50%/</entry></row><row><entry/><entry>mixed ratio</entry><entry>NNS50%&#x2002;&#x2002;&#x2002;</entry><entry>NNS50%&#x2002;&#x2002;&#x2002;</entry><entry>NNS50%&#x2002;&#x2002;&#x2002;</entry><entry>NNS50%&#x2002;&#x2002;&#x2002;</entry></row><row><entry/><entry>mutagenesis</entry><entry>K70%/</entry><entry>R70%/</entry><entry>F70%/</entry><entry>Y70%/</entry></row><row><entry/><entry/><entry>NNS30%&#x2002;&#x2002;&#x2002;</entry><entry>NNS30%&#x2002;&#x2002;&#x2002;</entry><entry>NNS30%&#x2002;&#x2002;&#x2002;</entry><entry>NNS30%&#x2002;&#x2002;&#x2002;</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0211" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Mutagenic&#x2003;oligo&#x2003;design&#x2003;for&#x2003;IL-2R&#x3b1;-reduced&#x2003;binding</entry></row><row><entry>libraries</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="168pt" align="left"/><colspec colname="3" colwidth="21pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>SEQ</entry></row><row><entry>Oligo</entry><entry/><entry>ID</entry></row><row><entry>#</entry><entry>Sequence</entry><entry>NO:</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="28pt" align="char" char="."/><colspec colname="2" colwidth="168pt" align="left"/><colspec colname="3" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>1</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;NNS&#x2003;ctg&#x2003;acc&#x2003;NNS&#x2003;atg</entry><entry>171</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;ttc&#x2003;aag&#x2003;ttc&#x2003;tac&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>2</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;NNS&#x2003;ctg&#x2003;acc&#x2003;cgg&#x2003;atg</entry><entry>172</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;NNS&#x2003;aag&#x2003;ttc&#x2003;tac&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>3</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;NNS&#x2003;ctg&#x2003;acc&#x2003;cgg&#x2003;atg</entry><entry>173</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;ttc&#x2003;aag&#x2003;ttc&#x2003;NNS&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>4</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;aag&#x2003;ctg&#x2003;acc&#x2003;NNS&#x2003;atg</entry><entry>174</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;NNS&#x2003;aag&#x2003;ttc&#x2003;tac&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>5</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;aag&#x2003;ctg&#x2003;acc&#x2003;NNS&#x2003;atg</entry><entry>175</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;ttc&#x2003;aag&#x2003;ttc&#x2003;NNS&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>6</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;aag&#x2003;ctg&#x2003;acc&#x2003;cgg&#x2003;atg</entry><entry>176</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;NNS&#x2003;aag&#x2003;ttc&#x2003;NNS&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>7</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;NNS&#x2003;ctg&#x2003;acc&#x2003;NNS&#x2003;atg</entry><entry>177</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;NNS&#x2003;aag&#x2003;ttc&#x2003;tac&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>8</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;NNS&#x2003;ctg&#x2003;acc&#x2003;cgg&#x2003;atg</entry><entry>178</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;NNS&#x2003;aag&#x2003;ttc&#x2003;NNS&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>9</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;aag&#x2003;ctg&#x2003;acc&#x2003;NNS&#x2003;atg</entry><entry>179</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;NNS&#x2003;aag&#x2003;ttc&#x2003;NNS&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>10</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;AAG&#x2003;ctg&#x2003;acc&#x2003;CGG&#x2003;atg</entry><entry>180</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;GCC&#x2003;aag&#x2003;ttc&#x2003;TAC&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry><entry/></row><row><entry> </entry></row><row><entry>11</entry><entry>aac&#x2003;tac&#x2003;aag&#x2003;aac&#x2003;ccc&#x2003;AAG&#x2003;ctg&#x2003;acc&#x2003;CGG&#x2003;atg</entry><entry>181</entry></row><row><entry/><entry>ctg&#x2003;acc&#x2003;GCC&#x2003;aag&#x2003;ttc&#x2003;TAC&#x2003;atg&#x2003;cct&#x2003;aag&#x2003;aag</entry><entry/></row><row><entry/><entry>gcc&#x2003;acc</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0212" num="0202">Upper case nucleotide trimer is mixed at 50% WT and 50% NNS, or 70% WT and 30% NNS, where &#x201c;N&#x201d; refers to any nucleotide, and &#x201c;S&#x201d; refers to G or C. Three libraries were composed by multi-step PCR and overlapping PCR of above mutagenic oligos with WT IL2 sequence as template. Library 1 includes mutagenic oligos 1-6, library 2 includes mutagenic oligos 7-9, and library 3 includes mutagenic oligos 10-11 (Table 2). Those mutagenic libraries have been further modified to have in vitro transcription and translation signal at the N-terminus. A flag-tag sequence was also added to the C-terminus for selection and purification purpose.</p><heading id="h-0015" level="1">Example 2</heading><heading id="h-0016" level="1">Selection and Identification of IL2R&#x3b1;-Reduced Binding Clones</heading><p id="p-0213" num="0203">mRNA display technology was used to select IL2 mutants with IL2R&#x3b1;-reduced binding from the three IL2 mutagenic libraries. Briefly, the DNA libraries were first transcribed into mRNA libraries and then translated into mRNA-IL2 mutant fusion libraries by covalent coupling through a puromycin linker. The libraries were purified and converted to mRNA/cDNA fusion libraries. The fusion libraries were counter-selected with human and mouse IgGs (negative proteins) to remove nonspecific binders, then counter-selected against IL2R&#x3b1; three times. Library flow through (unbound molecules) was collected and PCR was performed to recover the IL2R&#x3b1; unbound molecules followed by gel purification. The recovered pool was subcloned into pET22b vector and expressed in <i>E. coli </i>Rosetta II strands. The supernatant of individual clones was tested in IL2R&#x3b1; binding ELISA. <figref idref="DRAWINGS">FIG. <b>2</b>A</figref> shows the ELISA results of supernatant of selected IL2 clones to IL2R&#x3b1;. <figref idref="DRAWINGS">FIG. <b>2</b>B</figref> shows the clone expression plotted against IL2R&#x3b1; binding with supernatant. <figref idref="DRAWINGS">FIG. <b>3</b></figref> shows a sequence alignment of the clones identified with IL2R&#x3b1;-reduced binding.</p><heading id="h-0017" level="1">Example 3</heading><heading id="h-0018" level="1">Binding Kinetics Analysis of IL2R&#x3b1;-Reduced Binding Clones</heading><p id="p-0214" num="0204">The binding kinetics of IL2R&#x3b1;-reduced binding clones to IL2R&#x3b1; was assessed utilizing SPR technology with a Biacore T200, software version 2.0. For each cycle, 1 ug/mL of human IL2R&#x3b1; was captured for 60 seconds at a flow rate of 10 uL/min on flow cell 2 in 1&#xd7;HBSP buffer on a Protein A sensor chip. 100 nM of each HIS and Flag tag purified IL2 mutant was injected onto both the reference flow cell 1 and IL2R&#x3b1; captured flow cell 2 for 150 seconds at a flow rate of 30 uL/min followed by washing for 300 seconds. The flow cells were then regenerated with Glycine pH 2.0 for 60 seconds at a flow rate of 30 uL/min. A HBSP+ buffer was included with each sample as a baseline control. The assay was set up in a 96-well format. The kinetics data was analyzed with Biacore T200 evaluation software 3.0. The specific binding response unit was derived from subtraction of binding to reference flow cell 1 from IL2R&#x3b1; flow cell 2 and subtraction of buffer control. WT IL2 was included as control. Relative response (RU) was determined for each IL2R&#x3b1;-reduced binding clone (<figref idref="DRAWINGS">FIG. <b>4</b></figref>, Table 3).</p><p id="p-0215" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Binding kinetics analysis of IL2R&#x3b1;-</entry></row><row><entry>reduced binding clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>Relevant </entry></row><row><entry/><entry/><entry/><entry/><entry>binding to </entry></row><row><entry/><entry/><entry>Cycle </entry><entry>RU </entry><entry>WT IL2 </entry></row><row><entry/><entry>Clone</entry><entry>Number</entry><entry>(at 100 nM)</entry><entry>(%)</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="63pt" align="char" char="."/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="63pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>Buffer</entry><entry>3</entry><entry>&#x2212;0.1</entry><entry>0</entry></row><row><entry/><entry>WT IL2</entry><entry>44</entry><entry>142</entry><entry>100</entry></row><row><entry/><entry>EP001</entry><entry>50</entry><entry>2.2</entry><entry>1.55</entry></row><row><entry/><entry>EP003</entry><entry>52</entry><entry>40.8</entry><entry>28.73</entry></row><row><entry/><entry>EP101</entry><entry>4</entry><entry>2.5</entry><entry>1.76</entry></row><row><entry/><entry>EP120</entry><entry>6</entry><entry>3.6</entry><entry>2.54</entry></row><row><entry/><entry>EP121</entry><entry>8</entry><entry>3.4</entry><entry>2.39</entry></row><row><entry/><entry>EP125</entry><entry>10</entry><entry>6.1</entry><entry>4.29</entry></row><row><entry/><entry>EP119</entry><entry>12</entry><entry>2.7</entry><entry>1.9</entry></row><row><entry/><entry>EP115</entry><entry>14</entry><entry>2.4</entry><entry>1.69</entry></row><row><entry/><entry>EP126</entry><entry>16</entry><entry>2.6</entry><entry>1.83</entry></row><row><entry/><entry>EP117</entry><entry>18</entry><entry>2.5</entry><entry>1.76</entry></row><row><entry/><entry>EP122</entry><entry>20</entry><entry>2.5</entry><entry>1.76</entry></row><row><entry/><entry>EP108</entry><entry>22</entry><entry>2.4</entry><entry>1.69</entry></row><row><entry/><entry>EP100</entry><entry>24</entry><entry>1.7</entry><entry>1.19</entry></row><row><entry/><entry>EP110</entry><entry>26</entry><entry>2.6</entry><entry>1.83</entry></row><row><entry/><entry>EP105</entry><entry>28</entry><entry>2.1</entry><entry>1.48</entry></row><row><entry/><entry>EP113</entry><entry>30</entry><entry>2.6</entry><entry>1.83</entry></row><row><entry/><entry>EP123</entry><entry>32</entry><entry>5.3</entry><entry>3.73</entry></row><row><entry/><entry>EP111</entry><entry>34</entry><entry>2.8</entry><entry>1.97</entry></row><row><entry/><entry>EP104</entry><entry>36</entry><entry>2.8</entry><entry>1.97</entry></row><row><entry/><entry>EP103</entry><entry>38</entry><entry>2.9</entry><entry>2.04</entry></row><row><entry/><entry>EP112</entry><entry>40</entry><entry>2.9</entry><entry>2.04</entry></row><row><entry/><entry>EP102</entry><entry>42</entry><entry>2.7</entry><entry>1.9</entry></row><row><entry/><entry>EP225</entry><entry>46</entry><entry>7.4</entry><entry>5.21</entry></row><row><entry/><entry>EP226</entry><entry>48</entry><entry>3</entry><entry>2.11</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0019" level="1">Example 4</heading><heading id="h-0020" level="1">Library Strategy to Generate IL2R&#x3b2; Agonists</heading><p id="p-0216" num="0205">Engineered IL2R&#x3b2; binding agonists were created by rational IL2 mutagenic library design followed by selection with mRNA display technology platform. Briefly, two WT IL2 binding regions to IL2R&#x3b2; were identified: IL2R&#x3b2; binding region 1 &#x201c;QLQLEHLLLDLQM&#x201d; (SEQ ID NO: 67) and IL2R&#x3b2; binding region 2 &#x201c;RPRDLISNINVIVLE&#x201d; (SEQ ID NO: 68) from structural analysis. For production of mutagenic libraries including mutations to IL2R&#x3b2; binding region 1, IL2R&#x3b2; binding region 2, or IL2R&#x3b2; binding region 1 and IL2R&#x3b2; binding region 2, two mutagenic oligomers (Oligo 1, Oligo 2) encoding the sequences of these two regions were designed (Table 4). For Oligo 1 and Oligo 2 sequences, each codon trimer with nucleotides shown as lower-case letters was a mixture of 50% WT and 50% NNS (with &#x201c;N&#x201d; referring to any nucleotide, and &#x201c;S&#x201d; referring to G or C). Additional oligomers (Oligo 3 to Oligo 12) coding WT IL2 sequences were designed from WT region for mutagenic library assembly (Table 4). Three mutagenic libraries were constructed using these oligos (<figref idref="DRAWINGS">FIG. <b>5</b></figref>). Library 4 was constructed using an overlapped PCR strategy with mutagenic oligo 1 and oligos 3-12. Library 5 was constructed using an overlapped PCR strategy with mutagenic oligo 2 and oligos 3-9, 11, and 12. Library 6 was constructed using an overlapped PCR strategy with mutagenic oligos 1 and 2 and oligos 3-8, 11, and 12. The three mutagenic libraries were further modified to have an in vitro transcription and translation signal at N-terminus and a Flag-tag at the C-terminus for selection with mRNA display.</p><p id="p-0217" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Mutagenic&#x2003;oligo&#x2003;design&#x2003;for&#x2003;IL-2R&#x2003;agonist&#x2003;libraries</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="175pt" align="left"/><colspec colname="3" colwidth="14pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>SEQ</entry></row><row><entry>Oligo</entry><entry/><entry>ID</entry></row><row><entry>#</entry><entry>Sequence</entry><entry>NO:</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="28pt" align="char" char="."/><colspec colname="2" colwidth="175pt" align="left"/><colspec colname="3" colwidth="14pt" align="center"/><tbody valign="top"><row><entry>1</entry><entry>AGT&#x2003;TCT&#x2003;ACA&#x2003;AAG&#x2003;AAA&#x2003;ACA&#x2003;cag&#x2003;cta&#x2003;caa&#x2003;ctg</entry><entry>69</entry></row><row><entry/><entry>gag&#x2003;cat&#x2003;tta&#x2003;ctg&#x2003;ctg&#x2003;gat&#x2003;tta&#x2003;cag&#x2003;atg&#x2003;ATT</entry><entry/></row><row><entry/><entry>TTG&#x2003;AAT&#x2003;GGA&#x2003;ATT&#x2003;AAT</entry><entry/></row><row><entry> </entry></row><row><entry>2</entry><entry>AGC&#x2003;AAA&#x2003;AAC&#x2003;TTT&#x2003;CAC&#x2003;TTA&#x2003;aga&#x2003;ccc&#x2003;agg&#x2003;gac</entry><entry>70</entry></row><row><entry/><entry>tta&#x2003;atc&#x2003;agc&#x2003;aat&#x2003;atc&#x2003;aac&#x2003;gta&#x2003;ata&#x2003;gtt&#x2003;ctg</entry><entry/></row><row><entry/><entry>gaa&#x2003;CTA&#x2003;AAG&#x2003;GGA&#x2003;TCT&#x2003;GAA&#x2003;ACA</entry><entry/></row><row><entry> </entry></row><row><entry>3</entry><entry>AATTACTATTTACAATTACAATGGCTAGCGCACCTACTTC</entry><entry>71</entry></row><row><entry/><entry>AAGTTCTACAAAGAAAACA</entry><entry/></row><row><entry> </entry></row><row><entry>4</entry><entry>CTTGGGCATGTAAAACTTAAATGTGAGCATCCTGGTGAG</entry><entry>72</entry></row><row><entry/><entry>TTTGGGATTCTTGTAATTATTAATTCCATTCAAAAT</entry><entry/></row><row><entry> </entry></row><row><entry>5</entry><entry>AAGTTTTACATGCCCAAGAAGGCCACAGAACTGAAACAT</entry><entry>73</entry></row><row><entry/><entry>CTTCAGTGTCTAGAAGAAGAACTCAAACCTC</entry><entry/></row><row><entry> </entry></row><row><entry>6</entry><entry>TAAGTGAAAGTTTTTGCTTTGAGCTAAATTTAGCACTTCC</entry><entry>74</entry></row><row><entry/><entry>TCCAGAGGTTTGA&#x2003;GTTCTTC</entry><entry/></row><row><entry> </entry></row><row><entry>7</entry><entry>CTAAAGGGATCTGAAACAACATTCATGTGTGAATATGCT</entry><entry>75</entry></row><row><entry/><entry>GATGAGACAGCAACCATTGTAGAATTTCTGAACAGA</entry><entry/></row><row><entry> </entry></row><row><entry>8</entry><entry>AGATGGTGCAGCCACAGTTCGAGTCAGTGTTGAGATGAT</entry><entry>76</entry></row><row><entry/><entry>GCTTTGACAAAAGGTAATCCATCTGTTCAGAAATTCTAC</entry><entry/></row><row><entry> </entry></row><row><entry>9</entry><entry>AGTTCTACAAAGAAAACACAGCTACAACTGGAGCATTTA</entry><entry>77</entry></row><row><entry/><entry>CTGCTGGATTTACAGATGATTTTGAATGGAATTAAT</entry><entry/></row><row><entry> </entry></row><row><entry>10</entry><entry>AGCAAAAACTTTCACTTAAGACCCAGGGACTTAATCAG</entry><entry>78</entry></row><row><entry/><entry>CAATATCAACGTAATAGTTCTGGAACTAAAGGGATCTG</entry><entry/></row><row><entry/><entry>AAACA</entry><entry/></row><row><entry> </entry></row><row><entry>11</entry><entry>AAGTTTTACATGCCCAAG</entry><entry>79</entry></row><row><entry> </entry></row><row><entry>12</entry><entry>TAAGTGAAAGTTTTTGC</entry><entry>80</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0021" level="1">Example 5</heading><heading id="h-0022" level="1">Selection and Identification of IL2R&#x3b2; Agonist Clones</heading><p id="p-0218" num="0206">An mRNA display technology platform was used for the identification of IL2R&#x3b2; agonists from three IL2 mutagenic libraries. The DNA libraries were first transcribed into mRNA libraries and then translated into mRNA-IL2 mutant fusion libraries by covalent coupling through a puromycin linker. The libraries were then purified and converted to mRNA/cDNA fusion libraries (see, e.g., U.S. Pat. No. 6,258,558, hereby incorporated by reference). The fusion libraries were first counter selected with human IgGs (negative proteins) to remove nonspecific binders, then counter selected to remove IL2R&#x3b1; binders, followed by selection against recombinant IL2R&#x3b2;/Fc protein captured on Protein G magnetic beads. The IL2R&#x3b2; binders were recovered and enriched by PCR amplification. A total of five rounds of selections were executed to generate highly enriched engineered IL2 mutants binding to IL2R&#x3b2;.</p><p id="p-0219" num="0207">Following five rounds of selection, enriched libraries were cloned into bacterial periplasmic expression vector pET22b and transformed into TOP10 competent <i>E. coli </i>cells. Each engineered IL2 molecule was engineered to have a C-terminus flag and 6&#xd7;HIS tag for purification and assay detection. Clones from TOP10 cells were pooled and the miniprep DNA were prepared and subsequently transformed into <i>E. coli </i>Rosetta II strain for expression. Single clones were picked, grown and induced with 0.25 mM IPTG in 96-well plates for expression. The supernatant was collected after 16 to 24 hours induction at 30&#xb0; C. for assays to identify binders.</p><p id="p-0220" num="0208">Supernatants containing engineered IL2 mutants were assessed with sandwich ELISA assay to screen for expression. Briefly, an anti-HIS tag antibody (R&#x26;D Systems) was immobilized in a 96-well plate at a final concentration of 2 &#x3bc;g/mL in 1&#xd7;PBS in a total volume of 50 &#x3bc;L per well. The plate was incubated overnight at 4&#xb0; C. followed by blocking with 200 &#x3bc;L of superblock per well for 1 hour. 100 &#x3bc;L of 1:10 1&#xd7;PBST diluted supernatant was added to each well and incubated for 1 hour with shaking. The expression level of engineered IL2 mutant was detected by adding 50 &#x3bc;l of anti-Flag HRP diluted at 1:5000 in 1&#xd7;PBST for one hour. In between each step, the plate was washed three times with 1&#xd7;PBST using a plate washer. The plate was then developed with 50 &#x3bc;L of TMB substrate for 5 minutes and stopped by adding 50 of 2N sulfuric acid. The plate was read at OD<sub>450 </sub>nm using a Biotek plate reader and the data was analyzed with Prism 8.1 software.</p><p id="p-0221" num="0209">Single clones were next screened for IL2R&#x3b2; binding. IL2R&#x3b2; binding screening ELISA was developed for the identification of individual engineered IL2 mutant. Briefly, 96-well plate was immobilized with human Fc and human IL2R&#x3b2;, respectively, at a final concentration of 2 &#x3bc;g/mL in 1&#xd7;PBS in total volume of 50 per well. The plate was incubated overnight at 4&#xb0; C. followed by blocking with 200 of superblock per well for 1 hour. 100 &#x3bc;l of supernatant was added to both Fc and IL2R&#x3b2; immobilized wells and incubated for 1 hour with shaking. The engineered IL2 mutant binding was detected by adding 50 &#x3bc;L of anti-Flag HRP diluted at 1:5000 in 1&#xd7;PBST. In between each step, the plate was washed three times with 1&#xd7;PBST in a plate washer. The plate was then developed with 50 &#x3bc;L of TMB substrate for five minutes and stopped by adding 50 &#x3bc;L of 2N sulfuric acid. The plate was read at OD450 nm using a Biotek plate reader and the binding and selectivity was analyzed. The correlation of expression and IL2R&#x3b2; binding was plotted with Prism 8.1 software.</p><p id="p-0222" num="0210">High IL2R&#x3b2;-binding clones (shown to the right of the vertical OD450 nm cutoff) were identified from library 5 for further characterization as engineered IL2R&#x3b2; agonists (<figref idref="DRAWINGS">FIG. <b>6</b></figref>). The IL2R&#x3b2;-binding activity of the clones generally correlated with expression level of the clones. Multiple sequence alignment of the IL2R&#x3b2; binding region 2 revealed both highly conserved and highly varied amino acids as compared to IL2 WT, as well as clone sequences that were identified multiple times independently (<figref idref="DRAWINGS">FIG. <b>7</b></figref>). No specific IL2R&#x3b2;-binding clones were identified from libraries 4 and 6.</p><heading id="h-0023" level="1">Example 6</heading><heading id="h-0024" level="1">Production of IL2R&#x3b2; Agonist Clones in E. <i>Coli </i>and Mammalian Cells</heading><p id="p-0223" num="0211">For production of the IL2R&#x3b2; agonists in <i>E. coli</i>, the glycerol stock of each engineered agonist clone was inoculated into TB medium for overnight growth. The next day, cells from the overnight culture were inoculated into TB medium and grown to a cell density of OD<sub>600 </sub>between 0.6-0.8. IPTG was added to a final concentration of 1 mM to induce the expression during culture at 30 degrees C. overnight. The supernatant was collected by centrifugation. The engineered agonists were purified by Ni-Sepharose (GE Healthcare) affinity column according to the manufacturer's protocol. The purity of the engineered agonists was further improved by Flag-tag affinity column purification (Sigma). The agonists were each concentrated and loaded to a Sephadex 200 Increase 10/300 GL column in AKTA for size exclusion chromatographic column purification. The high homogeneous monomeric peak fractions of the agonists were each pooled and concentrated. Endotoxin was further removed using endotoxin removal resin (Pierce) according to the standard protocol. The final endotoxin level was less than 10 EU/mg. Protein purity was confirmed by LC-MS spectrometry analysis and SDS gel (<figref idref="DRAWINGS">FIG. <b>8</b></figref>). The proteins were each stored in 1&#xd7;PBS buffer for binding and functional analysis.</p><p id="p-0224" num="0212">For production of the IL2R&#x3b2; agonists in mammalian cells, the DNA sequence corresponding to the amino-acid sequence was codon optimized, synthesized and subcloned into pCDNA3.4 (Invitrogen). Each engineered IL2 polypeptide was expressed transiently in ExpiHEK293-F cells in free style system (Invitrogen) according to standard protocol. The cells were grown in the above conditions for seven days before harvesting. The supernatant was collected by centrifugation and filtered through a 0.2 &#x3bc;m PES membrane. The agonists were first purified by Ni Sepharose Excel resin column (GE Healthcare) and buffer exchanged to PBS pH 7.4+300 mM NaCl (total) with 7 k Da Zeba columns. Each polypeptide was then concentrated to 1 mL and purified by a Superdex 200 Increase 10/300 GL column (GE Healthcare) to homogeneity. The monomeric peak fractions were pooled and concentrated. The final purified protein contained less 10 EU/mg endotoxin. The IL2 polypeptide identify was confirmed by LC-MS spectrometry analysis and purity analyzed by SDS gel. The proteins were stored in 1&#xd7;PBS/300 nM NaCl buffer for binding, functional and mechanism analysis.</p><heading id="h-0025" level="1">Example 7</heading><heading id="h-0026" level="1">Binding Kinetics Analysis of IL2R&#x3b2; Agonist Clones Using Surface Plasmon Resonance</heading><p id="p-0225" num="0213">The binding kinetics of <i>E. coli </i>produced WT IL2 and EP001-EP007 were assessed by surface plasmon resonance technology with Biacore T200 for engineered IL2 polypeptides produced in <i>E. coli </i>cells and engineered IL2 polypeptides produced in mammalian cells. The assay was run with Biacore T200 control software version 2.0. For each cycle, 1 &#x3bc;g/mL of human IL2R&#x3b2; or IL2R&#x3b1; was captured for 60 seconds at flow rate of 10 &#x3bc;L/min on flow cell 2 in 1&#xd7;HBST buffer on Protein A sensor chip. Two-fold serial diluted HIS tag purified engineered IL2 mutant was injected onto both reference flow cell 1 and IL2R&#x3b2; or IL2R&#x3b1; captured flow cell 2 for 150 seconds at flow rate of 30 &#x3bc;L/min followed by washing for 300 seconds. The flow cells were then regenerated with Glycine pH 2 for 40 seconds at a flow rate of 30 &#x3bc;L/mins. Eight concentration points from 0 to 100 nM were assayed for each IL2R&#x3b2; agonist clone 96-well plate format. The kinetics data was analyzed with Biacore T200 evaluation software 3000. The specific binding response unit was derived from subtraction of binding to reference flow cell 1 from target flow cell 2.</p><p id="p-0226" num="0214">WT IL2 was used to validate the binding protocols and was included in each run as a control (<figref idref="DRAWINGS">FIGS. <b>9</b>A &#x26; <b>9</b>B</figref>). Representative sensorgrams of binding kinetics of <i>E. coli </i>and mammalian produced IL2R&#x3b2; agonist binding to IL2R&#x3b1; (<figref idref="DRAWINGS">FIGS. <b>10</b>A-<b>10</b>H</figref> for <i>E. coli </i>produced, <figref idref="DRAWINGS">FIGS. <b>12</b>A-<b>12</b>D</figref> for mammalian produced) and IL2R&#x3b2; (<figref idref="DRAWINGS">FIGS. <b>11</b>A-<b>11</b>H</figref> for <i>E. coli </i>produced, <figref idref="DRAWINGS">FIGS. <b>13</b>A-<b>13</b>D</figref> for mammalian produced) are shown. Binding kinetics for <i>E. coli</i>-produced IL2 (Table 5) and mammalian-produced IL2 (Table 6) are summarized.</p><p id="p-0227" num="0215">IL2R&#x3b2; agonists EP001, EP006, and EP007 demonstrated no detectable IL2R&#x3b1; binding or a significant decrease (greater than a twenty-fold decrease) in IL2R&#x3b1; binding, but had a significant increase in IL2R&#x3b2; binding as compared to WT IL2 (Table 5, 6). In contrast, the IL2R&#x3b2; agonists EP002, EP003, EP004, and EP005 did not demonstrate a significant decrease in IL2R&#x3b1; (less than a twenty-fold decrease) as compared to wild-type IL2, but had a significant increase in IL2R&#x3b2; binding as compared to WT IL2 (Tables 5, 6).</p><p id="p-0228" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="280pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of IL2R binding kinetics of <i>E.coli</i>-produced IL2R&#x3b2; agonist clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="119pt" align="center"/><colspec colname="4" colwidth="91pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Relative activity</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="119pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry>IL2&#x3b1;</entry><entry>IL2R&#x3b2;</entry><entry>IL2R&#x3b1;</entry><entry>IL2R&#x3b2;</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry>KD*</entry><entry>Kon</entry><entry>Koff</entry><entry>KD</entry><entry>(KD:</entry><entry>(KD:</entry></row><row><entry>Clones</entry><entry>(M)</entry><entry>(1/Ms)</entry><entry>(1/s)</entry><entry>(M)</entry><entry>fold)</entry><entry>fold)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry>WT IL2</entry><entry>9.51E&#x2212;09</entry><entry>5.83E+04</entry><entry>0.253&#x2003;&#x2002;</entry><entry>4.34E&#x2212;06</entry><entry>&#x2014;</entry><entry>&#x2014;</entry></row><row><entry>EP001</entry><entry>ND</entry><entry>3.26E+06</entry><entry>0.003646</entry><entry>1.12E&#x2212;09</entry><entry>NA</entry><entry>&#x2002;3888</entry></row><row><entry>EP002</entry><entry>1.01E&#x2212;07</entry><entry>1.15E+06</entry><entry>0.002734</entry><entry>2.37E&#x2212;09</entry><entry>&#x2212;10.6&#x2003;</entry><entry>&#x2002;1834</entry></row><row><entry>EP003</entry><entry>2.14E&#x2212;08</entry><entry>2.18E+06</entry><entry>2.70E&#x2212;04</entry><entry>1.23E&#x2212;10</entry><entry>&#x2212;2.3&#x2002;</entry><entry>35194</entry></row><row><entry>EP004</entry><entry>4.05E&#x2212;08</entry><entry>3.05E+06</entry><entry>0.001892</entry><entry>6.20E&#x2212;10</entry><entry>&#x2212;4.3&#x2002;</entry><entry>&#x2002;7007</entry></row><row><entry>EP005</entry><entry>1.26E&#x2212;08</entry><entry>6.10E+06</entry><entry>0.005397</entry><entry>8.85E&#x2212;10</entry><entry>&#x2212;1.3&#x2002;</entry><entry>&#x2002;4909</entry></row><row><entry>EP006</entry><entry>4.81E&#x2212;07</entry><entry>8.19E+05</entry><entry>0.002541</entry><entry>3.10E&#x2212;09</entry><entry>&#x2212;50.6&#x2003;</entry><entry>&#x2002;1399</entry></row><row><entry>EP007</entry><entry>ND</entry><entry>7.09E+05</entry><entry>2.63E&#x2212;04</entry><entry>3.70E&#x2212;10</entry><entry>NA</entry><entry>11728</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0229" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="287pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of IL2R binding kinetics of mammalian-produced IL2R&#x3b2; agonist clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="126pt" align="center"/><colspec colname="4" colwidth="91pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Relative activity</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="126pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry>IL2&#x3b1;</entry><entry>IL2R&#x3b2;</entry><entry>IL2R&#x3b1;</entry><entry>IL2R&#x3b2;</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry>KD*</entry><entry>Kon</entry><entry>Koff</entry><entry>KD</entry><entry>(KD:</entry><entry>(KD:</entry></row><row><entry>Clones</entry><entry>(M)</entry><entry>(1/Ms)</entry><entry>(1/s)</entry><entry>(M)</entry><entry>fold)</entry><entry>fold)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry>WT IL2</entry><entry>1.35E&#x2212;08</entry><entry>3.26E+03</entry><entry>0.00329&#x2002;</entry><entry>1.01E&#x2212;06</entry><entry>&#x2014;</entry><entry>&#x2014;</entry></row><row><entry>EP001</entry><entry>ND</entry><entry>5.61E+06</entry><entry>0.00417&#x2002;</entry><entry>7.43E&#x2212;10</entry><entry>NA</entry><entry>1359</entry></row><row><entry>EP003</entry><entry>3.02E&#x2212;07</entry><entry>2.59E+06</entry><entry>0.000376</entry><entry>1.45E&#x2212;10</entry><entry>&#x2212;22.4&#x2003;</entry><entry>6966</entry></row><row><entry>EP004</entry><entry>2.88E&#x2212;08</entry><entry>5.18E+06</entry><entry>2.15E&#x2212;03</entry><entry>4.14E&#x2212;10</entry><entry>&#x2212;2.1&#x2002;</entry><entry>2422</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0027" level="1">Example 8</heading><heading id="h-0028" level="1">IL2R&#x3b2; Agonist P-STAT5 Activation in Human PBMCs</heading><p id="p-0230" num="0216">Human PBMCs were isolated from peripheral blood of three separate donors and plated at 250,000 cells/well in a 96-well plate in 75 &#x3bc;L of media. Cells were rested 1 hr at 37&#xb0; C. Cells were stimulated with human WT IL2 and engineered His-Flag tagged IL2 at 4&#xd7; concentration in 25 &#x3bc;L for 20 min at 37&#xb0; C. Stimulated PBMCs were immediately fixed, permeabilized, stained for cell lineage markers (CD3, CD56, CD4, CD8, FOXP3) and p-STAT5 and visualized on the Attune flow cytometer. CD8+ T cells were defined as CD3+CD56&#x2212;CD4&#x2212;CD8+. NK cells were defined as CD3&#x2212;CD56+. T regulatory cells were defined as CD3+CD56&#x2212;CD4+CD8&#x2212;FOXP3+. The % of cells that were p-STAT5+ was determined and graphed versus each IL2 titration (<figref idref="DRAWINGS">FIGS. <b>14</b>A-<b>14</b>C</figref> for blood donor 1, <figref idref="DRAWINGS">FIGS. <b>14</b>D-<b>14</b>F</figref> for blood donor 2, and <figref idref="DRAWINGS">FIGS. <b>14</b>G-<b>14</b>I</figref> for blood donor 3). EC50 values for P-STAT5 activation were determined using Prism software (Table 7).</p><p id="p-0231" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of P-STAT5 activation of </entry></row><row><entry>human CD8+ T cells, NK cells and Tregs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="140pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>EC50 (nM)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>WT</entry><entry>EP001</entry><entry>EP003</entry><entry>EP004</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>Blood</entry><entry>CD8+ T Cells</entry><entry>8.9E&#x2212;01</entry><entry>1.9E&#x2212;02</entry><entry>&#x2003;1.1E&#x2212;02</entry><entry>&#x2003;2.1E&#x2212;02</entry></row><row><entry>Donor 1</entry><entry>NK Cells</entry><entry>1.5E&#x2212;01</entry><entry>1.4E&#x2212;03</entry><entry>&#x2003;3.1E&#x2212;04</entry><entry>&#x2003;1.4E&#x2212;03</entry></row><row><entry/><entry>T Regulatory</entry><entry>9.5E&#x2212;05</entry><entry>2.2E&#x2212;03</entry><entry>&#x3c;1.0E&#x2212;5</entry><entry>&#x3c;1.0E&#x2212;5</entry></row><row><entry/><entry>Cells</entry><entry/><entry/><entry/><entry/></row><row><entry>Blood</entry><entry>CD8+ T Cells</entry><entry>5.6E&#x2212;01</entry><entry>1.6E&#x2212;02</entry><entry>&#x2003;1.7E&#x2212;02</entry><entry>&#x2003;7.1E&#x2212;03</entry></row><row><entry>Donor 2</entry><entry>NK Cells</entry><entry>1.5E&#x2212;01</entry><entry>1.4E&#x2212;03</entry><entry>&#x2003;4.2E&#x2212;04</entry><entry>&#x2003;7.1E&#x2212;04</entry></row><row><entry/><entry>T Regulatory</entry><entry>4.2E&#x2212;05</entry><entry>1.4E&#x2212;03</entry><entry>&#x3c;1.0E&#x2212;5</entry><entry>&#x3c;1.0E&#x2212;5</entry></row><row><entry/><entry>Cells</entry><entry/><entry/><entry/><entry/></row><row><entry>Blood</entry><entry>CD8+ T Cells</entry><entry>1.1E+00</entry><entry>2.3E&#x2212;02</entry><entry>&#x2003;2.6E&#x2212;02</entry><entry>&#x2003;1.2E&#x2212;02</entry></row><row><entry>Donor 3</entry><entry>NK Cells</entry><entry>2.6E&#x2212;01</entry><entry>3.3E&#x2212;03</entry><entry>&#x2003;1.4E&#x2212;03</entry><entry>&#x2003;1.8E&#x2212;03</entry></row><row><entry/><entry>T Regulatory</entry><entry>2.0E&#x2212;05</entry><entry>3.2E&#x2212;03</entry><entry>&#x3c;1.0E&#x2212;5</entry><entry>&#x3c;1.0E&#x2212;5</entry></row><row><entry/><entry>Cells</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0029" level="1">Example 9</heading><heading id="h-0030" level="1">Rational Generation of IL2R&#x3b2; Agonist Back-Mutation Clones</heading><p id="p-0232" num="0217">Rationally designed IL2R&#x3b2; agonist back-mutation strategy was carried out to create a range of IL2R&#x3b2; agonist candidate mutations. EP001 contains R81T, P82A, L85A, I86V, S87D, I89M, N90R, V93I and L94Q mutations. Four back mutations to WT IL2 were designed for each candidate. The I86 and I89 were back-mutated to 861 and 891 of WT IL2 for all mutations. A systemic back-mutation was then applied to the other two residues in combination with 861 and 891. A total of 21 back-mutation combinations were designed and the mutations were created by site directed mutagenesis using EP001 as template (Table 8). IL2R&#x3b2; agonist back-mutation clones were sequence verified after mutagenesis.</p><p id="p-0233" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 8</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Back mutations introduced into EP0001</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="10"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="14pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="14pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="14pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="14pt" align="center"/><colspec colname="9" colwidth="28pt" align="center"/><colspec colname="10" colwidth="14pt" align="center"/><tbody valign="top"><row><entry/><entry>81</entry><entry>82</entry><entry>85</entry><entry>86</entry><entry>87</entry><entry>89</entry><entry>90</entry><entry>93</entry><entry>94</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>WT IL2</entry><entry>R</entry><entry>P</entry><entry>L</entry><entry>I</entry><entry>S</entry><entry>I</entry><entry>N</entry><entry>V</entry><entry>L</entry></row><row><entry>EP001</entry><entry>T</entry><entry>A</entry><entry>A</entry><entry>V</entry><entry>D</entry><entry>M</entry><entry>R</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP242</entry><entry>T</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>S</entry><entry>I</entry><entry>R</entry><entry>V</entry><entry>Q</entry></row><row><entry>EP243</entry><entry>R</entry><entry>P</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP244</entry><entry>R</entry><entry>A</entry><entry>L</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP245</entry><entry>R</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>S</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP246</entry><entry>R</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>N</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP247</entry><entry>R</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>V</entry><entry>Q</entry></row><row><entry>EP248</entry><entry>R</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>L</entry></row><row><entry>EP249</entry><entry>T</entry><entry>P</entry><entry>L</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP250</entry><entry>T</entry><entry>P</entry><entry>A</entry><entry>I</entry><entry>S</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP251</entry><entry>T</entry><entry>P</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>N</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP252</entry><entry>T</entry><entry>P</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>V</entry><entry>Q</entry></row><row><entry>EP253</entry><entry>T</entry><entry>P</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>L</entry></row><row><entry>EP254</entry><entry>T</entry><entry>A</entry><entry>L</entry><entry>I</entry><entry>S</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP255</entry><entry>T</entry><entry>A</entry><entry>L</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>N</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP256</entry><entry>T</entry><entry>A</entry><entry>L</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>V</entry><entry>Q</entry></row><row><entry>EP257</entry><entry>T</entry><entry>A</entry><entry>L</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>L</entry></row><row><entry>EP258</entry><entry>T</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>S</entry><entry>I</entry><entry>N</entry><entry>I</entry><entry>Q</entry></row><row><entry>EP260</entry><entry>T</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>S</entry><entry>I</entry><entry>R</entry><entry>I</entry><entry>L</entry></row><row><entry>EP261</entry><entry>T</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>N</entry><entry>V</entry><entry>Q</entry></row><row><entry>EP262</entry><entry>T</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>N</entry><entry>I</entry><entry>L</entry></row><row><entry>EP263</entry><entry>T</entry><entry>A</entry><entry>A</entry><entry>I</entry><entry>D</entry><entry>I</entry><entry>R</entry><entry>V</entry><entry>L</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0031" level="1">Example 10</heading><heading id="h-0032" level="1">Characterization of IL2R&#x3b2; Agonist-Back-Mutation Clones</heading><p id="p-0234" num="0218">EP001 back-mutation clones were characterized for their binding activities to IL2R&#x3b2; and IL2R&#x3b1; receptors by ELISA. Briefly, 384 well plate was immobilized with human IL2R&#x3b1; and IL2R&#x3b2; Fc fusion proteins at a final concentration of 2 ug/mL in 1&#xd7;PBS in total volume of 25 uL per well. The plate was incubated overnight at 4 C and blocked with 80 uL of superblock per well for 1 hour. The purified EP001 back-mutation clones were serially diluted from 100 nM to 0 nM. Each dilution was added to IL2R&#x3b1; or IL2R&#x3b2; wells in parallel in duplicates. The IL2 mutant binding was detected by adding 25 uL of anti-Flag HRP diluted at 1:5000 in 1&#xd7;PBST. In between each step, the plate was washed three times with 1&#xd7;PBST using a plate washer. The plate was then developed with 25 uL of TMB substrate for five minutes and stopped by adding 25 ul of 2N sulfuric acid. The plate was read at OD450 nm Biotek plate reader and the EC50 was analyzed with Prism 8.1 software to generate EC50 values (<figref idref="DRAWINGS">FIG. <b>15</b>A</figref> for IL2R&#x3b1;, and <figref idref="DRAWINGS">FIG. <b>15</b>B</figref> for IL2R&#x3b2;, summarized in Table 9).</p><p id="p-0235" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 9</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Binding activity of back-mutation clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="91pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>IL2R&#x3b1;</entry><entry>IL2R&#x3b2;</entry></row><row><entry/><entry/><entry>Binding</entry><entry>Binding</entry></row><row><entry/><entry>Clone</entry><entry>EC50 (nM)</entry><entry>EC50 (nM)</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="91pt" align="center"/><tbody valign="top"><row><entry/><entry>WT IL2</entry><entry>1.2</entry><entry>ND</entry></row><row><entry/><entry>EP001</entry><entry>259.0</entry><entry>0.7</entry></row><row><entry/><entry>EP003</entry><entry>538.5</entry><entry>1.8</entry></row><row><entry/><entry>EP242</entry><entry>8.7</entry><entry>5.7</entry></row><row><entry/><entry>EP243</entry><entry>6.7</entry><entry>217.1</entry></row><row><entry/><entry>EP244</entry><entry>10.2</entry><entry>2830.0</entry></row><row><entry/><entry>EP245</entry><entry>4.8</entry><entry>122.8</entry></row><row><entry/><entry>EP246</entry><entry>7.0</entry><entry>269.0</entry></row><row><entry/><entry>EP247</entry><entry>8.3</entry><entry>4.7</entry></row><row><entry/><entry>EP248</entry><entry>13.4</entry><entry>188.0</entry></row><row><entry/><entry>EP249</entry><entry>20.2</entry><entry>576.1</entry></row><row><entry/><entry>EP250</entry><entry>13.2</entry><entry>23.4</entry></row><row><entry/><entry>EP251</entry><entry>16.8</entry><entry>2.5</entry></row><row><entry/><entry>EP252</entry><entry>13.0</entry><entry>2.2</entry></row><row><entry/><entry>EP253</entry><entry>48.5</entry><entry>4.8</entry></row><row><entry/><entry>EP254</entry><entry>4.3</entry><entry>556.1</entry></row><row><entry/><entry>EP255</entry><entry>4.3</entry><entry>359.5</entry></row><row><entry/><entry>EP256</entry><entry>5.3</entry><entry>361.9</entry></row><row><entry/><entry>EP257</entry><entry>5.6</entry><entry>ND</entry></row><row><entry/><entry>EP258</entry><entry>2.5</entry><entry>6.5</entry></row><row><entry/><entry>EP260</entry><entry>5.4</entry><entry>1.1</entry></row><row><entry/><entry>EP261</entry><entry>2.9</entry><entry>124.5</entry></row><row><entry/><entry>EP262</entry><entry>32.1</entry><entry>53.2</entry></row><row><entry/><entry>EP263</entry><entry>4.9</entry><entry>1.3</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0033" level="1">Example 11</heading><heading id="h-0034" level="1">Binding Kinetics of IL2R&#x3b2; Agonist Back-Mutation Clones Using Surface Plasmon Resonance</heading><p id="p-0236" num="0219">Binding kinetics analysis of EP001 back-mutation clones have been assessed by SPR technology with a Biacore T200. The assay was run with Biacore T200 control software version 2.0. For each cycle, 1 ug/mL of human IL2R&#x3b2; was captured for 60 seconds at flow rate of 10 uL/min on flow cell 2 in 1&#xd7;HBSP buffer on Protein A sensor chip. 100 nM of HIS and Flag tag purified each IL2 mutant was 2-fold serial diluted and injected onto both reference flow cell 1 and IL2R&#x3b2; captured flow cell 2 for 150 seconds at flow rate of 30 uL/min followed by washing for 300 seconds. The flow cells were then regenerated with Glycine pH2 for 60 seconds at a flow rate of 30 uL/min. The assay was set up with 8 serial diluted concentration points in 96-well format. The kinetics data was analyzed with Biacore T200 evaluation software 3.0. The specific binding response unit was derived from subtraction of binding to reference flow cell 1 from target flow cell 2 (<figref idref="DRAWINGS">FIGS. <b>16</b>A-<b>16</b>F</figref>, Table 10).</p><p id="p-0237" num="0000"><tables id="TABLE-US-00015" num="00015"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 10</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of binding kinetics forback-mutation clones. </entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="77pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="70pt" align="center"/><tbody valign="top"><row><entry/><entry>ka (1/Ms)</entry><entry>kd (1/s)</entry><entry>KD (M)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>EP001</entry><entry>3.86E+06</entry><entry>5.89E&#x2212;03</entry><entry>1.52E&#x2212;09</entry></row><row><entry>EP242</entry><entry>3.36E+06</entry><entry>2.41E&#x2212;02</entry><entry>7.16E&#x2212;09</entry></row><row><entry>EP247</entry><entry>4.20E+06</entry><entry>3.04E&#x2212;02</entry><entry>7.23E&#x2212;09</entry></row><row><entry>EP252</entry><entry>NA</entry><entry>NA</entry><entry>9.110E&#x2212;9*&#x2002;</entry></row><row><entry>EP253</entry><entry>NA</entry><entry>NA</entry><entry>2.947E&#x2212;8*&#x2002;</entry></row><row><entry>EP258</entry><entry>3.42E+06</entry><entry>3.01E&#x2212;02</entry><entry>8.81E&#x2212;09</entry></row><row><entry>EP260</entry><entry>1.06E+07</entry><entry>2.24E&#x2212;02</entry><entry>2.11E&#x2212;09</entry></row><row><entry>EP263</entry><entry>6.84E+06</entry><entry>1.91E&#x2212;02</entry><entry>2.79E&#x2212;09</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry namest="1" nameend="4" align="left" id="FOO-00001">(NA: data not available; *KD measured from steady state affinity fitting)</entry></row></tbody></tgroup></table></tables></p><heading id="h-0035" level="1">Example 12</heading><heading id="h-0036" level="1">Engineered IL2R&#x3b2; Agonists with Reduced IL2R&#x3b1; Activity</heading><p id="p-0238" num="0220">IL2 mutations with potentially reduced or eliminated IL2R&#x3b1; binding generated through mRNA library selection and screen were first expressed in <i>E. coli </i>and purified by Ni-Sepharose (GE Healthcare) affinity column and Flag tag affinity column purification (Sigma) according to the manufacturer's protocol. The IL2 mutations with significant reduced IL2R&#x3b1; binding activities confirmed by both Biacore SPR binding and ELISA binding were then selected for generating IL2R&#x3b2; agonists with reduced IL2R&#x3b1; binding activities. Briefly, mutations were introduced by site directed mutagenesis technologies to IL2R&#x3b2; agonist constructs in pCDNA3.4 mammalian expression vector and confirmed by DNA sequence analysis (Table 11). Each engineered IL2 polypeptide was expressed transiently in ExpiHEK293-F cells in free style system (Invitrogen) according to standard protocol. The cells were grown in above conditions for five days before harvesting. The supernatant was collected by centrifugation and filtered through a 0.2 &#x3bc;m PES membrane. The agonists were first purified by Ni Sepharose Excel resin column (GE Healthcare) and further purified by a Superdex 200 Increase 10/300 GL column (GE Healthcare) to more than 95% homogeneity (<figref idref="DRAWINGS">FIG. <b>17</b></figref>). The final purified proteins have less than 10 EU/mg endotoxin. The proteins were stored in 1&#xd7;PBS buffer for binding, functional and mechanism analysis.</p><p id="p-0239" num="0000"><tables id="TABLE-US-00016" num="00016"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 11</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Engineered IL2R&#x3b2; agonists with IL2R&#x3b1; </entry></row><row><entry>reduced-binding mutations</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><tbody valign="top"><row><entry/><entry>Engineered </entry><entry/><entry/><entry/></row><row><entry/><entry>IL2R&#x3b2;</entry><entry>Parental </entry><entry/><entry/></row><row><entry/><entry>agonist with</entry><entry>IL2R&#x3b1;-</entry><entry/><entry>Parental </entry></row><row><entry/><entry>IL2R&#x3b1;</entry><entry>Reduced</entry><entry/><entry>IL2R&#x3b2;</entry></row><row><entry/><entry>Reduced</entry><entry>Binding </entry><entry>IL2R&#x3b1; </entry><entry>Agonist </entry></row><row><entry/><entry>Activity</entry><entry>Clones</entry><entry>Mutations</entry><entry>Clone</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>EP329</entry><entry>EP103</entry><entry>K35G/R38E</entry><entry>EP260</entry></row><row><entry/><entry>EP330</entry><entry/><entry>K35G/R38E</entry><entry>EP258</entry></row><row><entry/><entry>EP331</entry><entry/><entry>K35G/R38E</entry><entry>EP252</entry></row><row><entry/><entry>EP332</entry><entry/><entry>K35G/R38E</entry><entry>EP253</entry></row><row><entry/><entry>EP333</entry><entry>EP104</entry><entry>K35S, F42G</entry><entry>EP260</entry></row><row><entry/><entry>EP334</entry><entry/><entry>K35S, F42G</entry><entry>EP258</entry></row><row><entry/><entry>EP335</entry><entry/><entry>K35S, F42G</entry><entry>EP252</entry></row><row><entry/><entry>EP336</entry><entry/><entry>K35S, F42G</entry><entry>EP253</entry></row><row><entry/><entry>EP337</entry><entry>EP110</entry><entry>K35L/R38D/F42R</entry><entry>EP260</entry></row><row><entry/><entry>EP338</entry><entry/><entry>K35L/R38D/F42R</entry><entry>EP258</entry></row><row><entry/><entry>EP339</entry><entry/><entry>K35L/R38D/F42R</entry><entry>EP252</entry></row><row><entry/><entry>EP340</entry><entry/><entry>K35L/R38D/F42R</entry><entry>EP253</entry></row><row><entry/><entry>EP341</entry><entry>EP112</entry><entry>R38D/Y45S</entry><entry>EP260</entry></row><row><entry/><entry>EP342</entry><entry/><entry>R38D/Y45S</entry><entry>EP258</entry></row><row><entry/><entry>EP343</entry><entry/><entry>R38D/Y45S</entry><entry>EP252</entry></row><row><entry/><entry>EP344</entry><entry/><entry>R38D/Y45S</entry><entry>EP253</entry></row><row><entry/><entry>EP345</entry><entry>EP121</entry><entry>R38V/Y45S</entry><entry>EP260</entry></row><row><entry/><entry>EP346</entry><entry/><entry>R38V/Y45S</entry><entry>EP258</entry></row><row><entry/><entry>EP347</entry><entry/><entry>R38V/Y45S</entry><entry>EP252</entry></row><row><entry/><entry>EP348</entry><entry/><entry>R38V/Y45S</entry><entry>EP253</entry></row><row><entry/><entry>EP349</entry><entry>EP239</entry><entry>F42A</entry><entry>EP260</entry></row><row><entry/><entry>EP350</entry><entry/><entry>F42A</entry><entry>EP258</entry></row><row><entry/><entry>EP351</entry><entry/><entry>F42A</entry><entry>EP252</entry></row><row><entry/><entry>EP352</entry><entry/><entry>F42A</entry><entry>EP253</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0037" level="1">Example 13</heading><heading id="h-0038" level="1">Binding Kinetics Analysis of Engineered IL2R&#x3b1;/IL2R&#x3b2; Clones Using Surface Plasmon Resonance</heading><p id="p-0240" num="0221">Kinetic analysis of the receptor binding activities of IL2R&#x3b2; agonist with IL2R&#x3b1; reduced activity mutations have been assessed by SPR technology with Biacore T200. The assay was run with Biacore T200 control software version 2.0. For each cycle, 1 ug/mL of human IL2R&#x3b2; was captured for 60 seconds at flow rate of 10 ul/min on flow cell 2 in 1&#xd7;HBSP buffer on Protein A sensor chip. 100 nM of HIS and Flag tag purified each IL2 mutant was 2 fold serial diluted and injected onto both reference flow cell 1 and IL2R&#x3b2; captured flow cell 2 for 150 seconds at flow rate of 30 ul/mins followed by wash for 300 seconds. The flow cells were then regenerated with Glycine pH2 for 60 seconds at flow rate of 30 ul/mins. The assay was set up with 8 serial diluted concentration points in 96 well format. The kinetics data was analyzed with Biacore T200 evaluation software 3.0. The specific binding response unit was derived from subtraction of binding to reference flow cell 1 from target flow cell 2. <figref idref="DRAWINGS">FIGS. <b>18</b>A-<b>18</b>H</figref> show titrated binding of engineered IL2R&#x3b2;/a clones to IL2R&#x3b1;, and <figref idref="DRAWINGS">FIGS. <b>19</b>A-<b>19</b>H</figref> show titrated binding of engineered IL2R&#x3b2;/a clones to IL2R&#x3b2;. A description of the clones as well as a summary of the kinetics data are shown in Table 12.</p><p id="p-0241" num="0000"><tables id="TABLE-US-00017" num="00017"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="273pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 12</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of binding kinetics of engineered IL2R&#x3b2;/IL2R&#x3b1; clones to human IL2R&#x3b1;</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="105pt" align="center"/><tbody valign="top"><row><entry/><entry>IL2R&#x3b1;</entry><entry>IL2R&#x3b2;</entry><entry/><entry>IL2R&#x3b2;</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry>Binding</entry><entry>Binding</entry><entry>IL2R&#x3b1;</entry><entry>ka</entry><entry>kd</entry><entry>KD</entry></row><row><entry>Clone</entry><entry>Mutations</entry><entry>Mutations</entry><entry>Binding</entry><entry>(1/Ms)</entry><entry>(1/s)</entry><entry>(M)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry>EP397</entry><entry>K35G/R38E</entry><entry>WT</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry></row><row><entry>EP398</entry><entry>K35G/R38E</entry><entry>EP001</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry></row><row><entry>EP399</entry><entry>K35G/R38E</entry><entry>EP003</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry></row><row><entry>EP400</entry><entry>K35S/F42G</entry><entry>WT</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry></row><row><entry>EP401</entry><entry>K35S/F42G</entry><entry>EP001</entry><entry>ND</entry><entry>7.21E+06</entry><entry>0.006164</entry><entry>8.55E&#x2212;10</entry></row><row><entry>EP402</entry><entry>K35S/F42G</entry><entry>EP003</entry><entry>ND</entry><entry>3.68E+06</entry><entry>3.97E&#x2212;04</entry><entry>1.08E&#x2212;10</entry></row><row><entry>EP403</entry><entry>K35L/R38D/F42R</entry><entry>WT</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry></row><row><entry>EP404</entry><entry>K35L/R38D/F42R</entry><entry>EP001</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry></row><row><entry>EP405</entry><entry>K35L/R38D/F42R</entry><entry>EP003</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry></row><row><entry>EP406</entry><entry>R38D/Y45S</entry><entry>WT</entry><entry>ND</entry><entry>NA</entry><entry>NA</entry><entry>NA</entry></row><row><entry>EP407</entry><entry>R38D/Y45S</entry><entry>EP001</entry><entry>ND</entry><entry>8.34E+06</entry><entry>0.005094</entry><entry>6.11E&#x2212;10</entry></row><row><entry>EP408</entry><entry>R38D/Y45S</entry><entry>EP003</entry><entry>ND</entry><entry>2.56E+06</entry><entry>5.98E&#x2212;04</entry><entry>2.33E&#x2212;10</entry></row><row><entry>EP409</entry><entry>R38V/Y45S</entry><entry>WT</entry><entry>Low</entry><entry>1.49E+05</entry><entry>0.005308</entry><entry>3.57E&#x2212;08</entry></row><row><entry>EP410</entry><entry>R38V/Y45S</entry><entry>EP001</entry><entry>Low</entry><entry>7.19E+06</entry><entry>0.00594&#x2002;</entry><entry>8.27E&#x2212;10</entry></row><row><entry>EP411</entry><entry>R38V/Y45S</entry><entry>EP003</entry><entry>Low</entry><entry>1.82E+06</entry><entry>8.39E&#x2212;04</entry><entry>4.61E&#x2212;10</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry namest="1" nameend="7" align="left" id="FOO-00002">NA: data not available. ND: Non-detectable binding. Low: Binding signal below 10 RU.</entry></row></tbody></tgroup></table></tables></p><p id="p-0242" num="0222"><figref idref="DRAWINGS">FIGS. <b>20</b>A-<b>20</b>G</figref> show IL2R&#x3b1; single concentration binding, and <figref idref="DRAWINGS">FIGS. <b>21</b>A-<b>21</b>G</figref> show IL2R&#x3b2; single concentration binding, and <figref idref="DRAWINGS">FIGS. <b>22</b>A and <b>22</b>B</figref> show IL2R&#x3b1; multi-concentration binding, which are summarized in Table 13).</p><p id="p-0243" num="0000"><tables id="TABLE-US-00018" num="00018"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="406pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 13</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of binding kinetics of engineered IL2R&#x3b2;/IL2R&#x3b1; clones to human IL2R by SPR</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="245pt" align="center"/><colspec colname="3" colwidth="133pt" align="center"/><tbody valign="top"><row><entry/><entry>Single-Concentration KD (M)</entry><entry>Multi-Concentration KD (M)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="12"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="35pt" align="center"/><colspec colname="10" colwidth="35pt" align="center"/><colspec colname="11" colwidth="35pt" align="center"/><colspec colname="12" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry>WT IL2</entry><entry>EP329</entry><entry>EP333</entry><entry>EP337</entry><entry>EP341</entry><entry>EP345</entry><entry>EP349</entry><entry>EP337</entry><entry>EP338</entry><entry>EP339</entry><entry>EP340</entry></row><row><entry namest="1" nameend="12" align="center" rowsep="1"/></row><row><entry>IL2R&#x3b1;</entry><entry>1.05E&#x2212;08</entry><entry>Very low</entry><entry>Very low</entry><entry>ND</entry><entry>ND</entry><entry>Low</entry><entry>Low</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry></row><row><entry>IL2R&#x3b2;</entry><entry>NA#</entry><entry>1.22E&#x2212;09</entry><entry>1.41E&#x2212;09</entry><entry>3.80E&#x2212;09</entry><entry>2.54E&#x2212;09</entry><entry>1.25E&#x2212;08</entry><entry>2.79E&#x2212;09</entry><entry>1.44E&#x2212;08</entry><entry>3.83E&#x2212;08</entry><entry>3.59E&#x2212;08</entry><entry>NA#</entry></row><row><entry namest="1" nameend="12" align="center" rowsep="1"/></row><row><entry namest="1" nameend="12" align="left" id="FOO-00003">ND: Non-detectable binding. Low: Binding signal below 5 RU</entry></row></tbody></tgroup></table></tables></p><heading id="h-0039" level="1">Example 14</heading><heading id="h-0040" level="1">ELISA Binding Analysis of Engineered IL2R&#x3b1;/IL2R&#x3b2; Clones</heading><p id="p-0244" num="0223">Recombinant Fc-tagged human IL2R&#x3b1; and IL2R&#x3b2; were added in 25 uL of 1&#xd7;PBS to wells of 384-well plate and incubated overnight at 4&#xb0; C. to coat the plates. Plates were washed three times with 0.05% Tween20/1&#xd7;PBS. Plates were blocked with 100 uL of SuperBlock for 1 hr at RT and then washed 3 times with 0.05% Tween20/1&#xd7;PBS. IL2 mutants were diluted in 0.05% Tween 20/1&#xd7;PBS from 1000 nM to 0 nM and added to plates for 2 hrs at room temperature. Plates were then washed 6 times with 0.05% Tween20/1&#xd7;PBS. Anti-HisTag-HRP was diluted 1:5000 in 0.05% Tween20/1&#xd7;PBS and added to plates for 1 hr at RT. Plates were then washed 6 times with 0.05% Tween 20/1&#xd7;PBS, and TMB was added to develop blue color. Reactions were stopped with 2N hydrogen sulfide and light absorbance at 450 nm was read on a BioTek plate reader. Single point absorbance for human IL2R&#x3b1; and titrations for human IL2R&#x3b1; and IL2R&#x3b2; are graphed (<figref idref="DRAWINGS">FIGS. <b>23</b>A-<b>23</b>E</figref> for IL2R&#x3b1;, <figref idref="DRAWINGS">FIGS. <b>24</b>A-<b>24</b>D</figref> for IL2R&#x3b2;). A summary of the EC50 values of ELISA binding is shown (Table 14).</p><p id="p-0245" num="0000"><tables id="TABLE-US-00019" num="00019"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="280pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 14</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of ELISA binding to human IL2R&#x3b1; and IL2R&#x3b2;</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="252pt" align="center"/><tbody valign="top"><row><entry/><entry>EC50 (nM)</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="10"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="28pt" align="center"/><colspec colname="9" colwidth="28pt" align="center"/><colspec colname="10" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry>WT IL2</entry><entry>EP001</entry><entry>EP252</entry><entry>EP331</entry><entry>EP335</entry><entry>EP339</entry><entry>EP343</entry><entry>EP347</entry><entry>EP351</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>IL2R&#x3b1;</entry><entry>11.5&#x2002;</entry><entry>ND</entry><entry>13.81</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry></row><row><entry>IL2R&#x3b2;</entry><entry>ND</entry><entry>8.1</entry><entry>24.5&#x2002;</entry><entry>39.3&#x2002;</entry><entry>59.1&#x2002;</entry><entry>96.3&#x2002;</entry><entry>19.7&#x2002;</entry><entry>77.6&#x2002;</entry><entry>21.2&#x2002;</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry/><entry/><entry>EP253</entry><entry>EP332</entry><entry>EP336</entry><entry>EP340</entry><entry>EP344</entry><entry>EP348</entry><entry>EP352</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>IL2R&#x3b1;</entry><entry/><entry/><entry>8.9</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry></row><row><entry>IL2R&#x3b2;</entry><entry/><entry/><entry>52.8&#x2002;</entry><entry>44.0&#x2002;</entry><entry>133.0&#x2003;</entry><entry>185.0&#x2003;</entry><entry>50.7&#x2002;</entry><entry>123.7&#x2003;</entry><entry>33.8&#x2002;</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry/><entry/><entry>EP258</entry><entry>EP330</entry><entry>EP334</entry><entry>EP338</entry><entry>EP342</entry><entry>EP346</entry><entry>EP350</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>IL2R&#x3b1;</entry><entry/><entry/><entry>9.1</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry></row><row><entry>IL2R&#x3b2;</entry><entry/><entry/><entry>119.2&#x2003;</entry><entry>ND</entry><entry>28.6&#x2002;</entry><entry>105.3&#x2003;</entry><entry>58.9&#x2002;</entry><entry>ND</entry><entry>39.9&#x2002;</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry/><entry/><entry>EP260</entry><entry>EP329</entry><entry>EP333</entry><entry>EP337</entry><entry>EP341</entry><entry>EP345</entry><entry>EP349</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>IL2R&#x3b1;</entry><entry/><entry/><entry>12.9&#x2002;</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry></row><row><entry>IL2R&#x3b2;</entry><entry/><entry/><entry>295.9&#x2003;</entry><entry>11.4&#x2002;</entry><entry>11.4&#x2002;</entry><entry>137.9&#x2003;</entry><entry>64.1&#x2002;</entry><entry>152.1&#x2003;</entry><entry>947.8&#x2003;</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0041" level="1">Example 15</heading><heading id="h-0042" level="1">P-STAT5 Activation of Human PBMCs by Engineered IL2R&#x3b1;/IL2R&#x3b2; Clones</heading><p id="p-0246" num="0224">Human PBMCs were isolated from peripheral blood of two donors and plated at 250,000 cells/well in a 96-well plate in 75 &#x3bc;L of media. Cells were rested 1 hr at 37&#xb0; C. Cells were stimulated with human IL2 WT and engineered His-Flag tagged IL2 at 4&#xd7; concentration in 25 &#x3bc;L for 20 min at 37&#xb0; C. Stimulated PBMCs were immediately fixed, permeabilized, stained for cell lineage markers (CD3, CD56, CD4, CD8, FOXP3) and p-STAT5 and visualized on the Attune flow cytometer. CD8+ T cells were defined as CD3+CD56&#x2212;CD4&#x2212;CD8+. NK cells were defined as CD3&#x2212;CD56+. T regulatory cells were defined as CD3+CD56&#x2212;CD4+CD8&#x2212;FOXP3+. The % of cells that were p-STAT5+ was determined and graphed versus each IL2 titration (<figref idref="DRAWINGS">FIGS. <b>25</b>A-<b>25</b>D</figref> for donor 656 CD8+ T cells, <figref idref="DRAWINGS">FIGS. <b>26</b>A-<b>26</b>D</figref> for donor 648 CD8=+ T cells, <figref idref="DRAWINGS">FIGS. <b>27</b>A-<b>27</b>D</figref> for donor 656 NK cells, <figref idref="DRAWINGS">FIGS. <b>28</b>A-<b>28</b>D</figref> for donor 648 NK cells, <figref idref="DRAWINGS">FIGS. <b>29</b>A-<b>29</b>D</figref> for donor 656 T regulatory cells, and <figref idref="DRAWINGS">FIGS. <b>30</b>A-<b>30</b>D</figref> for donor 648 T regulatory cells). A summary of the EC50 values of P-STAT5 activation in each cell type is shown in Table 15 for blood donor 1 and Table 16 for blood donor 2.</p><p id="p-0247" num="0000"><tables id="TABLE-US-00020" num="00020"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="301pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 15</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of P-STAT5 activation of human CD8+ T cells, NK cells and Trees for donor 1.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="252pt" align="center"/><tbody valign="top"><row><entry/><entry>EC50 (nM)</entry></row><row><entry/><entry>Blood Donor 1</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="10"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="28pt" align="center"/><colspec colname="9" colwidth="28pt" align="center"/><colspec colname="10" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry>WT</entry><entry>EP001</entry><entry>EP252</entry><entry>EP331</entry><entry>EP335</entry><entry>EP339</entry><entry>EP343</entry><entry>EP347</entry><entry>EP351</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>CD8 + T Cells</entry><entry>6.1E&#x2212;01</entry><entry>4.7E&#x2212;02</entry><entry>2.4E&#x2212;02</entry><entry>5.6E&#x2212;01</entry><entry>3.6E&#x2212;01</entry><entry>1.2E&#x2212;01</entry><entry>1.9E&#x2212;01</entry><entry>9.4E&#x2212;02</entry><entry>9.7E&#x2212;02</entry></row><row><entry>NK Cells</entry><entry>2.8E&#x2212;01</entry><entry>1.0E&#x2212;02</entry><entry>1.1E&#x2212;02</entry><entry>1.3E&#x2212;01</entry><entry>8.2E&#x2212;02</entry><entry>3.8E&#x2212;02</entry><entry>1.3E&#x2212;02</entry><entry>1.2E&#x2212;02</entry><entry>9.9E&#x2212;03</entry></row><row><entry>T Regulatory</entry><entry>2.0E&#x2212;03</entry><entry>1.8E&#x2212;02</entry><entry>2.5E&#x2212;05</entry><entry>2.9E&#x2212;01</entry><entry>6.1E&#x2212;02</entry><entry>1.0E&#x2212;01</entry><entry>4.3E&#x2212;02</entry><entry>7.6E&#x2212;03</entry><entry>1.1E&#x2212;02</entry></row><row><entry>Cells</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry>WT</entry><entry>EP001</entry><entry>EP253</entry><entry>EP332</entry><entry>EP336</entry><entry>EP340</entry><entry>EP344</entry><entry>EP348</entry><entry>EP352</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>CD8 + T Cells</entry><entry>6.1E&#x2212;01</entry><entry>4.7E&#x2212;02</entry><entry>4.5E&#x2212;02</entry><entry>8.1E&#x2212;01</entry><entry>1.0E&#x2212;01</entry><entry>3.1E&#x2212;01</entry><entry>4.0E&#x2212;01</entry><entry>4.8E&#x2212;01</entry><entry>1.4E&#x2212;01</entry></row><row><entry>NK Cells</entry><entry>2.8E&#x2212;01</entry><entry>1.0E&#x2212;02</entry><entry>1.1E&#x2212;02</entry><entry>3.2E&#x2212;01</entry><entry>1.5E&#x2212;02</entry><entry>1.0E&#x2212;01</entry><entry>5.5E&#x2212;02</entry><entry>1.2E&#x2212;01</entry><entry>1.3E&#x2212;02</entry></row><row><entry>T Regulatory</entry><entry>2.0E&#x2212;03</entry><entry>1.8E&#x2212;02</entry><entry>3.7E&#x2212;04</entry><entry>3.2E&#x2212;01</entry><entry>1.3E&#x2212;02</entry><entry>1.3E&#x2212;01</entry><entry>9.1E&#x2212;02</entry><entry>3.9E&#x2212;02</entry><entry>1.2E&#x2212;02</entry></row><row><entry>Cells</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry>WT</entry><entry>EP001</entry><entry>EP258</entry><entry>EP330</entry><entry>EP334</entry><entry>EP338</entry><entry>EP342</entry><entry>EP346</entry><entry>EP350</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>CD8 + T Cells</entry><entry>2.7E&#x2212;01</entry><entry>8.6E&#x2212;02</entry><entry>2.2E&#x2212;02</entry><entry>8.0E+00</entry><entry>4.7E&#x2212;01</entry><entry>3.3E&#x2212;01</entry><entry>4.0E&#x2212;01</entry><entry>1.3E&#x2212;01</entry><entry>2.0E&#x2212;01</entry></row><row><entry>NK Cells</entry><entry>8.7E&#x2212;01</entry><entry>1.7E&#x2212;02</entry><entry>1.3E&#x2212;02</entry><entry>ND</entry><entry>ND</entry><entry>3.8E&#x2212;02</entry><entry>5.7E&#x2212;02</entry><entry>3.4E&#x2212;02</entry><entry>1.8E&#x2212;02</entry></row><row><entry>T Regulatory</entry><entry>2.4E&#x2212;04</entry><entry>1.9E&#x2212;02</entry><entry>&#x3c;1E&#x2212;4&#x2009;</entry><entry>2.8E&#x2212;01</entry><entry>2.7E&#x2212;02</entry><entry>9.6E&#x2212;02</entry><entry>9.1E&#x2212;02</entry><entry>N.D.</entry><entry>2.1E&#x2212;02</entry></row><row><entry>Cells</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry>WT</entry><entry>EP001</entry><entry>EP260</entry><entry>EP329</entry><entry>EP333</entry><entry>EP337</entry><entry>EP341</entry><entry>EP345</entry><entry>EP349</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>CD8 + T Cells</entry><entry>2.7E&#x2212;01</entry><entry>8.6E&#x2212;02</entry><entry>1.7E&#x2212;02</entry><entry>1.6E&#x2212;01</entry><entry>2.5E&#x2212;01</entry><entry>6.3E&#x2212;02</entry><entry>1.0E&#x2212;01</entry><entry>5.2E&#x2212;01</entry><entry>8.4E&#x2212;02</entry></row><row><entry>NK Cells</entry><entry>8.7E&#x2212;01</entry><entry>1.7E&#x2212;02</entry><entry>1.5E&#x2212;01</entry><entry>1.4E&#x2212;01</entry><entry>5.0E&#x2212;02</entry><entry>ND</entry><entry>1.2E&#x2212;02</entry><entry>8.1E&#x2212;02</entry><entry>2.8E&#x2212;02</entry></row><row><entry>T Regulatory</entry><entry>2.4E&#x2212;04</entry><entry>1.9E&#x2212;02</entry><entry>&#x3c;1E&#x2212;4&#x2009;</entry><entry>2.8E&#x2212;01</entry><entry>2.7E&#x2212;02</entry><entry>9.6E&#x2212;02</entry><entry>9.1E&#x2212;02</entry><entry>ND</entry><entry>2.1E&#x2212;02</entry></row><row><entry>Cells</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0248" num="0000"><tables id="TABLE-US-00021" num="00021"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="301pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 16</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of P-STAT5 activation of human CD8 + T cells, NK cells and Tregs for donor 2.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="252pt" align="center"/><tbody valign="top"><row><entry/><entry>EC50 (nM)</entry></row><row><entry/><entry>Blood Donor 2</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="10"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="28pt" align="center"/><colspec colname="9" colwidth="28pt" align="center"/><colspec colname="10" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry>WT</entry><entry>EP001</entry><entry>EP252</entry><entry>EP331</entry><entry>EP335</entry><entry>EP339</entry><entry>EP343</entry><entry>EP347</entry><entry>EP351</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>CD8 + T Cells</entry><entry>9.9E+00</entry><entry>6.8E&#x2212;02</entry><entry>3.5E&#x2212;01</entry><entry>5.7E&#x2212;01</entry><entry>2.6E&#x2212;01</entry><entry>3.0E&#x2212;01</entry><entry>1.5E&#x2212;01</entry><entry>1.7E&#x2212;01</entry><entry>1.1E&#x2212;01</entry></row><row><entry>NK Cells</entry><entry>1.3E+00</entry><entry>1.0E&#x2212;02</entry><entry>1.2E&#x2212;02</entry><entry>7.6E&#x2212;02</entry><entry>2.1E&#x2212;02</entry><entry>5.0E&#x2212;02</entry><entry>1.1E&#x2212;02</entry><entry>2.1E&#x2212;02</entry><entry>1.8E&#x2212;02</entry></row><row><entry>T Regulatory</entry><entry>3.8E&#x2212;03</entry><entry>1.3E&#x2212;02</entry><entry>2.5E&#x2212;06</entry><entry>7.0E&#x2212;02</entry><entry>1.1E&#x2212;02</entry><entry>1.7E&#x2212;01</entry><entry>1.7E&#x2212;01</entry><entry>1.0E&#x2212;02</entry><entry>1.8E&#x2212;02</entry></row><row><entry>Cells</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry>WT</entry><entry>EP001</entry><entry>EP253</entry><entry>EP332</entry><entry>EP336</entry><entry>EP340</entry><entry>EP344</entry><entry>EP348</entry><entry>EP352</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>CD8 + T Cells</entry><entry>9.9E+00</entry><entry>6.8E&#x2212;02</entry><entry>1.6E&#x2212;01</entry><entry>5.6E&#x2212;01</entry><entry>1.2E&#x2212;01</entry><entry>6.5E&#x2212;01</entry><entry>8.0E&#x2212;01</entry><entry>6.2E&#x2212;01</entry><entry>3.8E&#x2212;01</entry></row><row><entry>NK Cells</entry><entry>1.3E+00</entry><entry>1.0E&#x2212;02</entry><entry>4.5E&#x2212;02</entry><entry>8.6E&#x2212;02</entry><entry>1.2E&#x2212;02</entry><entry>9.2E&#x2212;02</entry><entry>2.9E&#x2212;01</entry><entry>1.3E&#x2212;01</entry><entry>7.1E&#x2212;02</entry></row><row><entry>T Regulatory</entry><entry>3.8E&#x2212;03</entry><entry>1.3E&#x2212;02</entry><entry>1.8E&#x2212;06</entry><entry>7.0E&#x2212;02</entry><entry>1.1E&#x2212;02</entry><entry>1.7E&#x2212;01</entry><entry>1.7E&#x2212;01</entry><entry>1.0E&#x2212;02</entry><entry>1.8E&#x2212;02</entry></row><row><entry>Cells</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry>WT</entry><entry>EP001</entry><entry>EP258</entry><entry>EP330</entry><entry>EP334</entry><entry>EP338</entry><entry>EP342</entry><entry>EP346</entry><entry>EP350</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>CD8 + T Cells</entry><entry>7.5E&#x2212;01</entry><entry>3.1E&#x2212;01</entry><entry>8.8E&#x2212;02</entry><entry>1.6E+00</entry><entry>3.4E+00</entry><entry>9.1E&#x2212;01</entry><entry>2.9E+00</entry><entry>3.2E&#x2212;01</entry><entry>3.9E&#x2212;01</entry></row><row><entry>NK Cells</entry><entry>3.2E&#x2212;01</entry><entry>1.0E&#x2212;02</entry><entry>7.6E&#x2212;02</entry><entry>2.9E&#x2212;01</entry><entry>ND</entry><entry>8.7E&#x2212;02</entry><entry>1.2E+01</entry><entry>3.2E&#x2212;02</entry><entry>7.6E&#x2212;02</entry></row><row><entry>T Regulatory</entry><entry>4.5E&#x2212;05</entry><entry>1.4E&#x2212;02</entry><entry>&#x3c;1E&#x2212;4&#x2009;</entry><entry>9.1E&#x2212;01</entry><entry>6.6E&#x2212;02</entry><entry>1.2E&#x2212;01</entry><entry>3.0E&#x2212;01</entry><entry>5.8E&#x2212;03</entry><entry>4.0E&#x2212;02</entry></row><row><entry>Cells</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry/><entry>WT</entry><entry>EP001</entry><entry>EP260</entry><entry>EP329</entry><entry>EP333</entry><entry>EP337</entry><entry>EP341</entry><entry>EP345</entry><entry>EP349</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>CD8 + T Cells</entry><entry>7.5E&#x2212;01</entry><entry>3.1E&#x2212;01</entry><entry>1.9E&#x2212;02</entry><entry>9.6E&#x2212;02</entry><entry>7.7E+00</entry><entry>6.6E&#x2212;01</entry><entry>3.4E&#x2212;01</entry><entry>1.6E+00</entry><entry>9.7E&#x2212;02</entry></row><row><entry>NK Cells</entry><entry>3.2E&#x2212;01</entry><entry>1.0E&#x2212;02</entry><entry>2.7E&#x2212;03</entry><entry>4.8E&#x2212;03</entry><entry>7.5E&#x2212;01</entry><entry>1.5E&#x2212;02</entry><entry>1.7E&#x2212;02</entry><entry>3.6E&#x2212;01</entry><entry>1.1E&#x2212;02</entry></row><row><entry>T Regulatory</entry><entry>4.5E&#x2212;05</entry><entry>1.4E&#x2212;02</entry><entry>&#x3c;1E&#x2212;4&#x2009;</entry><entry>2.0E&#x2212;02</entry><entry>3.4E&#x2212;01</entry><entry>3.2E&#x2212;02</entry><entry>4.5E&#x2212;02</entry><entry>1.2E&#x2212;01</entry><entry>ND</entry></row><row><entry>Cells</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0043" level="1">Example 16</heading><heading id="h-0044" level="1">P-STAT5 Activation of Murine Cells by Engineered IL2R&#x3b1;/IL2R&#x3b2; Clones</heading><p id="p-0249" num="0225">Murine splenocytes were plated at 250,000 cells/well in a 96-well plate in 75 &#x3bc;L of media. Cells were rested 1 hr at 37&#xb0; C. Cells were stimulated with human IL2 WT and engineered His-Flag tagged IL2 at 4&#xd7; concentration in 25 &#x3bc;L for 20 min at 37&#xb0; C. Stimulated mouse splenocytes were immediately fixed, permeabilized, stained for cell lineage markers (CD3, CD56, CD4, CD8, FOXP3) and p-STAT5 and visualized on the Attune flow cytometer. CD8+ T cells were defined as CD3+CD56&#x2212;CD4&#x2212;CD8+. The % of cells that were p-STAT5+ was determined and graphed versus each IL2 titration (<figref idref="DRAWINGS">FIGS. <b>31</b>A-<b>31</b>D</figref>). A summary of the EC50 values of P-STAT5 activation in each cell type is shown in <figref idref="DRAWINGS">FIG. <b>34</b></figref>.</p><p id="p-0250" num="0226">Isolated NK cells or mouse T regulatory cells were plated at 20,000 cells/well in a 96-well plate in 75 &#x3bc;L of media. Cells were rested 1 hr at 37&#xb0; C. Cells were stimulated with human IL2 WT and engineered His-Flag tagged IL2 at 4&#xd7; concentration in 25 &#x3bc;L for 20 min at 37&#xb0; C. Stimulated mouse NK cells or mouse T regulatory cells were immediately fixed, permeabilized, stained for P-STAT5 and visualized on the Attune flow cytometer. The % of cells that were p-STAT5+ was determined and graphed versus each IL2 titration (<figref idref="DRAWINGS">FIGS. <b>32</b>A-<b>32</b>D, <b>33</b>A-<b>33</b>D</figref>).</p><p id="p-0251" num="0227">A summary of the EC50 values of P-STAT5 activation in each cell type is shown in <figref idref="DRAWINGS">FIG. <b>34</b></figref>.</p><heading id="h-0045" level="1">Example 17</heading><heading id="h-0046" level="1">Design of IL2R&#x3b2; Agonist Fc-Fusion Proteins</heading><p id="p-0252" num="0228">To generate bivalent IL2R&#x3b2; agonist Fc-fusion protein, the protein sequences encoding engineered IL2 polypeptides of EP003 (SEQ ID NO: 2), EP007 (SEQ ID NO: 4), EP002 (SEQ ID NO: 6), EP004 (SEQ ID NO: 09), EP001 (SEQ ID NO: 11), EP006 (SEQ ID NO: 16), EP009 (SEQ ID NO: 18), and EP005 (SEQ ID NO: 19) were fused to the N-terminal site of the constant frame sequence of human IgG1 isoform to produce engineered agonist-Fc fusion proteins (SEQ ID NOs: 44, 46, 48, 51, 53, 58, and 61). L234A, L235A and P329G mutations in the human IgG1 were introduced to eliminate complement binding and Fc-&#x3b3; dependent antibody-dependent cell-mediated cytotoxity (ADCC) effects (Lo et al., JBC 2017) (<figref idref="DRAWINGS">FIG. <b>35</b>A</figref>).</p><p id="p-0253" num="0229">To generate monovalent IL2R&#x3b2; agonist Fc-fusion protein, the protein sequences encoding engineered IL2 polypeptides of EP003 (SEQ ID NO: 2), EP007 (SEQ ID NO: 4), EP002 (SEQ ID NO: 6), EP004 (SEQ ID NO: 09), EP001 (SEQ ID NO: 11), EP006 (SEQ ID NO: 16), EP009 (SEQ ID NO: 18), and EP005 (SEQ ID NO: 19) were fused to the N-terminal site of the constant frame sequences of respective human IgG1 and IgG4 isoforms, to produce engineered agonist-Fc fusion proteins (SEQ ID NOs: 44, 46, 48, 51, 53, 58, and 61). The knob mutations of S354C, T366W and K409A were introduced to the constructs. The hole mutations of Y349C, T366S, L368A, F405K, Y407V were introduced to CH2 and CH3 fragments of IgG1 and IgG4, respectively. The L234A, L235A and P329G mutations in the human IgG1 were introduced to eliminate complement binding and Fc-&#x3b3; dependent antibody-dependent cell-mediated cytotoxicity (ADCC) effects (Lo et al., JBC 2017) (<figref idref="DRAWINGS">FIGS. <b>35</b>B &#x26; <b>35</b>C</figref>). The DNA encoding the entire Fc fusion agonist protein was then synthesized with codon optimized for mammalian cell expression, and subcloned to pCDNA3.4 (Invitrogen).</p><heading id="h-0047" level="1">Example 18</heading><heading id="h-0048" level="1">Production of IL2R&#x3b2; Agonist Fc Fusion Proteins</heading><p id="p-0254" num="0230">For bivalent IL2-Fc fusion protein production, the agonist was expressed transiently in ExpiHEK293-F cells in free style system (Invitrogen) according to standard protocol. The cells were grown in above conditions for seven days before harvesting. The supernatant was collected by centrifugation and filtered through a 0.2 &#x3bc;m PES membrane. The Fc fusion agonist first was purified by Mab Select PrismA protein A resin (GE Health). The protein was eluted with 100 mM Gly pH2.5+150 mM NaCl and quickly neutralized with 20 mM citrate pH 5.0+300 mM NaCl. The agonist protein was then concentrated to 1 mL and further purified by a Superdex 200 Increase 10/300 GL column. The monomeric peak fractions were pooled and concentrated. The final purified protein has endotoxin of lower than 10EU/mg and kept in 20 mM citrate pH 5.0+300 mM NaCl. The purified IL2-Fc fusion agonists were run on an SDS gel (4-12% Bis-Tris Bolt gel, with MES running buffer), comparing samples of each treated under reducing versus non-reducing conditions (<figref idref="DRAWINGS">FIG. <b>36</b>A</figref>).</p><p id="p-0255" num="0231">For monovalent IL2-Fc fusion protein production, the &#x201c;knob&#x201d; and &#x201c;hole&#x201d; constructs in respective IgG1 and IgG4 backbone format were transfected to ExpiHEK293-F cells with the ratio of 1:1. The cells were grown in above conditions for five days before harvesting. The supernatant was collected by centrifugation and filtered through a 0.2 &#x3bc;m PES membrane. The Fc fusion agonist first was purified by MabSelect PrismA protein A resin (GE Health). The protein was eluted with 100 mM Gly pH2.5+150 mM NaCl and quickly neutralized with 20 mM citrate pH 5.0+300 mM NaCl. The agonist protein was then concentrated to 1 mL and further purified by a Superdex 200 Increase 10/300 GL column. The monomeric peak fractions were pooled and concentrated. The final purified protein has endotoxin of lower than 10EU/mg and kept in 20 mM citrate pH 5.0+300 mM NaCl. The purified monovalent IL2-Fc fusion agonists were run on an SDS gel (4-12% Bis-Tris Bolt gel, with MES running buffer), comparing samples of each treated under reducing versus non-reducing conditions (<figref idref="DRAWINGS">FIG. <b>36</b>B</figref>).</p><heading id="h-0049" level="1">Example 19</heading><heading id="h-0050" level="1">ELISA Binding Analysis of IL2R&#x3b2; Agonist Fc-Fusion Proteins</heading><p id="p-0256" num="0232">For bivalent Fc-fusion proteins, human IL2R&#x3b1;, and human IL2R&#x3b2; were each immobilized in a 384 well plate at final concentration of 2 &#x3bc;g/mL in 1&#xd7;PBS in total volume of 25 &#x3bc;L per well. The plate was incubated overnight at 4&#xb0; C. followed by blocking with 80 &#x3bc;L of superblock per well for 1 hour. The purified engineered IL2 mutant Fc fusion protein at 100 nM was 3-fold serial diluted 12 times. Each dilution was added to IL2R&#x3b1; and IL2R&#x3b2; wells in parallel. The engineered IL2 mutant binding was detected by adding 50 &#x3bc;L of anti-human Fc HRP diluted at 1:5000 in 1&#xd7;PBST. In between each step, the plate was washed 3 times with 1&#xd7;PBST in a plate washer. The plate was then developed with 25 &#x3bc;l of TMB substrate for 5 mins and stopped by adding 25 &#x3bc;l of 2N sulfuric acid. The plate was read at OD450 nm Biotek plate reader and the EC50 was analyzed with Prism 8.1 software. Absorbance versus IL-2 concentration is graphed for human IL2R&#x3b1; and IL2R&#x3b2; (<figref idref="DRAWINGS">FIGS. <b>37</b>A-<b>37</b>G</figref>). A summary of the EC50 values of ELISA binding is shown (Table 17).</p><p id="p-0257" num="0000"><tables id="TABLE-US-00022" num="00022"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 17</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of receptor binding analysis of</entry></row><row><entry>bivalent IL2R&#x3b2; Fc fusion proteins</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="77pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Relative </entry></row><row><entry/><entry/><entry/><entry>activity</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry>IL2&#x3b1;</entry><entry>IL2&#x3b2;</entry><entry>IL2R&#x3b1;</entry><entry>IL2R&#x3b2;</entry></row><row><entry/><entry>EC50</entry><entry>EC50</entry><entry>(EC50:</entry><entry>(EC50:</entry></row><row><entry>Clones</entry><entry>(nM)</entry><entry>(nM)</entry><entry>fold)</entry><entry>fold)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="28pt" align="char" char="."/><colspec colname="5" colwidth="49pt" align="char" char="."/><tbody valign="top"><row><entry>EP085</entry><entry>5.0E&#x2212;02</entry><entry>&#x2002;3.0E&#x2212;02*</entry><entry>1</entry><entry>1</entry></row><row><entry>EP079</entry><entry>6.4E&#x2212;01</entry><entry>4.1E&#x2212;01</entry><entry>&#x2212;12.7</entry><entry>727</entry></row><row><entry>EP083</entry><entry>4.6E&#x2212;02</entry><entry>2.8E&#x2212;01</entry><entry>1.09</entry><entry>1079</entry></row><row><entry>EP082</entry><entry>2.8E&#x2212;02</entry><entry>2.5E&#x2212;01</entry><entry>1.78</entry><entry>1189</entry></row><row><entry>EP078</entry><entry>4.1E&#x2212;02</entry><entry>2.1E+00</entry><entry>1.24</entry><entry>142</entry></row><row><entry>EP084</entry><entry>4.1E&#x2212;02</entry><entry>2.6E+00</entry><entry>1.23</entry><entry>117</entry></row><row><entry>EP081</entry><entry>8.7E&#x2212;02</entry><entry>2.0E&#x2212;01</entry><entry>&#x2212;1.73</entry><entry>1528</entry></row><row><entry>EP080</entry><entry>5.6E&#x2212;02</entry><entry>2.3E&#x2212;01</entry><entry>&#x2212;1.17</entry><entry>1278</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0258" num="0233">For monovalent Fc-fusion proteins, recombinant His-tagged human IL2R&#x3b1; and IL2R&#x3b2; were added in 25 uL of 1&#xd7;PBS to wells of 384-well plate and incubated overnight at 4&#xb0; C. to coat the plates. Plates were washed three times with 0.05% Tween20/1&#xd7;PBS. Plates were blocked with 100 uL of SuperBlock for 1 hr at RT and then washed 3 times with 0.05% Tween20/1&#xd7;PBS. IL2 mutants were diluted in 0.05% Tween 20/1&#xd7;PBS from 1000 nM to 0 nM and added to plates for 2 hrs at room temperature. Plates were then washed 6 times with 0.05% Tween20/1&#xd7;PBS. Anti-HisTag-HRP was diluted 1:5000 in 0.05% Tween20/1&#xd7;PBS and added to plates for 1 hr at RT. Plates were then washed 6 times with 0.05% Tween20/1&#xd7;PBS, and TMB was added to develop blue color. Reactions were stopped with 2N hydrogen sulfide and light absorbance at 450 nm was read on a BioTek plate reader. Absorbance versus IL2 concentration is graphed for human IL2R&#x3b1; and IL2R&#x3b2; (<figref idref="DRAWINGS">FIGS. <b>38</b>A-<b>38</b>B</figref>). A summary of the EC50 values of ELISA binding is shown (Table 18).</p><p id="p-0259" num="0000"><tables id="TABLE-US-00023" num="00023"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 18</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of receptor binding analysis </entry></row><row><entry>of monovalent IL2R&#x3b2; Fc fusion proteins</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="133pt" align="center"/><colspec colname="2" colwidth="84pt" align="center"/><tbody valign="top"><row><entry/><entry>EC50 (nM)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="133pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><tbody valign="top"><row><entry/><entry>hIL2R&#x3b1;</entry><entry>hIL2R&#x3b2;</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="133pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>WT-Fc, Monovalent (EP290/EP280)</entry><entry>1.9E&#x2212;02</entry><entry>9.4E+00</entry></row><row><entry>EP001, Monovalent (EP297/EP280)</entry><entry>2.7E+00</entry><entry>3.8E+00</entry></row><row><entry>EP003, Monovalent (EP291/EP280)</entry><entry>3.6E&#x2212;01</entry><entry>6.0E&#x2212;01</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0051" level="1">Example 20</heading><heading id="h-0052" level="1">Binding Kinetics of Monovalent IL2R&#x3b2; Fc Fusion Proteins</heading><p id="p-0260" num="0234">Binding kinetics of monovalent IL2R&#x3b2; Fc fusion proteins have been analyzed by SPR technology with Biacore T200. Briefly, anti-hFc antibody was immobilized on flow cell 1 and 2. For each cycle, 1 ug/mL of IL2 Fc fusion protein was captured for 60 seconds at flow rate of 10 ul/min on flow cell 2 in 1&#xd7;HBSP buffer on anti-hFc immobilized chip. 100 nM IL2R&#x3b1;-HIS tagged or IL2R&#x3b2;-HIS tagged was 2-fold serial diluted and injected onto both reference flow cell 1 and IL2 Fc fusion protein were captured at flow cell 2 for 150 seconds at flow rate of 30 ul/mins. 300 seconds wash was applied after the last injection. The assay was set up with 8 serial diluted concentration points in 96 well format. The kinetics data was analyzed with Biacore T200 evaluation software 3.0. The specific binding response unit was derived from subtraction of binding to reference flow cell 1 from target flow cell 2 (<figref idref="DRAWINGS">FIGS. <b>39</b>A-<b>39</b>D</figref>).</p><heading id="h-0053" level="1">Example 21</heading><heading id="h-0054" level="1">P-STAT5 Activation of Human PBMCs by IL2R&#x3b2; Agonist Fc-Fusion Proteins</heading><p id="p-0261" num="0235">Human PBMCs were isolated from peripheral blood and plated at 250,000 cells/well in a 96-well plate in 75 &#x3bc;l of media. Cells were rested 1 hr at 37&#xb0; C. Cells were stimulated with human IL2 WT and IL2R&#x3b2; agonist Fc-fusion proteins at 4&#xd7; concentration in 25 &#x3bc;l for 20 min at 37&#xb0; C. Stimulated PBMCs were immediately fixed, permeabilized, stained for cell lineage markers (CD3, CD56, CD4, CD8, FOXP3) and p-STAT5 and visualized on the Attune flow cytometer. CD8+ T cells were defined as CD3+CD56&#x2212;CD4&#x2212;CD8+. NK cells were defined as CD3&#x2212;CD56+. T regulatory cells were defined as CD3+CD56&#x2212;CD4+CD8&#x2212;FOXP3+. The % of cells that were p-STAT5+ was determined and graphed versus each IL2 titration (<figref idref="DRAWINGS">FIGS. <b>40</b>A-<b>40</b>C</figref> for bivalent fusion proteins and <figref idref="DRAWINGS">FIGS. <b>41</b>A-<b>41</b>C</figref> for bivalent fusion proteins; see Table 19 for a summary).</p><p id="p-0262" num="0000"><tables id="TABLE-US-00024" num="00024"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 19</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of P-STAT5 activation of human </entry></row><row><entry>PBMCs by IL2R&#x3b2; agonist Fc-fusion proteins</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="133pt" align="center"/><tbody valign="top"><row><entry/><entry>EC50 (nM)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>T </entry></row><row><entry/><entry>CD8+ </entry><entry>NK </entry><entry>Regulatory </entry></row><row><entry/><entry>T Cells</entry><entry>Cells</entry><entry>Cells</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>WT-Fc, Bivalent (EP085)</entry><entry>1.4E+01</entry><entry>7.7E&#x2212;02</entry><entry>2.8E&#x2212;04</entry></row><row><entry>EP001-Fc, Bivalent (EP079)</entry><entry>1.1E&#x2212;01</entry><entry>1.5E&#x2212;02</entry><entry>2.7E&#x2212;02</entry></row><row><entry>EP003-Fc, Bivalent (EP082)</entry><entry>3.4E&#x2212;01</entry><entry>2.9E&#x2212;02</entry><entry>1.9E&#x2212;03</entry></row><row><entry>EP004-Fc, Bivalent (EP078)</entry><entry>8.4E&#x2212;02</entry><entry>8.5E&#x2212;03</entry><entry>5.9E&#x2212;04</entry></row><row><entry>WT-Fc, Monovalent</entry><entry>&#x3e;5.0 + 01</entry><entry>&#x3e;5.0 + 01</entry><entry>1.3E&#x2212;02</entry></row><row><entry>(EP290/EP280)</entry><entry/><entry/><entry/></row><row><entry>EP001, Monovalent</entry><entry>7.4E&#x2212;01</entry><entry>1.6E&#x2212;01</entry><entry>5.7E&#x2212;02</entry></row><row><entry>(EP297/EP280)</entry><entry/><entry/><entry/></row><row><entry>EP003, Monovalent</entry><entry>4.1E&#x2212;01</entry><entry>9.4E&#x2212;02</entry><entry>1.1E&#x2212;02</entry></row><row><entry>(EP291/EP280)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0055" level="1">Example 22</heading><heading id="h-0056" level="1">IL2R&#x3b2; Agonist Murine In Vivo Pharmacokinetics Analysis</heading><p id="p-0263" num="0236">C57BL/6 mice were injected either i.v. or i.p. with 10 ug of IL2-WT, EP001, or EP003 in 200 uL of saline. Blood was collected at 0 min, 10 min, 30 min, 1 hr, 2 hrs, 4 hrs, 8 hrs, 16 hrs, 24 hrs and 48 hrs, and immediately centrifuged to separate out plasma. To determine plasma concentrations of IL2-WT and EP001, plasma was serially diluted and analyzed per instructions using the Duoset IL2 ELISA kit (R&#x26;D Systems). IL2-WT, EP001, and EP001 concentrations were determined by comparing absorbance values from plasma to spiked controls made in equally diluted untreated C57BL/6 mouse plasma. IL2 concentration is plotted versus time on a logarithmic scale (<figref idref="DRAWINGS">FIGS. <b>42</b>A-<b>42</b>B</figref>; Table 20).</p><p id="p-0264" num="0000"><tables id="TABLE-US-00025" num="00025"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="98pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="105pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 20</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Dosing (i.v.)</entry><entry/><entry>Dosing (i.p.)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry>WT IL2</entry><entry>EP001</entry><entry>EP003</entry><entry/><entry>WT IL2</entry><entry>EP001</entry><entry>EP003</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry>AUC</entry><entry>81.9&#x2002;</entry><entry>266.71&#x2002;</entry><entry>170.37&#x2002;</entry><entry>AUC</entry><entry>195.59&#x2002;</entry><entry>445.38&#x2002;</entry><entry>101.3&#x2003;</entry></row><row><entry>(ng &#xb7; h/mL)</entry><entry/><entry/><entry/><entry>(ng &#xb7; h/mL)</entry><entry/><entry/><entry/></row><row><entry>Clearance</entry><entry>113.1&#x2003;</entry><entry>34.72</entry><entry>54.35</entry><entry>Cmax</entry><entry>122.7&#x2003;</entry><entry>335.66&#x2002;</entry><entry>85.13</entry></row><row><entry>(mL/min/kg)</entry><entry/><entry/><entry/><entry>(ng/mL)</entry><entry/><entry/><entry/></row><row><entry>Volume of</entry><entry>10.85</entry><entry>&#x2002;3.16</entry><entry>&#x2002;5.25</entry><entry>Tmax (h)</entry><entry>2&#x2002;&#x2009;</entry><entry>1&#x2002;&#x2009;</entry><entry>1&#x2009;&#x2002;</entry></row><row><entry>Distribution</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>(L/kg)</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>T1/2 (h)</entry><entry>&#x2002;1.11</entry><entry>&#x2002;1.05</entry><entry>&#x2002;1.12</entry><entry>T1/2 (h)</entry><entry>&#x2002;0.47</entry><entry>&#x2002;0.56</entry><entry>&#x2002;0.61</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0057" level="1">Example 23</heading><heading id="h-0058" level="1">IL2R&#x3b2; Agonist Murine In Vivo Tumor Cell Infiltration</heading><p id="p-0265" num="0237">Seven (7)-week old, female C57BL/6 mice were injected with 100,000 MC38 cells in 50% matrigel subcutaneously on their back flank. Tumors were measured with calipers. Upon reaching an average volume of 100 mm<sup>3</sup>, mice were treated with 32 ug of WT IL2, EP001, EP003, or EP004 BID for 5 days. On day 6, mice were sacrificed and the tumor infiltrating immune cells were analyzed by flow cytometry. Tumor sections used for flow cytometry were weighed to obtain normalized cell counts. CD4+ T cells were defined as CD45+CD3+CD49b&#x2212;CD4+CD8-. CD8+ T cells were defined as CD45+CD3+CD49b&#x2212;CD4&#x2212;CD8+. NK cells were defined as CD45+CD3&#x2212;CD49b+. T regulatory cells NK cells were defined as CD45+CD3+CD49b&#x2212;CD4+CD8&#x2212;FOXP3+. Na&#xef;ve T cells were defined as CD44<sup>lo</sup>CD62L<sup>hi</sup>. Effector T cells were defined as CD44<sup>hi</sup>CD62L<sup>lo </sup>and central memory T cells were defined as CD44<sup>hi</sup>CD62L<sup>hi</sup>. The normalized counts of tumor infiltrating immune cells (<figref idref="DRAWINGS">FIGS. <b>43</b>A-<b>43</b>D</figref>), the effector cell to regulatory cell ratios (<figref idref="DRAWINGS">FIGS. <b>44</b>A &#x26; <b>44</b>B</figref>) and the T cell subtype (<figref idref="DRAWINGS">FIGS. <b>45</b>A-<b>45</b>C</figref>) are graphed versus IL2 clone treatment group.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-0"><sequence-list file="US20230002466A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An engineered interleukin-2 (IL2) polypeptide comprising an engineered IL2 receptor &#x3b2; (IL2R&#x3b2;) binding region 2 motif comprising:</claim-text><claim-text><tables id="TABLE-US-00026" num="00026"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="196pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry></row><row><entry/><entry>X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>-D-X<sub>4</sub>-X<sub>5</sub>-X<sub>6</sub>-N-X<sub>7</sub>-X<sub>8</sub>-X<sub>9</sub>-X<sub>10</sub>-X<sub>11</sub>-X<sub>12</sub>-X<sub>13</sub>,</entry></row></tbody></tgroup></table></tables><claim-text>wherein X<sub>1</sub>, X<sub>3</sub>, X<sub>6</sub>, X<sub>8</sub>, X<sub>12</sub>, and X<sub>13 </sub>each comprise any residue,</claim-text><claim-text>wherein X<sub>2</sub>, X<sub>4</sub>, and X<sub>10 </sub>are uncharged residues,</claim-text><claim-text>wherein X<sub>5</sub>, X<sub>7</sub>, X<sub>9</sub>, and X<sub>11 </sub>each comprise uncharged, nonpolar residues, and</claim-text><claim-text>wherein the engineered IL2 polypeptide binds to IL2R&#x3b2; at a K<sub>D </sub>at least 10-fold greater than a wild-type IL2.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. (canceled)</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein:<claim-text>X<sub>1 </sub>is selected from C, T, G, W, I, S, E, and K;</claim-text><claim-text>X<sub>2 </sub>is selected from Y, P, V, W, L, A, and G;</claim-text><claim-text>X<sub>3 </sub>is selected from S, T, Q, G, M, E, R, and K;</claim-text><claim-text>X<sub>4 </sub>is selected from A, V, S, and T;</claim-text><claim-text>X<sub>5 </sub>is selected from I, L, T, and V;</claim-text><claim-text>X<sub>6 </sub>is selected from S, T, E, D, and R;</claim-text><claim-text>X<sub>7 </sub>is selected from I, A, M, and V;</claim-text><claim-text>X<sub>8 </sub>is selected from S, T, N, Q, I, G, E, K, and R;</claim-text><claim-text>X<sub>9 </sub>is selected from V, L, and I;</claim-text><claim-text>X<sub>10 </sub>is selected from N, T, I, and L;</claim-text><claim-text>X<sub>11 </sub>is selected from V, A, and I;</claim-text><claim-text>X<sub>12 </sub>is selected from Q, L, G, K, and R; and</claim-text><claim-text>X<sub>13 </sub>is selected from A, D, and E.</claim-text></claim-text></claim><claim id="CLM-04-35" num="04-35"><claim-text><b>4</b>.-<b>35</b>. (canceled)</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. The engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the engineered IL2R&#x3b2; binding region 2 is selected from: GVTDSISNAIVLARE (SEQ ID NO: 2); KWGDAVSNARVLAGE (SEQ ID NO: 3); KWGDAVSNARVLAGA (SEQ ID NO: 4); TLMDTTDNIGVLVRE (SEQ ID NO: 5); EPSDVISNINVLVQE (SEQ ID NO: 6); SPQDSIENISVLVRE (SEQ ID NO: 7); WASDSIENITLLIQE (SEQ ID NO: 8); CPTDTIENITVLIQE (SEQ ID NO: 9); RYKDSLENMQIIIQE (SEQ ID NO: 10); TARDAVDNMRVIIQE (SEQ ID NO: 11); TPRDVVENMNVLVLE (SEQ ID NO: 12); TPSDVIENMEVLILD (SEQ ID NO: 13); TPSDAIENINVLIRE (SEQ ID NO: 14); TPSDVIENITVLVQE (SEQ ID NO: 15); GVGDTIDNINVLVKE (SEQ ID NO: 16); IGRDSIDNIKVIVQE (SEQ ID NO: 17); WATDTIRNVEVLVQE (SEQ ID NO: 18); TAEDVVTNITVLVQE (SEQ ID NO: 19); TAEDVISNIRVNVQE (SEQ ID NO: 20); and TPSDVIDNVSITVQE (SEQ ID NO: 21); TARDAISNIRVIVQE (SEQ ID NO: 210); RARDAIDNIRVIVQE (SEQ ID NO: 211); TPRDAIDNINVIIQE (SEQ ID NO: 212); TPRDAIDNIRVIVQE (SEQ ID NO: 213); TPRDAIDNIRVIILE (SEQ ID NO: 214); TARDAISNINVIIQE (SEQ ID NO: 215); and TARDAIDNINVIVQE (SEQ ID NO: 216); and TARDAIDNIRVIVLE (SEQ ID NO: 217).</claim-text></claim><claim id="CLM-37-53" num="37-53"><claim-text><b>37</b>.-<b>53</b>. (canceled)</claim-text></claim><claim id="CLM-00054" num="00054"><claim-text><b>54</b>. The engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the engineered IL2 polypeptide has a decrease in affinity for IL2R&#x3b1; as compared to wild-type IL2.</claim-text></claim><claim id="CLM-00055" num="00055"><claim-text><b>55</b>. (canceled)</claim-text></claim><claim id="CLM-00056" num="00056"><claim-text><b>56</b>. An engineered interleukin-2 (IL2) polypeptide comprising an engineered IL2 receptor &#x3b1; (IL2R&#x3b1;) binding region 1 comprising a substitution selected from: a substitution at position K35, a substitution at R38, a substitution at F42, a substitution at Y45, or any combination thereof, wherein the engineered IL2 polypeptide binds to IL2R&#x3b1; with at least 2-fold reduced binding kinetics as compared to wild-type IL2.</claim-text></claim><claim id="CLM-57-81" num="57-81"><claim-text><b>57</b>.-<b>81</b>. (canceled)</claim-text></claim><claim id="CLM-00082" num="00082"><claim-text><b>82</b>. The engineered IL2 polypeptide of <claim-ref idref="CLM-00056">claim 56</claim-ref>, comprising a substitution at least one of positions K35, R38, F42, and Y45, wherein:<claim-text>i) the substitution at position K35 is selected from: K35G, K35L, K35S, K35V, K35D, K35E, and K35C;</claim-text><claim-text>ii) the substitution at position R38 is selected from: R38V, R38D, R38E, R38S, R38I, R38A, R38Y, R38G, R38C, or R3 8N;</claim-text><claim-text>iii) the substitution at position F42 is selected from: F42A, F42R, F42G, F42I, F42L, F42P and F42H; and</claim-text><claim-text>iv) the substitution at position Y45 is Y45S, Y45P, Y45A, Y45V, Y45C, Y45T, and Y45F.</claim-text></claim-text></claim><claim id="CLM-83-84" num="83-84"><claim-text><b>83</b>.-<b>84</b>. (canceled)</claim-text></claim><claim id="CLM-00085" num="00085"><claim-text><b>85</b>. The engineered IL2 polypeptide <claim-ref idref="CLM-00056">claim 56</claim-ref>, wherein the engineered IL2R&#x3b1; binding region 1 is selected from:</claim-text><claim-text><tables id="TABLE-US-00027" num="00027"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="70pt" align="left"/><colspec colname="1" colwidth="147pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;183)</entry></row><row><entry/><entry>PVLTRMLTIKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;184)</entry></row><row><entry/><entry>PKLTRMLTLKFP;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;185)</entry></row><row><entry/><entry>PDLTSMLAFKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;186)</entry></row><row><entry/><entry>PGLTEMLTFKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;187)</entry></row><row><entry/><entry>PSLTRMLTGKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;188)</entry></row><row><entry/><entry>PELTIMLTPKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;189)</entry></row><row><entry/><entry>PCLTAMLTLKFA;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;190)</entry></row><row><entry/><entry>PCLTAMLTLKFA;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;191)</entry></row><row><entry/><entry>PKLTRMLTHKFV;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;192)</entry></row><row><entry/><entry>PCLTDMLTFKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;193)</entry></row><row><entry/><entry>PLLTDMLTRKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;194)</entry></row><row><entry/><entry>PLLTDMLTFKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;195)</entry></row><row><entry/><entry>PKLTDMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;196)</entry></row><row><entry/><entry>PKLTYMLTRKFY;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;197)</entry></row><row><entry/><entry>PKLTRMLTFKFC;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;198)</entry></row><row><entry/><entry>PKLTSMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;199)</entry></row><row><entry/><entry>PKLTSMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;200)</entry></row><row><entry/><entry>PKLTYMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;201)</entry></row><row><entry/><entry>PKLTYMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;202)</entry></row><row><entry/><entry>PKLTGMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;203)</entry></row><row><entry/><entry>PKLTVMLTFKFT;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;204)</entry></row><row><entry/><entry>PKLTYMLTFKFS;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;205)</entry></row><row><entry/><entry>PKLTVMLTFKFP;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;206)</entry></row><row><entry/><entry>PKLTVMLTFKFF;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;207)</entry></row><row><entry/><entry>PKLTCMLTFKFA;</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;208)</entry></row><row><entry/><entry>PKLTNMLTFKFA;</entry></row><row><entry/><entry>and</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;209)</entry></row><row><entry/><entry>PKLTNMLTFKFS.</entry></row></tbody></tgroup></table></tables></claim-text></claim><claim id="CLM-00086" num="00086"><claim-text><b>86</b>. (canceled)</claim-text></claim><claim id="CLM-00087" num="00087"><claim-text><b>87</b>. The engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising an engineered IL2R&#x3b1; binding region 1, wherein the engineered IL2R&#x3b1; binding region 1 is selected from: PVLTRMLTIKFY (SEQ ID NO: 183); PKLTRMLTLKFP (SEQ ID NO:184); PDLTSMLAFKFY (SEQ ID NO:185); PGLTEMLTFKFY(SEQ ID NO:186); PSLTRMLTGKFY (SEQ ID NO:187); PELTIMLTPKFY(SEQ ID NO:188); PCLTAMLTLKFA (SEQ ID NO:189); PCLTAMLTLKFA (SEQ ID NO:190); PKLTRMLTHKFV (SEQ ID NO:191); PCLTDMLTFKFY(SEQ ID NO:192); PLLTDMLTRKFY (SEQ ID NO:193); PLLTDMLTFKFY(SEQ ID NO:194); PKLTDMLTFKFS (SEQ ID NO:195); PKLTYMLTRKFY(SEQ ID NO:196); PKLTRMLTFKFC (SEQ ID NO:197); PKLTSMLTFKFS(SEQ ID NO:198); PKLTSMLTFKFS (SEQ ID NO:199); PKLTYMLTFKFS(SEQ ID NO:200); PKLTYMLTFKFS (SEQ ID NO:201); PKLTGMLTFKFS(SEQ ID NO:202); PKLTVMLTFKFT (SEQ ID NO:203); PKLTVMLTFKFS(SEQ ID NO:204); PKLTVMLTFKFP (SEQ ID NO:205); PKLTVMLTFKFF (SEQ ID NO:206); PKLTCMLTFKFA (SEQ ID NO:207); PKLTNMLTFKFA (SEQ ID NO:208); and PKLTNMLTFKFS (SEQ ID NO:209); and wherein the engineered IL2R&#x3b2; binding region 2 is selected from: GVTDSISNAIVLARE (SEQ ID NO: 2); KWGDAVSNARVLAGE (SEQ ID NO: 3); KWGDAVSNARVLAGA (SEQ ID NO: 4); TLMDTTDNIGVLVRE (SEQ ID NO: 5); EPSDVISNINVLVQE (SEQ ID NO: 6); SPQDSIENISVLVRE (SEQ ID NO: 7); WASDSIENITLLIQE (SEQ ID NO: 8); CPTDTIENITVLIQE (SEQ ID NO: 9); RYKDSLENMQIIIQE (SEQ ID NO: 10); TARDAVDNMRVIIQE (SEQ ID NO: 11); TPRDVVENMNVLVLE (SEQ ID NO: 12); TPSDVIENMEVLILD (SEQ ID NO: 13); TPSDAIENINVLIRE (SEQ ID NO: 14); TPSDVIENITVLVQE (SEQ ID NO: 15); GVGDTIDNINVLVKE (SEQ ID NO: 16); IGRDSIDNIKVIVQE (SEQ ID NO: 17); WATDTIRNVEVLVQE (SEQ ID NO: 18); TAEDVVTNITVLVQE (SEQ ID NO: 19); TAEDVISNIRVNVQE (SEQ ID NO: 20); and TPSDVIDNVSITVQE (SEQ ID NO: 21); TARDAISNIRVIVQE (SEQ ID NO: 210); RARDAIDNIRVIVQE (SEQ ID NO: 211); TPRDAIDNINVIIQE (SEQ ID NO: 212); TPRDAIDNIRVIVQE (SEQ ID NO: 213); TPRDAIDNIRVIILE (SEQ ID NO: 214); TARDAISNINVIIQE (SEQ ID NO: 215); and TARDAIDNINVIVQE (SEQ ID NO: 216); and TARDAIDNIRVIVLE (SEQ ID NO: 217).</claim-text></claim><claim id="CLM-00088" num="00088"><claim-text><b>88</b>. A fusion polypeptide comprising an engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref> fused to a half-life extending molecule.</claim-text></claim><claim id="CLM-00089" num="00089"><claim-text><b>89</b>. (canceled)</claim-text></claim><claim id="CLM-00090" num="00090"><claim-text><b>90</b>. The fusion polypeptide of <claim-ref idref="CLM-00088">claim 88</claim-ref>, wherein the half-life extending molecule comprises a half-life extending polypeptide, and the half-life extending polypeptide comprises an Fc domain, human serum albumin (HSA), an HSA binding molecule, or transferrin.</claim-text></claim><claim id="CLM-00091" num="00091"><claim-text><b>91</b>. (canceled)</claim-text></claim><claim id="CLM-00092" num="00092"><claim-text><b>92</b>. The fusion polypeptide of <claim-ref idref="CLM-00088">claim 88</claim-ref>, wherein the half-life extending molecule comprises poly-ethylene glycol (PEG) or polypropylene glycol (PPG).</claim-text></claim><claim id="CLM-00093" num="00093"><claim-text><b>93</b>. A fusion polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises an engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00094" num="00094"><claim-text><b>94</b>. The fusion polypeptide of <claim-ref idref="CLM-00093">claim 93</claim-ref>, wherein the second polypeptide comprises an antigen binding moiety.</claim-text></claim><claim id="CLM-00095" num="00095"><claim-text><b>95</b>. (canceled)</claim-text></claim><claim id="CLM-00096" num="00096"><claim-text><b>96</b>. The fusion polypeptide of <claim-ref idref="CLM-00094">claim 94</claim-ref>, wherein the antigen binding moiety comprises a Fab molecule, an scFv, a bi-specific T-cell engager, a diabody, a single domain antibody, or a nanobody.</claim-text></claim><claim id="CLM-00097" num="00097"><claim-text><b>97</b>. The fusion polypeptide of <claim-ref idref="CLM-00093">claim 93</claim-ref>, wherein the second polypeptide comprises a cytokine.</claim-text></claim><claim id="CLM-00098" num="00098"><claim-text><b>98</b>. The fusion polypeptide of <claim-ref idref="CLM-00097">claim 97</claim-ref>, wherein the second polypeptide comprises interleukin 2, interleukin-15, interleukin-7, interleukin-10, or C-C motif chemokine ligand 19 (CCL19).</claim-text></claim><claim id="CLM-00099" num="00099"><claim-text><b>99</b>. (canceled)</claim-text></claim><claim id="CLM-00100" num="00100"><claim-text><b>100</b>. An isolated polynucleotide encoding at least one polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00101" num="00101"><claim-text><b>101</b>. An expression vector comprising the polynucleotide of <claim-ref idref="CLM-00100">claim 100</claim-ref>.</claim-text></claim><claim id="CLM-00102" num="00102"><claim-text><b>102</b>. A modified cell comprising the isolated polynucleotide of <claim-ref idref="CLM-00100">claim 100</claim-ref>.</claim-text></claim><claim id="CLM-00103" num="00103"><claim-text><b>103</b>. The modified cell of <claim-ref idref="CLM-00102">claim 102</claim-ref> further comprising an engineered T cell receptor or chimeric antigen receptor.</claim-text></claim><claim id="CLM-00104" num="00104"><claim-text><b>104</b>. A pharmaceutical composition comprising the engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref> and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="CLM-00105" num="00105"><claim-text><b>105</b>. A method of modulating an immune response in a subject in need thereof, comprising administering an effective amount of an engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref> to the subject.</claim-text></claim><claim id="CLM-00106" num="00106"><claim-text><b>106</b>. The method of <claim-ref idref="CLM-00105">claim 105</claim-ref>, wherein the modulating the immune response comprises at least one of: enhancing effector T cell activity, enhancing NK cell activity, and suppressing regulatory T cell activity.</claim-text></claim><claim id="CLM-00107" num="00107"><claim-text><b>107</b>. A method of treating a disease in a subject in need thereof, comprising administering an effective amount of an engineered IL2 polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref> to the subject.</claim-text></claim><claim id="CLM-00108" num="00108"><claim-text><b>108</b>. The method of <claim-ref idref="CLM-00107">claim 107</claim-ref>, wherein the disease comprises cancer or immunosuppression.</claim-text></claim><claim id="CLM-00109" num="00109"><claim-text><b>109</b>. The method of <claim-ref idref="CLM-00108">claim 108</claim-ref>, wherein the cancer comprises breast cancer, pancreatic cancer, lung cancer, glioblastoma, renal cell carcinoma, or melanoma.</claim-text></claim><claim id="CLM-110-120" num="110-120"><claim-text><b>110</b>.-<b>120</b>. (canceled)</claim-text></claim></claims></us-patent-application>